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Abstract:
Background: Cluster randomized trials (CRTs) are a widely used research design in
healthcare, health services, public health and education research. CRTs randomly assign
groups of individuals to different experimental arms. Because CRTs randomize groups
rather than individual subjects, they pose ethical challenges that do not arise in
individually-randomized clinical trials.
Research Questions: This dissertation sought to examine how ethical challenges in
CRTs, particularly challenges relating to obtaining informed consent, are addressed in
practice. This dissertation also sought to provide principled guidance as to who must be
considered a research subject in a CRT, and when consent must be sought from research
subjects in CRTs.
Methods: The association between consent practices in healthcare CRTs and particular
trial features were examined using a multivariable logistic regression model.
Information on ethical challenges encountered by CRT researchers in practice was
obtained using descriptive qualitative analysis of semi-structured interviews with
experienced CRT investigators. Two normative questions, “Who is the research subject
in CRTs?” and “When is consent required in CRTs?” were addressed by appealing to a
conceptual framework derived from the basic principles of research ethics.
Results: Consent in CRTs is associated with publication after 2004, publication in
higher-impact journals, smaller cluster sizes, and the use of individual-level
experimental and data collection interventions. CRT researchers are most concerned
with issues around informed consent, and less concerned with issues related to the
analysis of harms and benefits in CRTs.
iii

Research subjects are individuals who are intervened upon by investigators,
either directly or via manipulation of their environment; who interact with investigators;
or who contribute identifiable private information. Consent must be sought for CRT
participation from research subjects. Seeking consent after randomization of clusters is
permissible if methodologically necessary. Some CRTs may meet criteria for a waiver
of informed consent. Consent is not required from cluster members who are not research
subjects.
Conclusions: This dissertation describes the state of the art of ethics practices in CRTs,
and presents guidance around consent issues in CRTs that will inform the development
of international ethics guidelines for CRTs.

Keywords:
Research ethics; Cluster randomized trials; Informed consent; Public health research;
Health services research.
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Chapter 1

Introduction

2

This dissertation will address ethical challenges associated with cluster randomized
trials (CRTs). It asks two related questions: 1) what is currently being done in CRTs to
address some of the unique ethical challenges that stem from the CRT design? 2) How
ought two key ethical challenges—the identification of research subjects in CRTs and
adherence to proper informed consent practices—be addressed?
The cluster randomized trial is an experimental design that has become increasingly
commonplace in health services research, quality improvement, education, public health
and a variety of other fields1-4. It differs from individually-randomized controlled trials
(RCTs) in fundamental ways1. In an RCT, subjects are recruited individually and then
randomly assigned to different intervention arms. Subjects are subjected to different
experimental interventions in each study arm. Outcome data is collected from the
individual subjects and analyzed. Based on the data collected, inferences are then made
about the comparative effectiveness of the experimental interventions.
In a CRT, groups of individuals are randomly assigned to different intervention
arms. Depending on the kind of interventions under study, the experimental interventions
may be applied either to the entire group, or to the members individually. Data may be
collected from all group members, from a sample of group members, or from other sources
that may reflect the group members’ response to the intervention such as hospital
administrative data. After the data analysis, inferences may be made about the effects of the
experimental interventions on the group-level outcomes, on individual-level outcomes or
both.
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Thus, in typical RCTs, the individual research subject is the unit of randomization,
intervention, and analysis. In CRTs, the cluster is the unit of randomization. The unit of
intervention may be the cluster, individual cluster members, or another entity closely
associated with the cluster (such as a health professional) such that the intervention on that
entity produces a cluster-level effect. The unit of analysis may be the cluster, the
individual, or both1,5.
The randomization of groups leads to a host of ethical challenges that are unique to
the CRT design. It is not always obvious who is the research subject in CRTs4,6-8. This is
especially true in CRTs with interventions that are administered broadly at the cluster level,
such as in large scale CRTs of public health interventions. Are all residents of a community
participating in a CRT research subjects? What if they are not affected by the study
intervention? Identifying the research subject is also complicated in CRTs in such fields as
healthcare or education, in which the study interventions are administered to an individual
such as a health professional or teacher, and the effect evaluated by collecting data on
group members such as patients or students4,6-8. Are the research subjects the cluster
members, individuals who receive interventions in order to produce cluster-level effects
(such as health professionals or teachers), or both?
In some large CRTs, it may not be feasible to obtain informed consent from all
cluster members2,4,9. It may also not be possible for some cluster members to avoid
experimental interventions that are designed to affect the entire cluster2,4,9. There are also
concerns that obtaining informed consent from subjects in some CRTs may threaten the
validity of trial findings2,4,9. Because of these challenges, investigators’ obligations with
respect to obtaining informed consent in CRTs are not well-established.
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It is not clear whether the typical criteria that are used to evaluate the harms and
benefits of interventions performed on individual subjects in traditional RCTs can be easily
applied to CRTs of group-level interventions5,6.
The moral status of groups is unclear. Some clusters may be groups of individuals
with legitimate structure and representation, such as communities10. Other kinds of clusters
are less well defined with no clear leadership, such as customers in a shopping mall that is
participating in a CRT11. There is little principled guidance as to who has the authority to
decide on behalf of clusters whether or not to participate in a trial12, nor is there any
normative work outlining the scope of authority of these “gatekeepers”. Furthermore, there
is no normative work addressing the question whether groups of individuals may have
collective interests that are in need of protection as that group participates in a CRT.
Communities may have collective interests that require regulatory protection10, but the
status of groups that are not communities (e.g. sports teams, schools, medical practices) is
not clear.
Recent research ethics guidelines recognize some of the difficult ethical challenges
that arise in CRTs. The United Kingdom Medical Research Council included
recommendations for ethical CRT conduct within its methodological guidelines for
CRTs12. The Council of International Organizations of Medical Science’s 2009 ethical
guidelines for epidemiological research also take note of the logistical challenges in
obtaining informed consent in some CRTs13. However a systematic examination of the
ethical challenges related to CRTs has yet to be undertaken. As a result, there is no
authoritative, comprehensive guidance on the ethical conduct of CRTs to aid investigators
in performing research with high ethical standards.
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Similarly, research ethics committees have no standard to guide their review of
CRT protocols6,14. The lack of comprehensive, authoritative guidance on the ethical
conduct of CRTs has lead to substantial variability in the findings of research ethics
committees who have evaluated CRT protocols14. This variability in research ethics review
has become an impediment to the conduct of multicenter CRTs6,14. One group of authors
highlighted this problem, writing that “…the moral hazard of this uncertainty is that few
formal patient safety studies may be undertaken, resulting in a slowdown in progress…”15.
This dissertation is undertaken in the context of a larger project, funded by the
Canadian Institutes of Health Research16. This project, which includes both empirical
methods and philosophical reflection by a group of experienced CRT investigators and
ethicists, is designed to comprehensively evaluate the key ethical challenges related to
CRTs, and to spearhead the development of international consensus guidelines for the
ethical conduct of CRTs16. The conclusions of each of the papers that comprise this
dissertation will contribute to the body of scholarly work that addresses the ethical
challenges of CRTs. This work will be invaluable in informing the guideline development
process, and will also provide useful guidance to investigators and research ethics boards
who deal with the ethical challenges of CRTs on a daily basis.
In order to address the two questions posed at the beginning of this chapter, the
dissertation will proceed as follows:
Chapter two will review the basic methodological features of CRTs and the ethical
challenges that stem from this design. Chapter two will also outline the basic principles of
research ethics that form the conceptual basis for research ethics guidelines and
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regulations. The basic principles of research ethics will be used as the framework for
evaluating the empirical findings in chapters three and four, and as the basis for normative
work in chapters five and six.
Chapter three provides a quantitative description of current informed consent
practices in healthcare CRTs. It examines consent practices in a sample of 161 CRTs in
primary and hospital care settings. The chapter includes descriptive statistics on the
proportion of CRTs that obtained informed consent from patients. The chapter also
describes a logistic regression analysis that identifies methodological features of CRTs that
are independently associated with the practice of obtaining informed consent from patients
in healthcare CRTs.
Chapter four describes an empirical study in which 20 CRT investigators were
interviewed about the ethical challenges associated with CRTs and their experiences in
addressing these challenges. Qualitative analysis methods were used to provide a rich
descriptive summary of researchers’ experiences addressing the ethical challenges that are
unique to CRT design and conduct.
Chapter five addresses a key ethical question: “Who is a research subject in
healthcare CRTs?” In this chapter I argue for a principled, comprehensive definition of
“research subject” and I apply it to the CRT context. This work allows the formulation of
guidelines that adequately protect subjects in CRTs while avoiding excessive regulatory
burdens on CRT investigators, and enables research ethics boards to consider protections
for research subjects on a more pragmatic level.
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Chapter six reviews the challenges associated with obtaining informed consent in
CRTs, including the feasibility of seeking informed consent in large-scale CRTs, the
potential for bias introduced by the consent process, and the timing and content of consent
discussions. This chapter then draws on one moral theory that underpins the requirement
for informed consent for research participation to argue when, and from whom, informed
consent is required in CRTs, and what information must be disclosed to potential subjects
during consent discussions.
Chapter seven summarizes the preceding chapters, and reflects on the findings of
the empirical work in the light of the conclusions of the two normative chapters. This
chapter includes a reflection on the relationship between empirical work and normative
work in the scholarly enterprise of research ethics. It considers the implications of the
findings in this dissertation for the development of ethical guidelines for CRTs. It also
considers the implications of this work for other study designs that are used in the quality
improvement, health services and public health fields. Finally, chapter seven lays out plans
for future work that stems from both the content and the methodology used in this
dissertation.
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Chapter 2

Literature Review and Glossary of Terms
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This chapter introduces the CRT design and the ethical questions that arise from its
methodological features. First, the features of the CRT design will be explained. Basic
statistical issues, the uses of the CRT design, and CRT typology will be reviewed. Second,
a conceptual framework for the evaluation of ethics challenges in human subjects research
will be described. Third, this conceptual framework will be used to guide a comprehensive
review of the literature outlining the ethical problems relating to CRTs

Introduction: Cluster Randomized Trials
What is a Cluster Randomized Trial?
A cluster randomized trial (CRT) is an experiment in which groups of individuals
(clusters) are randomly assigned to different intervention arms, so that the same
intervention is delivered to the entire cluster1. The efficacy of the experimental intervention
may be evaluated using data from several sources. Data may be obtained from all cluster
members or from a sample of the cluster membership. Cluster-level data may also be
obtained from other sources, such as administrative databases.
CRTs are becoming an increasingly important methodological tool in a variety of
fields, including public health, education, health services research, and for the evaluation of
quality improvement and knowledge translation interventions in healthcare.
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What are the methodological differences between CRTs and RCTs?

Randomization of Groups Instead of Individuals
In an individual randomized, controlled trial (RCT), individual subjects are randomly
assigned to one trial arm or another. The hallmark feature of the CRT is that, rather than
randomly assigning individual research subjects to study arms, groups of individuals are
randomly assigned to different study arms.
It is important at this point to distinguish between the cluster—the actual group of
individuals under study --andthe unit of randomization—the entity that is actually
randomly assigned. In many CRTs, the cluster and the unit of randomization are the same.
This happens most often when the cluster is an intact social unit, such as a community,
family or sports team. Alternatively, the unit of randomization can be an entity that is
distinct from the cluster, but whose association with the cluster results in randomization of
the entire cluster. For example, in a primary care CRT, a clinic may be the the unit of
randomization, creating clusters comprised of that clinic’s patients.

Correlation of outcomes between cluster members
Cluster members’ responses to the experimental intervention are often correlated
with one another. In other words, the effect of the intervention may vary between clusters
for reasons unrelated to the efficacy of the intervention, but related instead to common
characteristics of cluster members. Depending on the type of cluster and the type of
intervention under study, responses between cluster members may be correlated for several
reasons:
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•

Cluster members may share similar environments, such as in CRTs of public
health interventions in which all members of the same community receive a
cluster-level intervention;

•

Cluster members may have genetic similarities, such as when families or
isolated communities are used as clusters in a CRT.

•

Individuals with particular traits that are relevant to treatment response may
self-select cluster membership because of a particular cluster characteristic. For
example, older patients may choose a physician with a reputation for being
skilled in geriatric medicine.

•

Personal interactions between cluster members that result in sharing of
information about experimental interventions may create a clustering effect.
Similarly, personal interactions between cluster members may lead to rapid
spread of communicable diseases1.

Increased sample size, decreased precision
The correlation in responses between cluster members violates an assumption of
standard statistical tests that observations on different subjects are independent.
Accordingly, sample size calculations and hypothesis tests must be adjusted to account for
the correlation between cluster members. The degree of within-cluster correlation may be
quantified using the intra-cluster correlation coefficient (ICC, ρ). One interpretation of the
ICC is simply the pairwise Pearson correlation between any two members of the same
group or cluster1. An ICC of 0 indicates that there is no within-cluster correlation of
subjects’ responses to an experimental intervention, while an ICC of 1 indicates perfect

14

correlation. In practice, the ICC may be estimated based on existing literature, or measured
empirically in a pilot sample.
Formulae for sample size and hypothesis tests must be adjusted to account for the
within-cluster correlation. To account for clustering effects, the estimate of the required
number of individuals in each trial arm should be multiplied by a variance inflation factor,
[1+(m-1)ρ], where m is the number of individuals in each cluster, and ρ is the ICC. This
gives a sample size that accounts for within-cluster correlation1. Because of these
adjustments, CRTs generally require larger sample sizes than do individually-randomized
trials to achieve the same degree of precision.
Hypothesis testing involving procedures such as the t-test or chi-squared test, as well
as formulae for confidence interval estimation, must be similarly adjusted. These
adjustments result in larger p-values for hypothesis tests, and wider confidence intervals
around the estimated effect sizes1. A common approach to adjusting for within-cluster
correlation in the analysis of CRT data is to add a random effect term to a multivariable
regression model so that standard errors are adjusted for within-cluster variation. It is also
possible to conduct analyses of summary measures of outcomes at the cluster-level, thereby
avoiding the need to adjust for within-cluster correlation.
As a result of the need for larger sample sizes, CRTs often impose greater
administrative and financial burdens on study investigators and sponsors. For this reason,
the selection of the CRT design for a study must have a very good rationale.
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Why is a CRT used?
Given the statistical and logistical disadvantages of the CRT design, the use of the
CRT must be justified by some other methodological advantage. There are several reasons
for choosing the CRT design. For some studies, there may be multiple reasons for choosing
the CRT design.

The CRT Evaluates Group-level Interventions
CRTs are often used to evaluate interventions that are designed to affect the entire
group. For example the COMMIT study compared the efficacy of different public
education and media strategies aimed at increasing smoking cessation in participating
communities2. These interventions are administered to the entire community, and therefore
the community was used as the unit of randomization.
This same justification for cluster randomization may apply to some CRTs in
healthcare, particularly to CRTs evaluating knowledge translation (KT) or health service
interventions. KT CRTs evaluate training or educational interventions for health
professionals that are intended to improve patient care. Outcomes of interest may include
health professional behaviours as well as patient-level outcomes. For example, one CRT
evaluated the efficacy of different educational strategies for physicians designed to
improve evidence-based prescribing for patients with diabetes and cardiovascular disease3.
The outcomes evaluated included physicians’ perceptions of the efficacy of the
intervention, as well as objective changes in prescribing practices as ascertained from
patients’ prescription data accessed from a national pharmacy database. CRTs are used to
evaluate changes in health service provision or changes to healthcare systems, as these
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interventions are conducted only at the cluster level. For example, a CRT evaluating a
modification to patients’ electronic medical record to issue prescribing reminders for
patients with diabetes4 is most easily implemented at the practice level. For this reason, a
CRT design was chosen with the medical practice being the unit of randomization.

Avoidance of Treatment Contamination and Maximizing Adherence
The CRT design may be chosen in order to avoid treatment contamination. Treatment
contamination refers to a phenomenon observed in individually randomized trials in which
subjects assigned to one arm may share elements of their intervention with subjects in
another trial arm who are in close proximity1. For example, contamination might be
observed if individuals in the same family are participating in a trial of a dietary
intervention, and are randomly assigned to different arms. It is possible that subjects would
share elements of the different interventions with each other. Treatment contamination
tends to bias the outcome of a trial toward a null result. CRTs are therefore used to evaluate
individual-level interventions that are easily shared by individuals who may be
participating in the same trial1.
CRTs are also used to evaluate interventions directed at healthcare professionals or
organizations in which it would be difficult to apply the intervention to some patients and
not to others1. One example of such a trial evaluated the efficacy of early breastfeeding in
reducing the frequency of postpartum hemorrhage5. The unit of randomization for this trial
was the birth attendant rather than the individual patients, as the birth attendants may have
found it difficult to only advise early breastfeeding to half of their patients.
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Random assignment in clusters may also improve intervention adherence within the
cluster. A CRT evaluating the effect of treated nasal tissues on incidence of respiratory
illness randomized families rather than individuals6. Investigators believed that adherence
to use of the assigned tissue type would be enhanced if entire families were the unit of
randomization rather than individuals within families.

Evaluation of Individual- and Group-level outcomes
The CRT design permits the evaluation of both individual-level outcomes and grouplevel outcomes within the same study1. This is particularly advantageous in CRTs
evaluating vaccine efficacy7. A CRT randomly assigning communities to two different
vaccine programs allows for comparison between the relative efficacy of vaccine programs
for vaccinated persons (an individual-level outcome) as well relative vaccine efficacy at the
community level (a group-level outcome that includes both vaccinated and unvaccinated
individuals)7.

Political, Logistical and Administrative Reasons
The CRT design has sometimes been employed for political reasons, often in
developing countries in which communities were the unit of randomization. Investigators
have encountered situations in which community leaders have refused to allow random
assignment of individuals within communities, and have insisted that all community
members be offered the same intervention. One example is a CRT evaluating the effect of
vitamin A supplementation on child mortality. 450 villages in Indonesia were randomly
assigned to either participate in mass vitamin A supplementation or to serve as control
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communities. Investigators reported that it was “not politically feasible” to randomly assign
individuals within communities to either intervention or control arms8.
The statistical inefficiency of the CRT design may be outweighed by administrative
or logistical factors9. Randomization in clusters may decrease the number of research
personnel required to collect data, and decrease the logistical challenges required for data
collection such as time and travel requirements9. Some subjects, such as patients, may only
be accessible through health professionals or health care organizations, so the use of these
professionals or health care organizations as the unit of randomization may be necessary9.
It may also be easier to access administrative data or private health information in some
circumstances if a health professional or health care organization is used as the unit of
randomization9.
In some CRTs, medical practices were randomized rather than individual patients in
order to assuage the fears of health professionals who were uncomfortable having their
patients randomly assigned to either the intervention or control arms1.

Typologies of CRTs
Two typologies have emerged to describe the variety of interventions that may be
evaluated in the multiple fields that employ the CRT design. The aim of developing a
typology is to be able to easily refer to CRTs or to CRT interventions that share common
features. These two typologies group CRTs and CRT interventions based on the ability of
individual cluster members to either consent or opt out of study interventions.
Edwards and colleagues created a dichotomous typology to describe CRTs10. Clustercluster CRTs are trialsin which experimental interventionsare administered at the cluster
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level and designed to affect all individuals in the cluster. Examples include public health
interventions such as mass media campaigns or water treatments, curricular innovations in
education, or healthcare quality improvement innovations that are implemented at the level
of a hospital or health system. Individual-cluster interventions are CRTs in which
experimental interventions are administered to individual cluster members, primarilyto
avoid experimental contamination, with the intent of producing an individual-level effect.
Examples include individual health interventions evaluated in CRTs that randomize
medical practices in order to avoid contamination.
Eldridge and colleagues expanded Edwards’ classification to four categories: clustercluster, individual-cluster, professional-cluster and external-cluster11. Importantly, Eldridge
et al recognize that a CRT may include both interventions administered at the cluster level
as well as interventions administered to individual cluster members. Therefore, the
Eldridge typology classifies CRT interventions, rather than classifying CRTs as a whole.
Cluster-cluster interventions have a similar meaning for Eldridge et al. as for
Edwards et al. The key feature of a cluster-cluster intervention is that the intervention is
applied at the cluster level, and affects all cluster members. Cluster members cannot avoid
or opt out of a cluster-cluster intervention.
Individual-cluster interventions are also similarly classified in the Eldridge and
Edwards typologies. These interventions are applied to individuals, who have the
opportunity to choose whether or not to participate in the CRT. The CRT is chosen to avoid
experimental contamination in the administration of the experimental intervention.
Professional-cluster interventions are used in CRTs in which the cluster is defined by
its relationship to a professional, such as a teacher or healthcare professional. These are
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typically educational or quality improvement interventions directed at professionals, and
are designed to influence how those professionals serve those for whom they are
responsible. An example is the use of automated reminders of optimal prescribing practices
of antiplatelet medications for diabetic patients in primary care4. Patients do not have the
opportunity to avoid the effects that the experimental intervention may have on their care,
although there may be an opportunity for patients to decline to have their data used11.
External-cluster interventions are primarily used in healthcare CRTs, and refer to
interventions that re-organize health systems by using additional or different healthcare
providers11. Randomization of clusters is done to avoid contamination, or for logistical or
financial reasons. An example of an external-cluster intervention is the use of a nurse
specialist to administer asthma care instead of or in addition to a primary care physician12.
Patients can opt out of studies using external-cluster interventions simply by refusing to
utilize the additional staff11.
These categories may be useful in categorizing interventions that have different
ethical implications, particularly respect to subjects’ ability to choose whether or not to
undergo a particular type of intervention. However, this typology hasa number of problems
that limit its widespread use without further clarification and validation.
First, these categories only refer to the experimental interventions under study in a
CRT. Trials also include interventions used solely to collect data13. In CRTs, these may be
interactions with, or interventions on individual subjects; they may consist of collection of
subjects’ identifiable private information; or they may use administrative data that allows
the evaluation of group-level outcomes. The categories in the Eldridge typology do not take
account of data-collection procedures.

21

Second, while it makes sense to categorize the experimental interventions in a CRT,
rather than categorizing the trials themselves (which may contain different kinds of
interventions), it is easy for users to conflate a typology describing the interventionsas
describing the trials themselves. Therefore, it is important to be clear on the distinction
between a subject’s ability to avoid or opt out of an intervention, and a subject’s ability to
avoid or opt out of a trial.Subjects can only opt out of a trial if they are able to avoid or opt
out of all experimental and data-collection interventions.
Third, Eldridge concedes that users may disagree on the categorization of a particular
intervention, and that there may be overlap between categories11.
Fourth, the typology does not capture all of the interventions in CRTs in which the
cluster is defined by its relationship to a professional such as a healthcare professional or
teacher. These CRTs may have interventions that are directed at those professionals, and
are designed to produce a specific effect on those professionals, such as in increase in
knowledge. These interventions do not necessarily have a measurable cluster-level effect,
and so describing them using the professional-cluster typology seems inappropriate.
Finally, the four-category Eldridge typology for CRT interventions may be reducible
to two categories that resemble Edwards’ classification. Professional-cluster interventions
closely resemble cluster-cluster interventions, in that they are administered at the cluster
level that cannot be avoided by individual cluster members. The fact that a cluster member
may opt out of data collection is a feature of the trial, not of the intervention in question, so
professional-cluster interventions are probably best thought of as a subspecies of clustercluster interventions. External-cluster interventions resemble individual-cluster
interventions, in that individual cluster members can choose not to participate in the trial or
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see the additional staff members. For CRTs of external-cluster interventions, cluster
randomization is undertaken for practical reasons, not because of the nature of the
interventions. It may be reasonable to think of external-cluster interventions as a subspecies
of individual-cluster interventions.
In this dissertation, the preferred terminology will refer to cluster-level interventions
and individual-level interventions. Cluster-level interventions are those that are directed at
the entire cluster, and intended to produce an effect on all cluster members, independent of
their ability to avoid the intervention. These include Eldridge’s cluster-cluster and
professional-cluster interventions. Individual-level interventions are those that are directed
at individual subjects and are intended to produce an effect on that particular subject. These
include Eldridge’s individual-cluster and external-cluster interventions. Interventions
directed at professionals that are designed to produce an effect on those professionals,
without necessarily producing a cluster-level effect, will be considered separately.

A Conceptual Framework for Addressing Ethics Questions in
CRTs
There is a small but growing literature that discusses the ethical issues of the CRT
design. Specifically, commentators have been concerned with the logistical feasibility of
obtaining consent from subjects in large trials9-11,14-16, the potential biasing effect of the
consent negotiations in CRTs of behavioural interventions9,10,15,17, the lack of benefit to
subjects in control groups14,15, and questions about who has the authority to speak on behalf
of a cluster 9,10,18.
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CRTs share many of the characteristics of individually-randomized clinical trials. It
therefore makes sense to appeal to the robust literature on the ethics of clinical trials as a
starting point for a discussion of the ethical questions of CRTs. In some instances,
however, there will be a lack of fit between research ethics guidelines for individuallyrandomized clinical trials and CRTs that randomize groups of individuals. Current research
ethics guidelines and regulations were developed to address ethical challenges in which
subjects are recruited individually, as in a typical RCT. The ethics of CRTs in which a
cluster is the unit of randomization and/or the unit of intervention are less clear.
In instances in which widely-accepted solutions for ethical challenges in individually
randomized trials do not address problems in CRTs, it is helpful to turn to a broadlyaccepted framework for the discussion of ethical issues in human subjects research. This
conceptual framework has been developed over more than forty years of scholarly work.
By using this approach, solutions to ethical problems posed by CRTs can be defended by
appealing to widely accepted ethical principles, and to the moral theories on which these
principles are based.

The Ethics and Regulation of Human Subjects Research
The study of the ethics of research involving human subjects evolved largely in the
second half of the twentieth century19,20. Scholarly work in research ethics occurred in
parallel with the development of regulations governing human research that have been
promulgated by various international bodies and federal governments. Both normative
reflections on human subjects research and regulatory documents generally refer to
research in which subjects are identified and recruited individually, prior to the application
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of research interventions. With a few notable exceptions, CRTs are not specifically
mentioned in most scholarly work and regulatory documents, meaning that the application
of research ethics principles and guidance to CRTs is left to the interpretation of ethicists,
researchers and research ethics boards. Below, we review first the evolution of scholarly
work that lays out the basic principles of the ethics of human subjects research, then review
in detail the key regulatory documents that researchers and research ethics boards may
draw upon while reflecting on the ethical questions posed by CRTs.

Basic Ethical Principles for Human Subjects Research
The most broadly accepted articulation of the basic ethical principles for human
subjects research comes from the Belmont Report, the 1979 Report of the US National
Commission for the Protection of Human Subjects in Biomedical and Behavioral Research
(referred to hereafter as the “National Commission”)21. The Belmont Report outlines three
basic ethical principles that guide the conduct of human subjects research: respect for
persons, beneficence, and justice. The Belmont report also specifies moral rules that stem
from each of these principles21.
The principle of respect for persons is derived from a philosophical heritage that
emphasizes the unconditional worth of all autonomous individuals21-23. Therefore, the
principle of respect for persons requires that the choices of autonomous individuals be
respected, and that individuals with diminished autonomy be protected. The Belmont
Report states that to respect an autonomous individual is to respect that individual’s wishes
with regard to research participation, and to maintain the confidentiality of private
information. Thus, the principle of respect for persons entails moral rules requiring the
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informed consent for research participation from research subjects, as well as requirements
for safeguarding subjects’ private information. The Belmont Report also recognizes that
individuals with diminished autonomy are vulnerable to exploitation. To respect these
individuals requires extending additional protections. These include requirements for
consent from an authorized substitute decision-maker, the requirement for the potential
subjects’ assent for research participation, and limits on the kinds of risks to which an
individual with diminished autonomy may be exposed as a result of research
participation21.
The principle of beneficence encompasses two moral obligations: to refrain from
doing harm, and to maximize possible benefits while minimizing harms. The principle of
beneficence entails moral rules with respect to the analysis of harms and benefits that
particular studies pose to their subjects. Investigators and ethics committees are responsible
for ensuring that the risks and benefits to research subjects stand in reasonable relation21.
The principle of beneficence also applies more broadly to societal benefits that
accrue from scientific research. It is an issue of beneficence as to whether the knowledge
benefits of a scientific research program justify the risks that research poses both to
individual subjects and to our social fabric21.
The principle of justice refers to the fair distribution of the burdens and benefits of
research, and entails moral rules about selection of study populations and subjects. Justice
requires that no individuals or groups of individuals be systematically excluded from
research, thus depriving them of the benefits of research participation, unless that exclusion
can be justified on scientific grounds. This requirement is particularly relevant to groups
such as women and children, who might stand to benefit from research participation, but
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who have historically been unjustifiably excluded from research studies. Justice also
requires that a group not be unfairly burdened with the risks of research participation. This
means that a group should not be used as a population of convenience, as has occurred in
the past with hospitalized individuals, visible minorities, underprivileged persons, and
prisoners21.
More recently, a fourth principle, respect for communities, has been proposed and is
gaining increasing acceptance24. This principle recognizes the value of communities as a
source of personal values and self-understanding, and their importance for the well-being
of community members. Some types of communities legitimately exercise power to make
decisions that are binding on their members. The principle of respect for communities
demands that investigators respect communal values and social structures, and abide by
decisions of legitimate community authorities24.
These basic principles are intended to entail prima facie obligationsthat must be
fulfilled25. Ethical challenges arise when obligations stemming from one principle conflict
with obligations stemming from another. There is no implicit hierarchy of principles:
“Although we begin our discussion of principles of biomedical ethics with respect
for autonomy, our order of presentation does not imply that this principle has
priority over all other principles. A misguided criticism of our account is that the
principle of respect for autonomy overrides all other moral considerations. This we
firmly deny.25”.
It is the task of the research ethics committee to resolve ethical dilemmas resulting from a
conflict between principles. This can be done by a weighing of the competing moral
demands20,22,26, which requires a thoughtful appeal to the moral theories that underpin each
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of the basic principles22. In subsequent chapters, we will apply this approach to a critical
examination of the ethical questions posed by CRTs.

Ethical Guidelines for Human Subjects Research
Guidelines for the ethical conduct of research involving human subjects were
promulgated prior to the systematic articulation of basic ethical principles in the Belmont
Report 27,28. Although early guidelines are not obviously based on the Belmont Report
principles, these guidelines and the Belmont Principles reflect common moral norms25.
The promulgation of the Nuremberg Code marks the effective start of international
efforts to regulate the conduct of human subjects research. The Code comprises a set of
recommendations for the conduct of ethical research that emerged from the trial of Nazi
physicians who conducted medical experiments on non-consenting prisoners during the
Second World War. The experiments in question often caused terrible suffering to subjects,
and frequently had little scientific importance or methodological validity. These
experiments took place in spite of research regulations in German and Russian law that
required the informed consent of research subjects29. The Nuremberg Code’s first
requirement isabsolute: researchers must obtain informed consent from subjects. The
Nuremberg Code also requires that the research be scientifically valid, that unnecessary
suffering should be avoided, that risks be justified by the humanitarian importance of the
research, and that research be stopped if there is risk of death or injury to the subject29.
The Nuremberg Code does not specifically address the broad range of areas of
inquiry and variety of research methodologies in human subjects research. It does not
contemplate such challenges as research on individuals with limited decision-making
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capacity such as children or incapable adults, nor does it recognize that some human
research necessarily involves interventions that may pose serious risks to research subjects.
Taken literally, the Nuremberg requirements would curtail the biomedical research
enterprise.
The World Medical Association has promulgated its own ethical guidelines, which
have become known as the Declaration of Helsinki. Initially published in 1964, and revised
on eight occasions, most recently in 2008, the Declaration of Helsinki has become the most
widely utilized international guideline for the conduct of human subjects research. The
Declaration of Helsinki differs from the Nuremberg Code in that it explicitly allows for
research on subjects with diminished autonomy, even though it pays more attention to the
use of vulnerable or disadvantaged populations in research.
Revisions of the Declaration of Helsinki27, Guidelines from the Council of
International Organizations of Medical Science30,31, and guidelines from the Canadian
Institutes of Health Research, National Science and Engineering Research Council and
Social Sciences and Humanities Research Council32, along with the Australian National
Health and Medical Research Council33 include their own statements of basic principles.
Although each agency’s guidelines articulate basic principles differently, all are clearly
indebted to the authors of the Belmont Report27,30-33. Numerous research ethics guidelines
therefore outline specific moral rules that stem from the basic principles of respect for
persons, beneficence and justice outlined in the Belmont Report.
In 1981, US Department of Health and Human Services issued new human subjects
research regulations in 1981 based on the recommendations of the National Commission. A
subpart of these regulations that includes informed consent requirements and rules for
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Institutional Review Board review are known as the Common Rule because, as of 1991,
they apply to all human subjects research conducted or funded by US Federal
departments34. The Common Rule offers specific guidance as to the procedural
requirements for research ethics review. It also outlines, in great detail, requirements for
informed consent, including a provision for a waiver of consent for certain kinds of
research34. Human subjects research in Canada is governed by the guidelines adopted by
the country’s three major research funding agencies, namely the Tri-Council Policy
Statement: Ethical Conduct of Research Involving Humans32. The Tri-Council Policy lays
out eight basic ethical principles that are largely reducible to the three Belmont Principles.
This framework of ethical principles gives rise to detailed guidance for consent processes,
the assessment of the harms and benefits of research, and the just recruitment and treatment
of research subjects32.

Guidelines for CRTs
Two guidelines address specific ethical problems in CRTs, but neither
comprehensively addresses the breadth of ethical questions that have been encountered in
CRTs.
The 2009 revision of the Council of International Organization of Medical Science
(CIOMS) International Ethical Guidelines for Epidemiological Studies30 clearly derives
from three Belmont Report principles of respect for persons, beneficence, and justice.
CRTs are one of five types of studies for which the CIOMS guidelines state that a waiver
of consent may be permissible: If a CRT is evaluating cluster-level interventions that are
difficult to avoid, then a waiver of consent may be permissible.
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The CIOMS guidelines suggest that even if consent is not possible, that community
residents should still be notified that a CRT is being conducted30. If consent from
individual cluster members is not possible, the CIOMS guidelines require that investigators
identify an entity that has the authority to give permission for the cluster to be enrolled in
the CRT. According to CIOMS, the decision-maker should have the authority to make
decisions to undertake interventions similar to those being evaluated by the CRT. The
decision-maker may also choose to consult the community more broadly prior to agreeing
to CRT participation. The CIOMS guidelines give research ethics committees the latitude
to require that investigators consult with community members prior to commencing a
study, in order to seek the community’s input into the study protocol. The CIOMS
guidelines also contain sections pertaining to research performed on underprivileged
populations that may be applicable to CRTs conducted in developing countries30.
The 2002 UK Medical Research Council’s statement Cluster Randomized Trials:
Methodological and Ethical Concerns18 contains guidance with respect to consent
procedures and the role of cluster decision makers. The MRC guidelines require
investigators to seek consent from individual cluster members whenever possible (i.e. for
CRTs involving individual-level experimental interventions or interventions on individual
cluster members for the purpose of data collection)18. The MRC guidelines also set out
detailed guidelines for the function of individuals who make decisions on behalf of
clusters, referred to in the guidelines as Cluster Representation Mechanisms (CRMs)18.
CRMs must act in the interests of both the cluster and the individual cluster members,
which may be difficult if these interests conflict. The CRM has rights similar to those of an
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individual subject in an individually randomized trial, including the right to withdraw the
cluster from the CRT.
Neither set of guidelines clearly identifies when seeking informed consent is
necessary and when using a waiver of consent is acceptable. They only specify
circumstances in which consent may not be required. Nor do these guidelines detail the
essential elements of disclosure in consent negotiations. Neither the CIOMS nor MRC
guidelines lay out clear rules for the analysis of harms and benefits in CRTs.

Using a conceptual framework for research ethics to address ethics questions in CRTs
This dissertation will employ a conceptual framework rooted in the basic ethical
principles of respect for persons, beneficence, and justice. Ethical questions arising from
the CRT design will be framed in terms of conflicts between obligations that stem from
conflicting principles. Ethical challenges in CRTs will then be addressed by evaluating the
competing moral demands of each conflicting principle. By appealing to the moral theories
on which each principle is founded, and to associated moral concepts articulated in the
research ethics literature, one can hope to identify a justifiable solution to the ethical
problems associated with the CRT design. This work will, in turn, inform the development
of comprehensive research ethics guidance that adequately addresses the breadth of ethical
questions arising in CRTs35.
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Ethical Questions in CRTs
Many of the ethical problems relating to CRT conduct have been identified in the
literature by CRT investigators who have encountered these challenges in practice. This
dissertation contributes to the activities of a working group of experienced CRT
investigators and ethicists, funded by the Canadian Institutes of Health Research. This
working group systematically reviewed the literature on the ethics of CRTs and identified
key ethical questions raised in the literature. Using the conceptual framework outlined
above, the working group identified important ethical issues that had not surfaced in the
CRT literature35,36 as well as questions arising from the conceptual framework for research
ethics. It identified six broad questions that, once addressed, will provide comprehensive
guidance to investigators and research ethics committees:
1)

Who is the research subject in CRTs?

2)

When, from whom, and how must consent be obtained?

3)

Does clinical equipoise apply to CRTs?

4)

How should the risks and potential benefits of CRTs be evaluated?

5)

How ought vulnerable groups be protected in CRTs?

6)

Who are cluster gatekeepers, and what are their responsibilities?

Each of these questions will now be briefly considered.

1)

Who is the research subject in CRTs?
A key ethical problem in CRTs is the identification of research subjects36. In typical

RCTs it is generally obvious who the research subjectis. The subject is any individual who
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is recruited, enrolled, and intervened upon. In CRTs it may be unclear who the research
subjectsare. CRTs often target groups of individuals, but it is not obvious that all group
members who may be affected by CRT interventions are, in fact, research subjects. For
example, a CRT may randomly assign communities to different mass media campaigns
aimed at increasing residents’ participation in physical activity37. Although there are no
direct interventions on the community residents, they may still be research subjects. What
if a resident is not exposed to the campaign? What about individuals who may be visiting
that community? What about residents of control communities that do not receive any
intervention?
Some CRTs may intervene upon professionals (e.g., physicians or teachers) and
evaluate the effect of the intervention using data from the individuals that the professionals
serve (e.g. patients or students). It is unclear whether the research subjects arethe
professionals who are intervened upon, the individuals that they serve, or both9,38-40. In one
example, a trial randomized primary care clinics to different continuing education
strategies, and evaluated the effect of the education strategies on prescription patterns by
abstracting data from patients’ prescriptions41. Are the patients research subjects? How
about the health professionals who are the recipients of the study interventions?
There are two important reasons to examine the question of who the research subject
is in CRTs. First, failure to correctly identify who is and who is not a research subject in
CRTs may result in the failure to adequately protect some research subjects or may,
conversely, lead to overzealous protection of individuals who are not research subjects,
leading to the hindrance of important research. Second, research subjects in CRTs must be
identified before other ethical challenges, such as consent issues or the analysis of harms
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and benefits, may be considered either as a normative question or as a pragmatic issue for
investigators and research ethics boards.
Both the MRC ethics guidelines for CRTs18 and the CIOMS guidelines for
epidemiologicresearch 30 assume that cluster members will necessarily be subjects, without
providing any justification. The issue of whether or not professionals who are the recipients
of educational or quality improvement interventions in CRTs are research subjects has been
addressed in two papers in the research ethics literature; both concluded that health
professionals are research subjects39,40. Several other papers offer diverging views on
whether consent is required from health professionals, without explicitly considering
whether or not the professional is, in fact, a research subject. Some authors argue that
consent should be sought from health professionals9,38, while others argue that consent
requirements should be waived42.
Only one paper has explicitly considered whether the patients of health professionals
participating in a CRT need to be considered research subjects39. The paper concluded that
patients of a health care provider whose care may be indirectly affected as a result of
interventions on the provider are research subjects. However, no argument is offered in
support of this conclusion39. Further normative work is required to examine arguments that
may support or refute these conclusions. The question of who is a research subject will be
addressed in detail in Chapter Five of this dissertation.

2)

When must consent be obtained in CRTs?
The bulk of the literature on the ethical challenges of CRTs focuses on issues around

obtaining informed consent from research subjects1,9-11,14-16,42. Ethical problems relating to
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informed consent in CRTs can be grouped into four broad categories. Each of the issues
described below will be addressed in more detail in Chapter Six of this dissertation.

2.1) Feasibility of obtaining informed consent in CRTs
CRTs have become the gold standard methodological technique for evaluating the
efficacy of public health interventions applied to groups such as neighborhoods,
communities or larger social-political entities. Assuming that citizens of communities
participating in public health CRTs are research subjects (something that is not a foregone
conclusion), the logistical effort and expense that would be required to obtain consent for
research participation from all subjects would make many large community-based CRTs
unfeasible1,9,10,14,15,18,39,40. Some research ethics guidelines include rules for waiving the
requirement for obtaining informed consent if this is not feasible18,27,30,32,34. However, there
has been no principled examination of the moral justification for the use of a waiver of
consent. Identifying a justification for the use of a waiver of consent will be helpful in
developing clear guidelines that specify when the use of a waiver of consent is permissible
for CRTs.

2.2) Threats to internal validity due to consent requirements
CRTs are often used to evaluate interventions designed to modify the behaviour of
the research subjects. Several commentators have suggested when information is disclosed
to subjects during consent negotiations about the study’s purpose and interventions, this
may be sufficient to prompt a behavioural change among subjects10,15,17,42. This unintended
behavioural change effect may be sufficient to threaten the validity of effect estimates.
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Some have argued that the potential for bias in CRTs of behavioural interventions is
sufficient to justify either a waiver of consent for some CRTs, or an alteration of the
information that is disclosed to potential subjects during consent negotiations10,15. A
principled moral justification for waiving consent requirements because of potential threats
to validity from disclosure in consent negotiations has yet to be articulated in the CRT
literature.
One strategy for minimizing bias and for increasing sample sizes has been to use a
passive consent, or “opt-out” model for subject enrollment. This has been used frequently
in education43 and health services research44-46. Subjects are assumed to be agreeable to
CRT participation unless they (or their substitute decision-maker) explicitly opt out.
Although national and international ethics guidelines allow for waivers or alterations of
consent requirements in specific circumstances, none discuss the use of an opt-out consent
model18,27,30-34. Furthermore, there has been no substantive normative work that examines
whether or not an opt-out consent model is sufficiently respectful of subjects’ autonomy so
as to be a reasonable substitute for seeking informed consent.

2.3) Timing and Meaning of informed consent in CRTs
In typical RCTs, subjects give consent for trial participation at the time of enrolment.
This consent includes consent to random assignment, to receive the study intervention, and
to undergo any interventions necessary to gather data. In many CRTs, investigators may
not be able to seek subjects’ consent for random assignment or for the experimental
interventions11,42. Whether obtaining consent for CRT participation is possible prior to
randomization depends, in large part, on the type of cluster and unit of randomization47. It
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may be possible to enroll a cluster and obtain consent prior to randomization if the cluster
is small and all members are easily accessible, such as in a family. If clusters are large, or if
cluster members are not identifiable at the outset of a trial, obtaining consent after
randomization is the only option47.
If random assignment of clusters is done before subjects are enrolled, then consent
for random assignment is not possible. It is also unclear what information must be
disclosed to subjects who are enrolled in a CRT after random assignment of clusters. Some
commentators have expressed concern that obtaining consent after randomization of
clusters violates subjects’ autonomy rights14,15,42.
The experimental intervention may be a cluster-level intervention that individual
subjects may not be able to avoid. In these cases, refusal would be meaningless11,42. Some
cluster-level interventions which are unavoidable may be eligible for a waiver of consent,
but consent for some data-collection interventions may still be required. Some of the
conceptual work in this dissertation will examine whether the pragmatic challenges relating
to obtaining informed consent in CRTs can be reconciled with investigators’ obligations to
respect subjects’ autonomy.

2.4) Can professional obligations mandate CRT participation?
Many professionals must engage in continuing education in order to maintain their
licensure. Similarly, organizations such as hospitals or school boards may undertake
quality improvement initiatives. Continuing education and quality improvement programs
may be evaluated using CRTs. Can a professional obligation to partake in continuing
education entail an obligation to participate in a CRT evaluating a continuing education
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program? Can organizations that choose to participate in a quality improvement CRT
mandate participation by their employees? Commentators42 have offered several arguments
as to why professional obligations should necessarily entail CRT participation by
professionals. These arguments will be examined in Chapter Six.

3)

Does clinical equipoise apply to CRTs?
In individually-randomized medical clinical trials, the random assignment of patient-

subjects to trial arms is justified by the concept of clinical equipoise. Clincal equipoise
refers to a state of honest professional disagreement in a community of experts as to the
preferred treatment. If such a state exists, then subjects are not disadvantaged by random
assignment to one arm or another. The RCT must be designed to disturb this state of
clinical equipoise, and thus change practice48.
Although equipoise is pointed to in the CRT literature as a moral requirement14, it is
not obvious whether the traditional conception of clinical equipoise is easily applied to
CRTs49. Clinical equipoise in typical RCTs is grounded in the fiduciary duties that
physicians owe their patients; a physician is only justified in recommending enrolment in
an RCT to her patient if clinical equipoise exists48,49. In many CRTs, the researcher-subject
relationship is not analogous to the physician-patient relationship. So, it is not obvious
whether clinical equipoise may be used as a moral justification for random cluster
assignment49.
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4)

How should the risks and potential benefits of CRTs be evaluated?
Neither the literature nor ethics guidelines offer substantive advice on how

investigators and REBs should consider the harms and benefits in a CRT. REBs may be
able to consider the harms and benefits of interventions in a CRT that are directly applied
to individual subjects using the same criteria as those used in individually-randomized
clinical trials13. The principle of beneficence requires that investigators maximize benefits
to research subjects, while minimizing harms. Investigators and ethics committees are thus
charged with ensuring that the risks posed to subjects in CRTs are reasonable in relation to
the potential benefits.
A widely accepted approach, called component analysis, provides a systematic
framework for the assessment of harms and benefits in human subjects research13.
Component analysis first divides study interventions into two categories. Therapeutic
interventions are typically the interventions being evaluated in a clinical research study.
They offer the prospect of direct benefit to subjects. In a clinical trial, therapeutic
procedures must satisfy the conditions of clinical equipoise, must be consistent with
competent care, and may only pose risks that are justified by the expected therapeutic
benefit. Non-therapeutic interventions are those that are used to collect data, and thus
solely serve a scientific purpose. The risks of non-therapeutic interventions must be
minimized, consistent with sound scientific design, and must stand in reasonable relation to
the knowledge that is expected to be gained from these interventions13.
Component analysis may be applied to CRTs in which the study interventions are
directed at individual subjects. It is not obvious whether component analysis can be applied
as easily to CRTs that evaluate cluster-level interventions36. It remains an open question
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whether public health interventions administered at the cluster level can be considered in
the same way as therapeutic interventions that are administered to individual subjects. It is
also unclear how to evaluate the harms and potential benefits of complex interventions that
are designed to modify professional behaviour such as in healthcare knowledge translation
or quality improvement studies36.

5)

How ought vulnerable groups be protected in CRTs?
The principle of justice entails moral rules for subject selection, requiring that no

individuals or groups be inappropriately excluded from research while also ensuring that
vulnerable groups or individuals are not exploited as a population of convenience21. CRTs
using vulnerable groups such as individuals in developing countries or populations with
low socioeconomic status face similar justice issues to typical RCTs. CRTs must be
responsive to the health needs of the population under study. In other words, the population
under study must be selected because the use of that population is necessary to the
scientific question of the trial, and the study itself must address the needs of that
population27. Other questions of justice that have proven to be challenging for RCTs also
apply to CRTs36. What ethical standards for subject protections ought to apply: local
standards, or the standards of the study sponsor’s country? Should subjects in the control
arm be offered the best proven control intervention, or thebest intervention that is locally
available? What obligations do investigators and study sponsors have to subjects and host
communities after a CRT is completed?
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6)

Who is a gatekeeper, and what are their responsibilities?
There may be ethical, logistical or political reasons for seeking permission to enroll a

group in a CRT. This permission is typically sought from an entity that has been described
in various publications as a decision-maker30, guardian10, gatekeeper15,18, or cluster
representation mechanism18. Requirements to seek permission from a cluster decisionmaker leads to several important questions. Who is empowered to speak on behalf of a
community or group of individuals with respect to CRT enrolment? What is the source of
their authority? What is the scope of their authorization for CRT participation: does it
supplement or obviate the need for consent from individual cluster members? What out to
be done if no legitimate cluster decision-maker can be identified? What criteria ought
cluster decision-makers use to guide their decisions whether or not to enroll a cluster in a
CRT?
Many communities, whether geographic, cultural, religious or otherwise, have
legitimate political representatives who are empowered to protect the collective interests of
that community24. Examples of such individuals may include a mayor or tribal leader. The
status of other groups that may be recruited as clusters in CRTs, including hospitals,
schools, sports teams, workplaces, and many others, is less clear. Some of these groups
may even have clear leaders, such as a hospital CEO or the coach of a sports team. The
diversity of groups that may be involved in CRTs leads to difficulties defining the scope of
a gatekeeper’s authority, and the criteria they ought to use when deciding whether or not
the cluster they lead should participate in a CRT.
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Summary
Current research ethics guidance does not comprehensively address the numerous
ethical challenges that arise from the CRT design. A systematic enumeration of these
ethical questions and a plan to address each key ethical problem is necessary in order to
provide investigators and research ethics committees with guidance as to how to conduct
important research while simultaneously safeguarding the interests of research subjects.
This dissertation will contribute to the systematic evaluation of ethics challenges in
CRTs. This literature review enabled an enumeration of the key ethical questions stemming
from the CRT design. This review also provided a summary of a robust conceptual
framework for the ethics of human subjects research. This framework will be used to
critically reflect on the findings of the empirical evaluation of ethics practices in CRTs
described in the following two chapters. This framework will also form the basis of
normative analysis of the questions “Who is a research subject?” and “When is consent
required in CRTs?” in chapters five and six.
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Glossary of terms
Bias: The distortion of a measure of association between an exposure or intervention and
an outcome due to some sort of systematic error. Subtypes include (but are not limited to)
information bias, such as measurement error, or selection bias, which is a systematic
problem with subject recruitment that influences study findings50.

Clinical Equipoise: The ethical justification for random assignment in a clinical trial.
Clinical equipoise exists if there is “state of honest, professional disagreement in the
community of expert practitioners as to the preferred treatment.48” If clinical equipoise
exists, then subjects are not disadvantaged by random assignment to one trial arm or
another.

Cluster: In a CRT, a cluster is a group of individuals with common features. The cluster
may be the unit of randomization, unit of intervention, unit of analysis, unit of inference, or
any combination of the above.

Contamination: A source of bias that results from subjects in one trial arm having access to
the interventions delivered in another trial arm.

Knowledge Translation: Activities or processes that facilitate the transfer of high-quality
evidence from research into effective changes in health policy and clinical practice51. May
include such activities as practitioner education or processes of care such as electronic
reminders of best practices.
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Quality Improvement: Interventions that arelinked to assessment and that have thegoal of
improving the process, outcome,and efficiency of complex systemsof health care52. These
most often are intended to result in local improvements in quality of healthcare delivery,
and are not necessarily generalizable to other settings.
Randomization/Random Assignment: The random assignment of individual subjects (in an
RCT) or clusters into different arms of a clinical trial. This ensures that the features of
subjects that may influence the study’s findings are similarly distributed in each trial arm.

Research: A systematic investigation designed to develop or contribute to generalizable
knowledge34.

Risk: The probability and magnitude of harm posed to a research subject by a research
intervention

Unit of Randomization: The entity that undergoes randomization to create trial arms. In a
CRT, this may be the cluster itself (e.g. a community), or it may be an individual with an
affiliation with a cluster that enables randomization of the cluster (e.g. a physician whose
practice defines the cluster).

Unit of Intervention: The entity that undergoes the experimental intervention. In a CRT,
this may be the cluster itself (e.g. a community), or individuals within the cluster.
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Unit of Analysis: The entity to which statistical inferences are imposed. Depending on the
scientific question of a CRT, this may be the individual cluster member, the cluster as a
group, or both.
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Chapter 3

Factors Associated with Reporting of Patient Consent in Healthcare Cluster
Randomized Trials
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Introduction
Cluster Randomized Trials (CRTs) have become an important research tool in
evaluating the effectiveness of interventions designed to improve the quality or
efficiency of health care services. CRTs may evaluate several kinds of healthcare
interventions. They may evaluate the effect of a therapeutic intervention that is
directed at individual subjects, and randomly assign subjects to trial arms in groups
in order to avoid experimental contamination within groups1. Alternatively, some
CRTs randomly assign healthcare professionals or organizations to trial arms in
order to evaluate the effect of an intervention on the professional or healthcare
organization. These trials may evaluate patient outcomes as well as professional or
organization-level outcomes.
The CRT design poses several unique challenges with respect to obtaining
informed consent from study subjects. In studies with large clusters, such as
communities, it may be logistically very difficult to obtain consent from all cluster
members1,2. Some studies may include several types of subjects who receive
different interventions in the same study. For example, in CRTs of educational
interventions administered to health professionals, the professionals themselves are
subjects and, in certain circumstances, their patients may be subjects as well3-5. In
some studies, subject recruitment occurs after clusters have been randomly assigned
to trial arms. Therefore, it is only possible to obtain consent for trial participation
post-randomization. Some commentators have expressed concern that this may
infringe on subjects’ autonomy rights1,2. Some methodologists have also expressed
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concern that the information disclosed during the consent process may bias the
findings of CRTs of behavioural interventions6,7.
It has been postulated1-3 and observed empirically8 that consent practices in
healthcare CRTs may vary depending on the kinds of interventions under study.
Consent requirements for CRTs have been noted to vary between jurisdictions and
ethics committees9,10, and over time10. Uncertainty over whether some CRTs
constitute research or quality improvement (QI)11,12 may have also led to variability
in consent practices in CRTs that evaluate healthcare QI interventions.
This study has two objectives. 1) To estimate the frequency of reporting of
informed consent from patients in healthcare CRTs; 2) To determine whether
reporting of informed consent from patients in healthcare CRTs is associated with
particular methodological features of a CRT or with secular features such as
country of study conduct or the quality of journal in which a trial is published.
Multivariable regression modelling was used to test for the presence of independent
association between reporting of informed consent and these features of healthcare
CRTs.

Methods
This study was conducted in the context of a larger project, funded by the
Canadian Institutes of Health Research. This larger project is using multiple
methods to examine ethical challenges posed by CRTs, with the ultimate goal of
developing consensus-based international ethics guidelines for the conduct of
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CRTs. One of the components of this project was to examine reporting of various
ethical issues in published CRTs in health research. The search strategy described
below was used to identify a sample of 300 published CRTs in health research.
However, this thesis focuses solely on the reporting of obtaining informed consent
from patients in CRTs that randomize health care providers or organizations.
Sample
A highly sensitive electronic search strategy (sensitivity 90.1%, precision
18.4%)13 was implemented in Medline to identify reports of CRTs published
between 2000 and 2008. This search strategy identified 27149 study reports that
may have been cluster randomized trials. These were sorted in random order, and
screened serially until a sample of 300 CRTs was reached. The following inclusion
and exclusion criteria were applied to define the population of candidate CRTs for
the larger study:
Inclusion criteria
(i) Random allocation by cluster;
(ii) English language;
(iii) Year of publication 2000 to 2008;
(iv) Outcomes of interest pertain to individual or population health;
(v) At least some outcomes observed on (or aggregated from) individuals
within clusters.
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Exclusion criteria
(i) Quasi-randomized design;
(ii) Further random or non-random allocation of individuals within clusters;
(iii) Use of standardized patients only;
(iv) Pilot or feasibility studies;
(v) Trial protocols or methods papers;
(vi) Obvious secondary analyses of trials with main results published
elsewhere;
(vii) Short communications, conference proceedings, letters to editor;
(viii) Studies randomizing households, or dyads of different individuals (e.g.,
patient-caregiver, parent-child);
The sample for this thesis is a subset of the sample of 300 CRT reports
conducted in primary care and hospital settings. Therefore, an additional inclusion
criterion was applied to identify this sub-sample:
(i)

CRTs in which the unit of randomization or unit of

intervention was a healthcare provider, teams of healthcare providers or
healthcare organization (e.g., primary care practice or group of practices,
hospital or hospital wards, nursing home), or CRTs which were conducted
in a healthcare organization. Two authors (MT and CB) determined whether
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or not studies met this criterion. Disagreements were resolved with input
from a third author (AM).
It was estimated a priori that studies in primary and hospital care would
comprise approximately half of the sample of 300 CRTs identified for the larger
CIHR-funded study. A previous review of primary care CRTs published from 19972000 demonstrated a frequency of patient consent reporting of 39%8. CRT
investigators perceive that consent requirements have become more stringent in
recent years10. Therefore, for the purposes of sample size calculations, we will
postulate a frequency of consent reporting of 50% in our sample of CRTs. A sample
size of 150 trials is sufficient to give a 95% two-sided confidence interval extending
± 8% from an observed proportion of 50%. If, as Eldridge observed8, the
frequency of consent reporting is less than 50%, this conservative sample size
estimate will provide greater precision around a smaller proportion. 150 trials with
a postulated prevalence of 50% for the reporting of patient consent will also be
sufficient to allow a multivariable logistic regression model to include
approximately seven predictor variables, according to a widely used rule of
thumb14.
Data Abstraction
The 65-item abstraction form (Appendix A) includes items on the
characteristics of the study design, study interventions, outcomes collected, consent
procedures at the patient, health professional and cluster levels, and details of the
ethics review process. Questions regarding the methodological features of the CRTs
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were drafted and revised based on input from members of the study team with
methodological expertise. Questions regarding ethical issues were drafted and
revised based on input from study team members with research ethics expertise.
The abstraction form was then pilot tested on a sample of 25 healthcare CRTs. This
sample of 25 studies was also used for calibration of data abstraction by 4
reviewers. Afterward, data was abstracted from each study report by a pair of
reviewers, working independently. Disagreements were resolved by consensus.
Statistical Analysis
All analyses were performed using SAS, version 9.2 (SAS Institute, Cary,
NC). Bivariable associations between the dependent and independent variable were
evaluated using Pearson’s χ2, with Fisher’s exact test used if the expected
frequency of events was small. Multivariable logistic regression modeling was used
to generate adjusted odds ratios for the relationships between the dependent
variable and each independent variable.
Specification of Variables
Dependent Variable
Reporting of informed consent from individual patients.
Whether or not investigators reported obtaining informed consent from
patients was coded as a binary variable. The reference level, “no”, was recorded if
the study explicitly stated that consent from individuals was not obtained, if the
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study reported that a waiver of informed consent was used, or if the study did not
report obtaining informed consent from individual patients. The variable was coded
“yes” if articles explicitly state that consent was obtained from individual patients.
The purpose of this dichotomization was to model actual consent practice. It was
assumed that if informed consent from patients was not reported that it was not
sought.
Independent variables
Twelve candidate independent variables relating to trial methodology were
specified a priori by co-investigators on the CIHR project. Four authors (AM, AD,
CW, MT) discussed the candidate independent variables, and came to a consensus
that date of publication, country of study conduct, journal impact factor, unit of
randomization, reporting of a study as quality improvement, type of experimental
interventions, type of data collection interventions, and average cluster size would
be included in the regression model.
Five candidate variables which were initially put forward were not entered as
candidate predictors: total sample size, trial type (individual- vs. cluster-level
interventions), unit of randomization, unit of inference, and type of outcome
observed.
The trial sample size was considered less likely to be predictive of consent
practices than average cluster size. Large individually-randomized RCTs obtain
informed consent from all participants. However, obtaining informed consent may
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be logistically more challenging in CRTs that randomize large clusters, such as
communities15.
The trial type (either cluster-cluster or individual-cluster, according to the
typology proposed by Edwards et al.6 was considered likely to be correlated with
the type of experimental intervention and type of data collection intervention
variables.
The unit of randomization was difficult to dichotomize into a conceptually
meaningful binary variable with an easily interpretable odds ratio because of the
heterogeneity of units of randomization (health care providers, institutions,
communities, blocks of time).
The unit of inference (patient-level vs. cluster-level) was considered likely to
be correlated with the unit of randomization and the two variables describing trial
interventions.
The type of outcome observed (patient-level health outcomes vs. professionallevel outcomes, process measures or economic outcomes) was considered likely to
be correlated with the data collection intervention variable.
The seven variables chosen for the bivariable and multivariable regression
analyses are specified as follows:
Date of Publication
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Date of publication was recorded as a binary variable comparing the periods
of 2000-2004 and 2005-2008. This dichotomization point is approximately two
years following the November 2002 publication of the UK Medical Research
Council’s guidelines for the conduct of CRTs16, which also addresses the issue of
informed consent. Studies whose consent practices may have been influenced by
the promulgation of these guidelines would likely have been published in 2005 or
later. We hypothesize that, because of the influence of the MRC guidelines and
because of trends toward more restrictive research ethics review of CRTs observed
by CRT researchers10, studies published in 2005 or later will be more likely to
obtain informed consent from individual cluster members.
Country of Study Conduct
The variable country of study conduct grouped CRTs conducted in the United
States and Canada as the alternate level, and CRTs conducted elsewhere as the
reference level. We chose to dichotomize this variable in this way because research
regulations in the US and Canada share many similarities, and evolved historically
at different times and under different influences than ethics guidelines elsewhere.
The practices of research ethics committees in the US and Canada are similar, but
may differ from those elsewhere in the world.
Journal Impact Factor
We hypothesized that studies published in lower quality journals would be
less likely to report obtaining patient consent. An empirical logit plot identified the
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appearance of a discontinuity in the relationship between reporting of patient
consent and journal impact factor occurring around the first quartile. It appeared
that journals in the lower one quarter of impact factor were less likely to report
obtaining patient consent, with journals in the upper three quartiles having a higher
but roughly similar probability of reporting consent. Therefore, journal impact
factor was dichotomized into a binary variable at the second quartile (2.219). The
alternate value for the variable includes studies published in a journal with an
impact factor less than 2.219. The reference value includes studies published in
journals with an impact factor greater than or equal to 2.219. There were a small
number of studies that had missing data for journal impact factor. The decision to
dichotomize this variable allowed us to estimate a plausible value for impact factor
either above or below the second quartile, thus avoiding their exclusion from the
multivariable logistic regression analyses.
Quality Improvement
This variable will identify CRTs that are self-described as a trial of a
healthcare quality improvement (QI) intervention. The reference level included
CRTs that are not identified as QI, while the alternative level of the variable
included reports of CRTs that specifically describe the study as an evaluation of a
QI intervention. Informed consent from patients for healthcare QI activities is
generally not required11,17. We hypothesized that studies that are identified as QI
evaluations will be less likely to report informed consent from individual patients.
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Type of Experimental Intervention
Interventions targeted at individual patients, such as medical treatments,
typically require informed consent and are distinct from interventions directed at
the cluster-level which may have indirect effects on individual patients, such as
educational interventions for health professionals or health system QI initiatives3.
The reference level for this variable included studies which have only cluster-level
experimental interventions and no patient-level experimental interventions. The
alternate level included studies that have any patient-level experimental
interventions. We hypothesized that studies that include patient-level experimental
interventions will be more likely to report obtaining informed consent from
patients.
Type of Data Collection interventions
The reference level for this variable included studies that do not employ any
intervention upon or interaction with patients for data collection purposes, and use
only routinely available data such as administrative or medical records. The
alternate level included studies that do use direct interventions on patients, such as
additional examinations or medical tests, or interactions such as surveys or
interviews, for data collection purposes. The use of administrative data or private
health information does not routinely require the use of informed consent18,19,
although some jurisdictions and ethics committees have required consent for use of
private health information20. We hypothesized that studies in which investigators
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interact with or intervene upon patients for data collection purposes will be more
likely to report obtaining informed consent from patients.
Average Cluster Size
It has been noted that obtaining informed consent from individual cluster
members is logistically difficult in CRTs with large cluster sizes10,15. We therefore
hypothesized that CRTs with larger cluster sizes would be less likely to report
obtaining informed consent from patients. The average cluster size was calculated
by dividing the number of individual patients included in each CRT at the time of
baseline data collection by the number of clusters in the CRT at the time of baseline
data collection. In cases in which the number of clusters at baseline was not
reported, the number of clusters randomized was used. Empirical logit plots with
average cluster size divided into deciles confirmed that the odds of reporting
consent tended to decrease as average cluster size increased. Since there remained a
small number of trials for which cluster size could not be determined, a decision
was made to dichotomize mean cluster size into a binary variable, split at the
median. This decision allowed us to estimate a plausible value for mean cluster size
either above or below the median value for most studies, thus avoiding their
exclusion from the multivariable logistic regression analyses. The reference level
includes studies with an average cluster size less than 29.5, while the alternate level
includes studies with an average cluster size of 29.5 or greater.
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Bivariable Analyses
Bivariable associations between the dependent variable and each independent
variable were examined with contingency tables. Relationships were tested for
statistical significance using Pearson’s χ2 or Fisher’s exact test in the case of small
expected frequencies. Odds ratios with 95% confidence intervals were generated for
the unadjusted associations between the dependent variable and each of the
independent variables.
Logistic Regression Analysis
The adjusted association between the dependent variable (reporting of
individual informed consent) and the independent variables was examined using a
multivariable logistic regression model. The aim of this analysis was to estimate the
association between the dependent variable and all candidate independent variables,
rather than to develop the most parsimonious model. We planned to estimate effect
measures for each independent variable, which we hypothesized a priori based on
conceptual and empirical work to be associated with consent practices. For this
reason, all independent variables with no linear dependencies as revealed by
multicollinearity diagnostics were entered into the model with no stepwise variable
selection procedure. Multicollinearity was evaluated using the VIF and TOL
options in SAS PROC REG.
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Handling of Missing Data
Missing data were observed for the variables Impact Factor and Average
Cluster Size. Both of these variables were coded as binary variables, split at the
median value. Values for missing data were estimated as follows. For studies with
missing impact factor data (n=7), a value, either above or below the median value
for this variable (3.052), was estimated. For studies with missing data on average
cluster size (n=23), the full text of the article was examined for references to the
number of subjects as well as for text that would allow estimation of the number of
clusters. An estimate of the number of subjects and number of clusters was
substituted so that a plausible value of average cluster size either below or above
the median value for this variable (29.5) could be included in the dataset. We could
estimate with reasonable certainty whether the average cluster size for most CRTs
with missing data was either greater or lesser than the median value for this
variable. Studies were excluded if no plausible value for number of subjects or
number of clusters could be estimated (n=7), meaning that 16 studies had estimated
data for the mean cluster size variable. Given that there were only seven remaining
studies with missing data, the additional complexity of multiple imputation was not
considered justified. A sensitivity analysis, to evaluate how estimation of missing
data influenced the results of the analysis, was planned. A regression model was
fitted using all independent variables, but eliminating studies with estimated data.
Odds ratio estimates were compared to those generated by the model fit in the
primary analysis that employed the dataset with estimated values.
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Regression Model Diagnostics
The calibration of the model was evaluated using the Hosmer-Lemeshow test
using ten strata. Calibration refers to the ability of a model to match predicted and
observed event rates across the spread of data.
The discriminative power of the model was evaluated using the c-statistic,
also known as the area under the ROC curve, which measures concordance between
predicted and actual outcomes21-23. The c-statistic denotes the frequency with which
the model can successfully discriminate between pairs of CRT reports, with one
CRT reporting patient consent and one CRT that does not. A value of 0.5 indicates
a discriminative value no better than chance, while a value of 1.0 indicates perfect
discriminative power21-23.
For logistic regression, there is no widely accepted analog to the coefficient of
determination (R2), which is used in linear regression to quantify the proportion of
variation explained by the regression model24-27. Several R2 analogs have been
proposed in the literature. Two in particular make most conceptual and
mathematical sense, and are used here. The first, R2 O , is the squared Pearson
correlation between the observed and predicted values of the dependent
variable24,25. This approach is appealing because it is mathematically equivalent to
the R2 used in linear regression. However, it is not a true measure of the proportion
of variation explained, because R2 in linear regression and R2 O in logistic regression
are based on minimizing two different quantities24. The second, called R2 L , is the
proportional reduction in the value of the -2 log likelihood test between the null and
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complete models. Although this is mathematically different from R2 and R2 O , it has
a more useful interpretation than R2 O as the proportional reduction in prediction
error between the null and complete models24.
Secondary Analyses
A prespecified secondary analysis was performed after dichotomizing country
of study conduct as either a developing country or as developed country (identified
by the International Monetary Fund as an Emerging or Developing Economy28).
The relationship between reporting of consent from individual subject and country
of study conduct (developing vs. developed) was examined in a bivariable analysis,
and using a logistic regression model including the other independent variables
described above.

Results
The final sample of primary care and hospital-based CRTs, selected from a
sample of 300 CRTs published 2000-2008, included 168 studies. Seven studies
were excluded because of missing data for which plausible values could not be
estimated. The analyses described below are based on a sample of 161 studies
(Figure 1).
Of the 161 studies included in the final sample, 86 (53.4%, 95% CI 45.761.1%) reported obtaining informed consent from individual patients. 11 studies
(6.8%) reported using a waiver of informed consent. 64 studies (39.8%) did not
report obtaining informed consent from patients.
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Bivariable Analyses (Table 1).
No significant associations were observed between reporting of informed
consent from patients and the country of study conduct. A significant bivariable
association was observed between the reporting of informed consent from patients
and the journal impact factor, the year of study publication, reporting of the study as
QI, the use of patient-level experimental interventions, the use of patient-level data
collection interventions, and average cluster size.
Studies published in journals in the lower quartile of impact factor were less
likely to report obtaining informed consent from patients. Studies published 20052008 reported obtaining informed consent from individual cluster members more
frequently than did studies published 2000-2004. CRTs reported as evaluating a QI
intervention report obtaining informed consent from individual cluster members
less frequently than non-QI CRTs. Studies evaluating patient-level experimental
interventions reported obtaining informed consent from individual cluster members
more frequently than did studies with only cluster-level experimental interventions.
CRTs employing patient-level data collection interventions reported obtaining
informed consent from individual cluster members more frequently than did studies
that only used examination of medical or administrative data to evaluate outcomes.
Studies with an average cluster size below the median value for this variable (29.5)
reported obtaining informed consent from individual cluster members more
frequently than did studies with a larger average cluster size.
Multivariable Analyses
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There was no statistical evidence of multicollinearity between the independent
variables. Therefore, all candidate independent variables were included in the
logistic regression analysis. Significant adjusted associations were observed
between the dependent variable and journal impact factor, the year of publication,
average cluster size, type of experimental interventions and type of data collection
interventions (Table 2). These independent variables may be considered
independent predictors of reporting of informed consent in healthcare CRTs.
The country of study conduct (North America vs. others), and whether or not
the study evaluated a QI intervention were not associated with reporting of
informed consent from individual subjects after accounting for the other variables
in the model.
Regression Model Diagnostics
The Hosmer-Lemeshow test indicates adequate goodness of fit for the
multivariable model (C2 6.01, DF=8, p=0.645). Thus, the number of CRT reports
that describe obtaining informed consent from individual cluster members is not
significantly different than the number that would be predicted by the model.
The model’s discriminative power is very good, indicated by a c-statistic
value of 0.863.
The pairwise correlation between the observed and predicted reporting of
informed consent from individual cluster members is 0.616. R2 O , the square of the
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correlation, is 0.379. R2 L , the relative reduction in predictive error between the null
and complete model is 0.320.
Effect of Missing Data (Table 3)
Seven studies required estimation of data for the journal impact factor, while
16 had required estimation of data for the average cluster size (2 studies had
estimated data for both variables). A logistic regression model was fitted with all
independent variables after excluding all studies with estimated data (n excluded=
21, n included=140). The adjusted odds ratios were similar to the multivariable
analysis that included all studies, although the adjusted odds ratio for journal impact
factor was no longer statistically significant in this analysis.
Secondary Analyses (Table 4)
12 CRTs in the sample were performed in developing countries. Because of
the relatively small number of studies performed in developing countries, Fisher’s
Exact Test was used for the bivariable analysis, rather than Pearson’s χ2. A
significant association between reporting of informed consent from individual
cluster members and country of study conduct (developing vs. developed) was
identified in a bivariable analysis. CRTs performed in developing countries
reported obtaining informed consent from cluster members less frequently than in
studies performed in developed countries (Unadjusted OR 0.21, 95% CI 0.06-0.79,
p=0.012).
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After adjusting for the other independent variables, the association between
study conduct in developing vs. developed countries and reporting of individual
informed consent remained statistically significant (Adjusted OR 0.20, 95% CI
0.04-0.86, p=0.030). In this adjusted analysis, odds ratios for the other independent
variable did not qualitatively change. However, the odds ratio for the Quality
Improvement variable became statistically significant (Table 4), while the adjusted
odds ratio for journal impact factor only approached statistical significance.

Discussion
Just over 60% of the CRT reports in this sample described the patient consent
procedures used: 86 (53.4%) studies reported seeking patient consent, while 11
(6.8%) reported using a waiver of consent. It is a source of concern that nearly 40%
of studies did not report describe consent procedures. For these studies, it is
unknown whether consent was sought, whether a waiver was used as provided in
research ethics guidelines16,19,29-31, or whether consent was not sought for some
other reason. CRT reporting guidelines32 do not explicitly require reporting of
consent procedures, but this has been suggested in the CRT literature1, and is
required in general research reporting guidelines33. Researchers’ omission of
reporting of consent procedures is a source of concern, as no indication is given in
these CRT reports whether subjects’ interests were adequately protected.
This study has identified independent associations between reporting of
informed consent from patients in healthcare CRTs and the journal impact factor,
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the year of publication, average cluster size and the use of both patient-level
experimental interventions and patient-level data collection interventions. These
features have been previously noted in the CRT and bioethics literature as being
likely to influence consent practices. This study provides empirical evidence to
support these intuitions.
All of the demonstrated associations between the reporting of informed
consent and the independent variables fit our hypotheses. Investigators were more
likely to report obtaining informed consent from patients if the CRT used patientlevel experimental interventions, if the study used patient-level data collection
interventions, and if the study was published in 2005 or later. Investigators were
less likely to report obtaining informed consent from patients if the average cluster
size was large, if the CRT was described as evaluating a QI intervention, or if the
study was published in a lower-quality journal. There is also evidence to suggest
that patient consent is less likely to be reported in CRTs conducted in developing
countries.
The increased likelihood of reporting of informed consent in later years may
be related to a number of factors. The UK Medical Research Council’s
methodological guidelines for CRTs includes ethical guidelines that emphasize that
individual informed consent should be obtained when possible16. These guidelines
were published in 2002 and may have influenced investigators’ practices and ethics
committees’ determinations in more recent years, both in the UK and in other
countries. An ever-growing number of publications on the ethical challenges of
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CRTs may have had similar influence. The association between reporting of patient
consent and date of publication fits with researchers’ anecdotal observations that
consent requirements have become more stringent in recent years10. Increasing
awareness of reporting requirements for informed consent33 may have also
contributed to increased reporting of patient consent in recent years.
Studies with large cluster sizes were less likely to report obtaining informed
consent from patients. In many cases, this is likely related to the logistical difficulty
in obtaining consent from members of large clusters, such as all patients in a
hospital system. The logistical effort required to obtain consent from all patients in
some large CRTs would make some studies infeasible2,15. Current research ethics
guidelines permit a waiver of consent for research posing only minimal risk that
would otherwise not be feasible without the waiver19,29,30. Many healthcare CRTs
meet these criteria and would be eligible for a waiver of informed consent3. This
may account for the finding that studies with large cluster sizes were less likely to
report patient consent.
It has previously been observed that reporting of informed consent from
patients was more likely in CRTs that include patient-level experimental
interventions8. This study confirms that the use of patient-level experimental
interventions is independently associated with the reporting of informed consent
from individual patients.
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Eldridge et al. conducted a review of 199 CRTs conducted in primary care
settings. They developed a four-level typology of the kinds of experimental
interventions used in these CRTs.
• Individual-cluster interventions include such things as
experimental treatments, information provided to patients, or the use
of information on individual patients by health professionals to
customize care. These interventions are targeted primarily at
individual patients, and patients will ordinarily be able to choose
whether or not to participate in the trial. The CRT design was
typically chosen to avoid experimental contamination
• External-cluster interventions refer to the use of additional
staff in patient treatment that would not be available in routine care.
These changes in cluster organization are intended to directly affect
patient care, and patients will ordinarily be able to choose whether or
not to participate in the trial. The CRT design is most often chosen in
trials of external-cluster interventions for logistical reasons, in that it
is easier to assign additional staff to a cluster such as a medical
practice than it is to randomly assign patients from the same practice
to either have or not have access to the additional staff.
• Professional-cluster interventions are interventions that are
directed at the health professionals, such as continuing professional
development activities. They may have an indirect effect on the care
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of individual patients, and patients are not able to avoid or opt out of
the intervention. The CRT design is chosen to avoid contamination,
as it is difficult for professionals to selectively apply new knowledge
to different patients.
• Cluster-Cluster interventions are targeted at the health
professional, cluster organization or cluster population. The CRT
design is chosen as the nature of the intervention is such that it can
only be applied at the cluster level. Individual patients are not able to
avoid or opt out of the intervention8.
Eldridge et al. observed that 31% of trials that included cluster-cluster
interventions (and possibly other interventions) reported obtaining patient consent.
49% of trials with professional-cluster interventions but no cluster-cluster
interventions reported obtaining patient consent. 80% of trials that contained no
cluster-cluster or professional-cluster interventions (meaning that they had only
external-cluster or individual-cluster interventions) reported obtaining patient
consent8.
Although our analytic approach was different from Eldridge et al., our
findings are similar. Our definition of patient-level interventions included those that
Eldridge et al. described as individual-cluster interventions (with the exception of
the provision of individualized patient information to healthcare providers) and
external-cluster interventions. Individual-cluster interventions are interventions
directed at patients. External-cluster interventions represent innovative modes of
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service delivery with unproven efficacy that can be likened to interventions directed
at individual subjects3. We observed that studies that included patient-level
interventions were more likely to report obtaining patient consent. Studies that
included patient-level interventions may have also included cluster-level
interventions. However, our analysis focused on whether or not a study included
any patient-level interventions3,8,16,34.
We also identified an independent association between reporting patient
consent and the use of patient-level interventions to collect data. We defined
patient-level data collection interventions as any procedure administered to patients
specifically to collect data, any interaction between researchers and patients to
collect data, such as surveys or interviews, or the use of identifiable private
information3,35. The use of de-identified or aggregate group data is not sufficient to
make a patient a research subject3, and so is not included in our definition of
patient-level data collection intervention. We observed a strong positive association
between the use of patient-level data collection interventions and the reporting of
informed consent.
Quality improvement interventions are generally targeted at healthcare
systems and practitioners, and rarely employ patient-level experimental
interventions. Generally, informed consent from patients is not required for
healthcare quality improvement activities11,17,36. This study demonstrates that this
notion is reflected in current practice as the reporting of a CRT as QI is inversely
associated with reporting of obtaining informed consent from individual patients,
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when examined in a bivariable analysis. After adjusting for the other independent
variables, the confidence interval crosses the null value, indicating a borderline
association.
Limitations
The primary limitation of this study is that the dependent variable, reporting
of informed consent from individual patients, may not reflect actual consent
practices. It is conceivable that informed consent from patients was obtained, but
not reported, for some studies. However, given that guidelines from the
International Committee of Medical Journal Editors require reporting of informed
consent procedures33, we believe that the reporting of informed consent is a
reasonable surrogate for the actual practice of obtaining consent from patients.
This review examines a sample of studies published between 2000 and 2008,
and is likely representative of all published CRTs within that timeframe. However,
quality improvement studies are frequently unreported in the literature11. Only 24 of
the 161 studies in this sample of published CRTs are explicitly identified as being
studies of quality improvement interventions, and therefore quality improvement
studies may be under-represented in this sample and in the population from which
they were drawn. One possibility for future work would be to repeat the analysis
after including a sample of CRTs taken from the Cochrane Effective Practice and
Organisation of Care Register of Studies37. However, studies in this database may
not conform to standard clinical trial reporting guidelines32,33 and may be missing
data with respect to other variables of interest.
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The number of studies in this sample that were performed in developing
countries was relatively small. For this reason, the confidence interval around the
adjusted odds ratio for whether or not informed consent was reported in trials
conducted in developing vs. developed countries is wide. In spite of the lack of
precision of this estimate, the finding that CRTs performed in developing countries
are less than 20% as likely to report obtaining informed consent compared to CRTs
performed in developed countries is noteworthy.
Some data were missing for the independent variables describing journal
impact factor and mean cluster sizes. Given the dichotomous nature of the
variables, plausible values for each missing data point were easily estimated. To
evaluate the possible effect of this estimation method on the validity of our
conclusions, a multivariable regression model was fitted using only data from
studies with complete data. Excluding seven studies with estimated data for impact
factor resulted in a loss of sufficient power to identify a statistically significant
relationship between consent reporting and impact factor. However, no qualitative
difference was observed for the estimated odds ratios for the other independent
variables in the sensitivity analysis, indicating that are findings are largely robust in
spite of the use of estimated data for two variables.
Conclusions
The methodological features that are independently associated with consent
practices for individual patients in healthcare CRTs in this sample generally reflect
the study features that have been identified in the cluster trial and bioethics
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literature as likely having an influence on consent practices. Researchers’
perceptions of temporal trends toward increased requirement for patient consent in
CRTs have been noted10, and are demonstrated empirically here. The notion that
obtaining consent from individual cluster members may not be feasible in studies
with large clusters2,15 appears to be reflected in current practice, according to this
multivariable analysis. The importance of the type of interventions for consent
practices has been discussed in the literature2,6,7,15 and observed empirically in a
descriptive analysis8. The types of interventions evaluated in CRTs are here shown
empirically to be independently associated with reporting of consent practices.
This paper represents an empirical description of current practices with regard
to obtaining informed consent from patients in healthcare CRTs. Whether or not
current practices are satisfactory in respecting the interests of individual patients
depends on the findings of further normative reflection. Conceptual work is
required to determine under what circumstances patients in healthcare CRTs need
be considered to be research subjects3,38, and then under what circumstances
consent for CRT participation is required34,38. Only then can we reflect on the
empirical findings to determine whether the current practices of researchers and
ethics committees are acceptable. Consideration of these findings, informed by
additional conceptual work that articulates a principled justification for consent
requirements in CRTs, is essential for reinforcing good practices in trial conduct
and ethics review, for remediation of errors in consent practices and ethics review,
and for the development of regulatory guidance for CRTs.
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Figure 1
Selection of studies for systematic review data abstraction
27149 study reports identified by
automated search strategy sorted
with assignment of random
number

300 CRT reports meeting inclusion
criteria from reports randomly
selected by automated selection
procedure
138 CRTs conducted in public
health or community health
168 CRTs conducted in primary care
or hospital settings
7 reports excluded because of
missing data
161 CRT reports in final sample
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Table 1. Bivariable associations between reporting of informed consent from cluster
members and independent variables. N=161
Independent Variable

Reporting of
Informed
consent from
cluster
members
Yes
No

Journal Impact Factor
(binary)
2.2.19+*
73 (59.8%)
<2.219
13 (33.3 %)
Country of Study
Conduct
North America
35 (53.0%)
Other*
51 (53.7%)
Year of Publication
2005-2008
57 (67.9%)
2000-2004*
29 (37.78%)
Quality Improvement
Yes
7 (29.2%)
No*
79 (57.7%)
Patient-level data
collection interventions
Yes
75 (68.2%)
No*
11 (21.6%)
Patient-level
experimental
interventions
Yes
54 (72.0%)
No*
32 (37.2%)
Average cluster size
29.5+
28 (35.9%)
<29.5*
58 (69.9%)
* indicates reference level of binary variable

Odds ratio (95%
CI)

p

49(40.2%)
26 (66.7%)

0.34 (0.16, 0.72)

0.004

31(47.0%)
44 (46.3%)

0.97 (0.52, 1.83)

0.935

27 (32.1%)
48 (62.3%)

3.49 (1.82, 6.69)

<0.001

17 (70.8%)
58 (42.3%)

0.30 (0.12, 0.78)

0.010

35(31.8%)
40 (78.4%)

7.79 (3.58, 16.97)

<0.001

21 (28.0%)
54 (62.8%)

4.34 (2.23, 8.46)

<0.001

51 (64.1%)
24 (30.1%)

0.23 (0.12, 0.44)

<0.001
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Table 2. Adjusted odds ratios between obtaining informed consent from cluster members
and independent variables. N=161.
Independent Variable
Adjusted Odds Ratio (95% CI)
p
Journal Impact Factor
0.35 (0.13, 0.95)
0.040
(2.219+* vs.<2.219)
Country of Study Conduct
0.85 (0.36, 2.04)
0.715
(North America vs.Other*)
Year of Publication
3.95 (1.74, 8.98)
0.001
(2005-2008 vs.2000-2004*)
Quality Improvement
0.33 (0.10, 1.05)
0.060
(Yes vs.No*)
Patient-level Data Collection
4.95 (1.89, 12.97)
<0.001
Interventions (Yes vs.No*)
Patient-level Experimental
2.63 (1.12, 6.18)
0.027
Interventions (Yes vs.No*)
Mean Cluster Size (29.5+
0.25 (0.11, 0.55)
0.001
vs.<29.5*)
* indicates reference level of binary variable
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Table 3. Adjusted odds ratios for obtaining informed consent from cluster members and
independent variables, using only non-estimated data. N=140.
Independent Variable
Adjusted Odds Ratio (95% CI)
p
Journal Impact Factor
0.40 (0.12, 1.38)
0.147
(2.219+* vs.<2.219)
Country of Study Conduct
0.75 (0.27, 2.05)
0.573
(North America vs.Other*)
Year of Publication
5.19 (2.00, 13.42)
<0.001
(2005-2008 vs.2000-2004*)
Quality Improvement
0.41 (0.12,1.43)
0.161
(Yes vs.No*)
Patient-level Data Collection
6.13 (2.11, 17.79)
<0.001
Interventions (Yes vs.No*)
Patient-level Experimental
3.11 (1.18, 8.23)
0.022
Interventions (Yes vs.No*)
Mean Cluster Size (29.5+ vs.
0.24 (0.10, 0.59)
0.002
<29.5*)
* indicates reference level of binary variable
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Table 4. Adjusted odds ratios between obtaining informed consent from cluster members
and independent variables, with country of study conduct comparing developed countries
to developing countries. N=161.
Independent Variable
Adjusted Odds Ratio (95% CI)
p
Journal Impact Factor
0.40 (0.15, 1.04)
0.059
(2.219+* vs.<2.219)
Country of Study Conduct
0.22 (0.05, 0.96)
0.043
(Developing vs. developed*)
Year of Publication
3.98 (1.73, 9.12)
0.001
(2005-2008 vs.2000-2004*)
Quality Improvement
0.28 (0.09, 0.88)
0.030
(Yes vs.No*)
Patient-level Data Collection
4.92(1.86, 13.03)
0.001
Interventions (Yes vs.No*)
Patient-level Experimental
2.63 (1.10, 6.26)
0.029
Interventions (Yes vs.No*)
Mean Cluster Size (29.5+
0.26 (0.12, 0.59)
0.001
vs.<29.5*)
* indicates reference level of binary variable
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Chapter 4

Researchers’ Perceptions of Ethical Challenges of Cluster Randomized Trials:
A Qualitative Analysis
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Introduction
Cluster randomization is a research design commonly used in public health,
educational, social science and health services implementation research1. Cluster
randomized trials (CRTs) are different from conventional randomized controlled
clinical trials (RCTs). RCTs randomly assign individual research participants to
different intervention arms and evaluate the comparative effectiveness of the study
interventions using data collected from each participant. CRTs randomly assign
groups of individuals to different intervention arms. The comparative effectiveness
of the interventions in each arm is evaluated using data collected from individual
cluster members, or from other sources such as administrative databases1.
CRTs pose unique ethical challenges that stem from their methodological
differences compared to conventional randomized trials. It can be difficult to identify
precisely who is the research subject in a CRT, particularly in large communitybased public health CRTs and in CRTs evaluating educational interventions aimed at
health professionals2-4. It is unclear under which circumstances, and from whom,
informed consent is required in large community-based CRTs1,5,6. Some CRTs have
employed “gatekeepers”, individuals who have made decisions regarding CRT
participation on behalf of randomized clusters. There is little clear information as to
how and when these individuals ought to be identified, and what is the scope of their
authority7. There is no authoritative guidance as to how the risks and potential
benefits in CRTs ought to be evaluated by research ethics committees5,7,8.
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The objective of this study was to examine how CRT investigators, in practice,
have addressed the ethical challenges in the CRTs they have conducted. A series of
interviews was conducted with experienced CRT investigators. A qualitative
analysis was then performed: 1) To describe how experienced Cluster Randomized
Trial (CRT) researchers have addressed ethical challenges arising from the CRT
design. 2) To describe CRT researchers’ views on the ethics review process. 3) To
document CRT researchers’ views on the need for comprehensive ethics guidelines
for CRTs.

Methods
A qualitative approach was employed to capture rich data on informants’
experiences and insights9,10. A descriptive analysis approach was chosen11, with the
goal of detailing the experiences and ideas of the informants. This descriptive
approach is used to provide a comprehensive depiction of everyday events11. This is
in contrast to the grounded theory type of analysis, which uses informants’ responses
to develop theories that explain social phenomena, and phenomenology, which seeks
to describe individuals’ lived experiences and perceptions in reaction to social
phenomena 9,11.
Sample Recruitment
Based on the suggestions of the members of a multidisciplinary team
assembled to study the ethical challenges associated with CRTs12, a purposive
sample of potential informants was identified. To be considered eligible, potential
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informants must have been the primary investigator on two or more clusterrandomized trials or have published papers addressing the ethics of clusterrandomized trials.
Initial contact with potential informants was made via e-mail by senior
members of the study team (RB, AD, ME, JG, MZ). The email introduced the study
design and purpose, and inquired about the potential informant’s willingness to
participate. If the potential informant was willing to participate, the interviewer (AM,
CB) arranged a time for the telephone interview A letter of information and a copy of
the interview template was sent by email. At the time of the interview, informants
were notified that the interview would be recorded and transcribed, but that no
identifiable features would be reported. Verbal consent for participation was
obtained, and the interview was conducted.
The target sample size in qualitative research is achieved when data saturation
occurs, that is when no new themes are identified with respect to a particular
question of interest in successive interviews. This typically occurs after 12-20
interviews. After analyzing 20 transcribed interviews, data saturation with respect to
responses around the issue of informed consent in CRTs had been achieved.
Final Sample
Twenty-five potential informants were approached to participate in the study.
Four individuals declined to participate. The interview from one informant was
discarded as the recording was of insufficient quality for transcription and analysis.
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The final sample included 20 experienced cluster trial researchers. There were ten
European informants, six American informants, and four Canadian informants. All
participants had been co-investigators on between two and twenty CRTs.
Data Collection
A semi-structured telephone interview guide was developed (Appendix A) and
pilot tested on colleagues. The interview guide included questions about informants’
experience with CRTs, ethical issues in CRTs, ethical challenges encountered with
particular CRTs and the ethics review process, and questions seeking input on ethics
guidelines for cluster-randomized trials. Two trained interviewers conducted the
interviews. The interview guide was modified in real-time by the interviewers to
allow them to seek clarification from the informants or to probe important issues
raised by the informants. The interview guide was also updated in an iterative
fashion to explore issues that were raised by informants in previous interviews. All
of the interviews were audiotaped, then transcribed verbatim. Transcripts were
reviewed for accuracy by the interviewers.
Data Analysis
Each interview transcript was imported into qualitative data analysis software
(NVivo 8, QSR Inc.). A directed content analysis approach was used, in that
predetermined text analysis categories were used 13. The initial coding template for
response categorization was developed by consensus of the investigators. Each
transcript was reviewed independently by two of the researchers (AM and CB), and
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responses assigned to the appropriate thematic coding categories. New categories
were added in an iterative fashion by each researcher to his or her coding template in
order to accommodate response themes that did not correspond to predetermined
coding themes.
After the initial coding, the researchers met and resolved disagreements in the
emerging coding assignments by consensus. The coding template was then revised to
include additional categories created in the first round of independent analysis, and to
delete unused categories. This template revision also ensured fidelity in a second
round of thematic coding, since both researchers were working from the same
revised template. A second round of thematic coding was performed by the two
researchers, using the new master coding template (Appendix B). Following this, the
researchers met again to resolve discrepancies by consensus.
Ethics Approval
This study was approved by the Ottawa Hospital Research Ethics Board (File
2007191-01H) and the University of Western Ontario Health Sciences Research
Ethics Board (File 13755E).

Results
Informants were asked questions based on the main pre-identified themes of
(1) ethical issues in the CRTs, (2) experiences with the ethics review process for
CRTs, and (3) the need for, and input on, possible ethics guidelines for CRTs.
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Ethical Issues in CRTs
1.

Informed consent

Informants’ comments on the question of when informed consent is required
from individual research participants varied widely. For many informants, whether or
not informed consent was required in a particular CRT depended on the kind of
intervention being evaluated.
“The type of intervention that is being trialed is...of crucial importance.
So, for example, whether...you are changing the way the entire service is
delivered, or whether you are intervening at an individual level and you are just
randomizing at a higher level for convenience. So it is about which level...is
the intervention being targeted at...” (Informant 11, Primary Care Researcher)
The type of data collection procedures used in a CRT could also determine the
need for consent from cluster members. Researchers almost universally obtained
consent from cluster members if they interacted with these cluster members or
intervened upon them to collect data.
“If we interact with the participant we get consent first. If we are
making observations in a public setting, we are not required to get
consent...Those activities don’t require consent.” (Informant 3, Public Health
Researcher)
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Many informants related concerns over the effect of obtaining informed
consent on the validity of a CRT’s findings. In particular, informants worried that
disclosure of the nature of the interventions under study in CRTs of behavioural
interventions may lead to bias if research participants modify their behaviour as a
result of information disclosed during consent negotiations rather than as a result of
the study interventions.
“One of the things I am concerned about is bias. If you get really
informed consent from people in trials it results in either bias or
contamination.” (Informant 5, Statistician)
Informants also shared a related concern with respect to studies of health
services or quality improvement interventions in which the only intervention on
individual patients is using health information for data collection. Informants
expressed concern that requiring informed consent may make such CRTs logistically
unfeasible. Several informants felt that these methodological challenges were
sufficient to justify a waiver of informed consent for cluster members.
“Wherever people propose that (requiring individual patient consent), it
is the death of those kinds of studies. It is the death of health services research.
You can quote me on that. If you require consent to use the data...to look at the
performance of a system, it will be a complete disaster.” (Informant 1, Hospital
Care/QI Researcher)
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With respect to healthcare implementation research, informants had different
perspectives on when, if ever, consent or permission from healthcare professionals is
required. Investigators often asked permission, either from individual healthcare
professionals or from a group practice, to enrol these professionals in their study.
“Normally [permission would be obtained] at a general practice level.
That would have been done at a partner level, so there would be a discussion
within the practice and then agreement at a practice level. There would have
been consensual agreement between the partners, between the individual
general practitioners that their practice would take part.” (Informant 11,
Primary Care Researcher)
Other informants proceeded with practice-based CRTs without securing the
agreement of all healthcare professionals in the practice who might be affected by the
intervention.
“For the ones targeted at practitioners, we had to install software in their
electronic medical records systems and computers in their offices so that it
would have been GPs in the practice who gave consent. Within a practice, they
didn’t all have to agree.” (Informant 2, Primary Care Researcher)
Some informants argued that healthcare professionals have a professional
obligation to participate in CRTs involving a knowledge translation or quality
improvement intervention, which therefore overrides any requirement to obtain
consent.
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“I would argue that [there is a] professional responsibility to practitioners
to take part in research that involves clinical knowledge.” (Informant 9,
Primary Care Researcher)
2.

Role of the cluster gatekeeper or decision-maker

Informants identified several ethical challenges related to the role of the
gatekeeper, the individual who makes a decision with respect to CRT participation
on behalf of a cluster. Informants noted challenges identifying the appropriate
gatekeeper for certain kinds of groups, particularly municipalities. Opinions varied
on whether municipal leaders had the appropriate authority to allow their community
to participate in a CRT.
“In some instances there really is no party to go to for permission when
we are doing a community study for example and we are randomly assigning
counties or cities. There really isn’t anybody that gives permission for that
kind of thing. Even in a city where there is a mayor, the mayor can’t give
permission for a city to participate in something. At least that has always been
my view.” (Informant 3, Public Health Researcher)
Informants also recognized that some clusters, such as schools and hospitals,
may have multiple gatekeepers because of the organizational structure of these
institutions.
“First off you have to have the district agree that you can even work in
this district. Then you have to get the principal to agree that they want to
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participate in the project. And then we had... the president of the local parent
leadership group.” (Informant 16, Public Health Researcher)
In situations in which researchers had difficulty identifying the appropriate
gatekeeper for community-based research, they typically sought the approval of
some local advisory committee.
“Our approach in virtually every instance was to organize a local
community advisory board made up of community residents in the city if we
were working with cities or in the county if we were working with counties.
We would get their input on a variety of things though the basic design was
set.” (Informant 3, Public Health Researcher)
Another ethical challenge concerning gatekeepers related to the scope of the
gatekeeper’s decision-making authority. Responses varied on whether the gatekeeper
possessed sufficient authority to provide consent on behalf of all cluster members, or
whether the gatekeeper was simply permitting access to individual cluster members
who would subsequently provide consent for CRT participation.
“I think the main issues for me still stem around the issue of consent.
Who [gives] consent? Whether consent needs to be achieved at every level of
cluster or whether almost guardian consent is acceptable and that has been
where the most discussion has happened really about in the ethical issues of
cluster trials for me.” (Informant 11, Primary Care Researcher)
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Some informants seemed comfortable accepting a gatekeeper’s consent on
behalf of an entire cluster for studies that were evaluating cluster-level interventions,
such as educational or quality improvement interventions targeted at health care
systems or practitioners.
“I would say most of them have been looking towards a cluster
guardian...consent because most of the interventions I have been involved have
been mainly around management interventions where the real intervention is at
the level of either the practitioner, the health professional or the health care
organization and this specific intervention hasn’t really been targeted at the
lower level of the cluster, the patient level.” (Informant 11, Primary Care
Researcher)
Other informants expressed a different opinion. They felt it was important to
obtain consent from individual patients in healthcare CRTs, regardless of whether
consent for cluster enrolment was obtained from a gatekeeper.
“So there is a consent for the patient and a consent for in our case, the
practice so there are 2 levels of consent if you like. If there wasn’t patient
consent involved, then obviously there would be very significant ethical issues
but I have come to the view that if patients are given information and they
consent, then that is fine.” (Informant 9, Primary Care Researcher)

100

3.

Risks and potential benefits

Our interview guide included items addressing the risks posed by CRT
participation. Informants had few concerns regarding the risks posed to cluster
members by CRTs. “Risks were none. I think we came up with some for the ethics
committee.” (Informant 14, Primary Care Researcher)
The interventions under evaluation in CRTs were perceived as standard care
with little or no incremental risk to cluster members. “None of the interventions that
we have evaluated have put anyone at any kind of risk... there is certainly little risk
involved” (Informant 3, Public Health Researcher)
For healthcare CRTs that evaluated the effect of interventions on health
professionals using patients’ health information, informants identified threats to
privacy as the sole risk. “I think the core risk is loss of privacy. That really is the
only issue because we weren’t studying...a therapeutic intervention.” (Informant 8,
Hospital Care/QI Researcher)
Some informants voiced concern that members of clusters assigned to control
groups may not benefit from an experimental intervention. “The dilemma and the
tension again was this trial that is basically about the QI where the controlled
practices got nothing. They didn’t get anything but normal care.” (Informant 14,
Primary Care Researcher)
One commonly employed solution to address this dilemma was to offer
the experimental intervention to the control clusters after the CRT had been
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completed. “Sometimes we are so concerned about the control arm feeling that
they don’t get anything that it might affect recruitment. We offer them the
intervention once the trial is over.” (Informant 14, Primary Care Researcher)
An additional risk identified by one informant was that CRT enrolment may
entail an increased clinical or administrative workload for participating medical
practices. “The only risk I feel in doing a lot of research here is practices become
overburdened by having to do research. (Informant 5, Statistician)
Experiences with the ethics review process
Many of the informants noted wide variability among research ethics
committees, and across jurisdictions, in both the ethics review process and in ethics
boards’ decisions. Informants noted that this variability has made it more difficult to
do multicenter CRTs. “cluster...trials of hospitals randomise independent institutions,
each of which has an [ethics committee]. Each [ethics committee], with its slightly
different application procedures, forms and timelines has been a separate and trying
process.” (Informant 7, Primary Care Researcher)
Several informants commented that the ethics review process was easier in the
past, and has become more cumbersome in recent years. “...generally it hasn’t been
too bad up until the last 5 years. Beforehand we were quite comfortably able to get
ethics approval ... but it is different now” (Informant 13, Primary Care Researcher)
However, other informants commented that as ethics boards become familiar
with the CRT design, the review process has gone more smoothly. “...Now CRTs are
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widely accepted research methods, particularly in primary care studies, primary care
settings. Ethics committees are now actually quite comfortable with them. ”
(Informant 14, Primary Care Researcher)
Informants’ opinions varied on the effect of the ethics review process and
regulatory requirements on the validity of a CRT. Half of the informants reported a
positive impact of the ethics review process on the quality of their studies, while the
other half reported negative effects. Perceived negative effects included threats to
validity from consent processes, and diminished enrolment because of consent
requirements.
“As the participation rates drop...then the results are less generalizable
and less helpful. There is no question that the higher hurdles for consent in
school studies and certainly in clinic based studies have made it more difficult
to do the work and to get high participation rates.” (Informant 3, Public Health
Researcher)
Perceived positive effects included requirements for greater methodological
rigor and thoughtfulness in study design, and improved protections for research
participants.
“I am a great believer that ethics committee do ask...searching
questions...Just the process of thinking about the ethical implications of your
design is something that we might not do if we didn’t have to go to ethics
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committees...I think I would say for all my research, it is improved the quality
of what we do.” (Informant 14, Public Health Researcher)
Developing ethics guidelines for CRTs
Informants were supportive of efforts to develop ethics guidelines for the
conduct and review of CRTs. “I think there does still need to be a discussion
document...on when is individual level consent an absolute requirement.” (Informant
11, Primary Care Researcher)
The most common suggestion for the content of ethics guidelines was to
include education for research ethics committees on the ethical and methodological
aspects of CRTs that make CRTs distinct from individually randomized trials.
“I think that there are issues which make cluster trials different to the sort
of trials that review boards normally see and that it would give me confidence
as an investigator if I knew that they fully understood the difference.”
(Informant 20, Hospital Care/QI Researcher)

Discussion
This study was designed to elicit the views of experienced CRT researchers on
the key ethical issues involved in the conduct of CRTs, and to describe their
experiences with the ethics review process for CRTs.
Informants’ opinions on whether or not informed consent should be obtained
from cluster members appeared to depend on the scientific question and experimental
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interventions in particular CRT. Informants asserted that individual informed consent
was necessary for CRTs in which cluster members were directly intervened upon.
Informants in this sample frequently used waivers of informed consent for individual
cluster members in large community-based CRTs, or in CRTs evaluating quality
improvement or implementation strategies in healthcare or education.
One reason often cited for avoiding obtaining informed consent from individual
cluster members was a concern over consent practices possibly inducing some sort of
bias that would threaten the validity of the CRT. This concern has been noted in the
literature6,14. Further conceptual work appears necessary to clarify when, if ever, it
may be permissible to waive requirements for informed consent from cluster
members, and to identify the moral underpinning for such a waiver. Ethics
guidelines, built on a robust conceptual foundation, should clearly lay out under what
circumstances obtaining informed consent from individual cluster members is
required, and under what circumstances the requirement for informed consent may be
waived.
Informants reported frequent challenges in identifying an appropriate
gatekeeper who has legitimate authority to grant permission for a cluster such as a
municipality or social group to be enrolled in a CRT. The gatekeeper for a
professional group, such as a medical practice, hospital or school, may be more
obvious. However it is unclear whether the agreement of all professionals (i.e.
doctors, teachers) is required prior to the participation of a professional group in a
CRT. Informants expressed concern over the scope of authority of the gatekeeper,
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particularly with respect to whether permission from the gatekeeper was ever
sufficient to obviate the need for informed consent from individual cluster members.
Future conceptual work and guidelines for the ethical conduct of CRTs, should
provide clear guidance on these issues.
Many informants identified the problem of variability in ethics review between
jurisdictions. They also described increasingly onerous oversight requirements
imposed by ethics boards in recent years. This variability may be attributable to the
fact that most jurisdictions do not have authoritative guidelines for the review of
CRTs. Ethics boards are therefore required to use their own judgment in applying
guidelines that do not address the unique ethical challenges posed by the CRT design,
potentially resulting in idiosyncratic decisions. This indicates the need for
comprehensive ethical guidelines that can direct the review of multi-jurisdictional
CRTs.
Several issues identified in the literature, and included in our interview guide,
were not mentioned by informants. With respect to the assessment of harms and
benefits of CRT participation, informants identified threats to privacy and risks of
suboptimal treatment in control arms, as well as burdens to medical practices that
participate in CRTs. Informants did not express concern about risks to individual
research participants, especially in studies in which individual cluster members were
not directly intervened upon. We suspect that this is because the interventions being
evaluated in CRTs are often low-risk interventions designed to improve medical care
or educational processes, and posed little ethical concern to investigators. However,
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the view expressed by informants that CRT interventions pose no risk is misguided,
as no experimental intervention in a trial can be considered to be free of risk15,16.
Guidance on the ethical conduct of CRTs should educate investigators and research
ethics committees on the identification of all important harms and benefits of CRT
enrolment. Ethics guidance should also address how the analysis of risks and
potential benefits for CRTs should be performed7,17.
Limitations
Our sample included experienced CRT researchers and individuals who have
contributed to the literature on the ethics of CRTs. Their experiences may not
necessarily be transferable to all CRT researchers. However, we are reassured that
experienced researchers from a variety of locations, and in a variety of fields, voiced
similar opinions on key ethical issues. Furthermore, the experience of the informants
interviewed in this study lends weight to their views, and to our conclusions.
Our informants worked mostly in developed countries, although some did
perform CRTs in marginalized or underprivileged populations. This may be the
reason that no informants voiced concerns about issues of distributive justice, such as
fair participant selection, the reasonable distribution of burdens of CRT participation,
and other issues encountered when conducting CRTs in developing countries.
Conclusions
Informants described challenges CRT investigators percieve with the ethics
review process, expressed concern over when informed consent is required from

107

cluster members, and over the authority of cluster gatekeepers. Other important
ethical challenges, such as the relationship between harms and benefits and issues of
distributive justice appeared to be either less concerning to CRT researchers, or were
under-appreciated. These views, offered by experienced CRT researchers, point to
the need for further conceptual work on the ethics of CRTs, as well as the need for
clear authoritative guidelines that address the unique ethical and methodological
challenges of CRTs.
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Chapter 5

Who is the Research Subject in Cluster Randomized Trials?
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Introduction
The CRT design is used in a diverse range of fields, including education,
criminology, public health and health services research. Who ought to be considered a
research subject in a CRT for the purposes of the regulation of research may be unclear.
Are individual cluster members always research subjects? Does it matter whether cluster
members directly receive an experimental intervention? Does it matter whether individual
cluster members’ identifiable private information is used to generate outcome data? In
some CRTs, individuals such as health professionals will be the ones randomly assigned to
receive an experimental intervention. Are the health care professionals research subjects?
Does it matter whether or not outcome data are collected from the professionals? Are
patients necessarily research subjects if the intervention administered to the healthcare
professional indirectly affects their care?
The question of who constitutes a research subject in a CRT is important for two
related reasons. First, the consequences of misidentifying research subjects in CRTs are
significant for both subjects and investigators. If we fail to identify individuals who ought
to be recognized as research subjects in a CRT, then we will fail to adequately protect their
interests. If we are overly inclusive in identifying individuals as research subjects in a CRT,
then investigators will be unnecessarily subjected to regulatory burdens that may hamper
important research. Second, as a pragmatic concern for research ethics committees,
research subjects must be appropriately identified before such issues as informed consent,
assessment of benefits and harms, and the appropriateness of subject selection procedures
may be considered.
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This paper aims to develop a principled definition of “research subject” that
investigators and research ethics committees can use in all types of human subjects
research. This definition will be particularly helpful to CRT investigators and research
ethics committees who review CRTs. We contend that the answer to the question “Who is a
subject in a CRT?” may vary, depending on the specific study design, the population, and
the interventions being evaluated.

Examples: Challenges in identifying the research subject in
CRTs
CRTs are heterogeneous with respect to design, population, and interventions. The
following four examples (a) illustrate the complexity of the question “Who is a research
subject in CRTs?”, and (b) highlight the need for a principled definition of research subject
that can be employed across the spectrum of CRTs.
Example 1: The COMMIT Trial
The COMMIT trial1,2 evaluated a multimodal community-level intervention aimed at
reducing cigarette consumption, including a media and billboard campaign as well as
targeted messaging toward smokers. Communities were randomly assigned to either the
intervention or control arm. The effect of this complex intervention was evaluated using
interviews with a random sample of smokers in each community, and also by comparing
the amounts of tobacco purchased by people living in the intervention and control
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communities. The study found that the intervention led to an improved quit rate for mild to
moderate smokers, with no effect on the quit rate of heavy smokers.
Who were the research subjects in this study? The survey respondents? Only
residents of the communities who smoke? Every resident of participating municipalities?
Example 2: A CRT of bed net distribution to reduce malaria prevalence
A CRT that evaluated malaria prevention interventions3 randomly assigned
Cambodian communities either to an intervention group in which bed nets were distributed
to all residents in the intervention communities, or to a control group in which no bed nets
were distributed. To evaluate local malaria prevalence, the population size was obtained
from local census data and the number exposed to malaria was obtained from blood tests
performed on a random sample of village residents. No identifying information on sampled
individuals was retained. The study identified non-significant trends toward decreased
malaria incidence and prevalence in the intervention communities.
Who were the research subjects in this study? Only citizens of intervention
communities who received bed nets? Citizens of control communities who provided blood
samples? All citizens in intervention and control communities?
Example 3: A CRT comparing interventions to improve primary care prescribing
Naughton et al.4 compared the efficacy of two quality improvement interventions
aimed at increasing prescribing by family physicians’ of antiplatelet and lipid lowering
medications for patients with cardiovascular disease (CVD) or diabetes mellitus (DM).
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Family physicians were randomly assigned to receive either a personalized summary of
their prescribing practices for patients with CVD or DM via an academic detailing visit, or
to receive a postal bulletin about optimal prescribing practices. The effect of the
intervention on prescribing practices was evaluated by surveying physicians’ perception of
the perceived effects of the intervention, as well as using objective data on prescribing
practices from the national pharmacy insurance program database. The data on the patients
and their prescriptions included the prescription type, age, gender, and a numeric identifier,
but no name or address. Both interventions led to similar improvements in prescribing
practices.
In this study, there was no direct intervention on patients or any use of identifiable
private information. Who were the research subjects in this study? All of the DM or CVD
patients in participating practices? All patients in participating practices? The physicians
receiving the interventions?5,6
Example 4: A CRT comparing modes of educating patients prior to breast cancer surgery
Goel et al.7 describe a CRT comparing the efficacy of two methods of informing
breast cancer patients of their surgical treatment options. The intervention under study was
directed at the patients, but administered by their surgeons. Surgeons were randomly
assigned either to discuss treatment options with patients using a specially developed
decision tool, or to use standard practice with the addition of extra printed information. The
study compared the effect of the decision tool on patient anxiety and knowledge regarding
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their options. No difference was observed in the study’s primary outcome between
intervention and control groups.
Who were the research subjects in this study? The patients? The surgeons?

Methods
The aim of this paper is to offer a principled definition of a research subject, and to
apply this definition to CRTs, in order to assist investigators and research ethics
committees. Currently available regulatory definitions of “research subject” are based on
lists of procedures, i.e., an individual may only be classified as a research subject if he or
she undergoes a procedure listed in regulations8-12. List-based criteria are not exhaustive,
and may not be helpful in identifying subjects in novel research designs such as CRTs.
Moreover, a principled definition of research subject may be used reflexively, to determine
the adequacy of current and future research ethics regulations.
Our analysis proceeds as follows. First, we review research ethics regulations and
guiding documents for criteria that identify research subjects. Second, we search for a
common theme on which we can build a definition of “research subject”. Third, we posit
that a research subject is an individual whose interests are put at risk in the context of a
research study. Fourth, we apply our definition of a research subject to CRTs and examine
whether the effects of group-level environmental interventions are, by themselves,
sufficient to make cluster members research subjects, and we consider the impact of
random assignment on an individual’s status as a research subject. Fifth, we discuss how
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our definition of research subject may be applied in a variety of CRT designs and contexts
to identify research subjects who are entitled to regulatory protections.

Who is a Research Subject?
1.

Regulatory definitions of “research subject”

The definition of a research subject is a foundational problem in the ethics of human
subjects research. However, there is very little regulatory guidance that helps to address
this problem. Most international and national research ethics guidelines, including those of
Canada and the UK,10,13-15 omit a definition of research subject. These documents were
promulgated to guide the ethical conduct of research in which subjects are recruited
individually, in which case it is usually clear from the outset who is the research subject. In
addition, The UK Medical Research Council’s ethical guidelines for CRTs16 and CIOMS
International Ethical Guidelines for Epidemiologic Studies17 fail to define a research
subject. Perhaps more problematically, they appear to assume that cluster community
members will necessarily be subjects, although they offer no meaningful rationale for this
assumption16,17.
One of the few national regulations to contain a definition of research subject is the
United States Federal research regulations 45 CFR 468. These regulations, known as the
Common Rule, govern all human subjects research conducted or funded by departments of
the US federal government. The Common Rule is accompanied by a wealth of background
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documents and commentary, and has been influential in other countries’ development of
their own research ethics guidelines.
The Common Rule offers the following criteria that identify a research subject. A
research subject, according to the Common rule, is a “living individual about whom an
investigator (whether professional or student) conducting research obtains
(1) Data through intervention or interaction with the individual, or
(2) Identifiable private information.
Intervention includes both physical procedures by which data are gathered (for
example, venipuncture) and manipulations of the subject or the subject's environment
that are performed for research purposes. Interaction includes communication or
interpersonal contact between investigator and subject. Private information includes
information about behavior that occurs in a context in which an individual can
reasonably expect that no observation or recording is taking place, and information
which has been provided for specific purposes by an individual and which the
individual can reasonably expect will not be made public (for example, a medical
record). Private information must be individually identifiable (i.e. the identity of the
subject is or may readily be ascertained by the investigator or associated with the
information) in order for obtaining the information to constitute research involving
human subjects8.”
Most other regulations that contain definitions of research subjects are narrowly
focused on one particular research design, namely clinical trials, and simply define research
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subjects as those individuals receiving an experimental intervention in a clinical trial9,10,12.
One exception is the Australian National Statement on Ethical Conduct in Human
Research11. The Australian National Statement includes a list of six types of activities that
make an individual a research subject, including:
• taking part in surveys, interviews or focus groups;
• undergoing psychological, physiological or medical testing or treatment;
• being observed by researchers;
• researchers having access to their personal documents or other materials;
• the collection and use of their body organs, tissues or fluids (e.g. skin,
blood, urine, saliva, hair, bones, tumour and other biopsy specimens) or their
exhaled breath;
• access to their information (in individually identifiable, re-identifiable or
non-identifiable form) as part of an existing published or unpublished source or
database11.
Four of these criteria describe different kinds of interventions upon, or interactions
with, subjects, and are therefore reducible to the first item in the Common Rule criteria.
The fourth and sixth item in the Australian National Statement criteria refer to the use of an
individual’s information, including both identifiable private information and information
with personal identifiers removed11.
Because of its comprehensiveness, and because it is supported by a great deal of
historical documentation, we will use the Common Rule criteria as a useful starting point
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from which we can attempt to elucidate a principled definition of research subject. We will
draw on other guidelines, such as the Australian National Statement, where applicable.
In attempting to develop a definition of “research subject”, we will ask whether the
components of the Common Rule criteria—obtaining data through intervention or
interaction with an individual or the use of identifiable private information—have a
common theme. If a common theme that unites the Common Rule criteria can be identified,
this may be a foundation on which we can build a principled definition of research subject.
2.

Distinctive features of research subjects
In attempting to identify a common theme between the criteria outlined in the

Common Rule and other regulations, we will be guided by normative work on the
distinction between a subject in clinical research and a patient in clinical practice. To do
this, it is first necessary to distinguish between research and clinical practice. In the
Appendices to the Belmont Report, Robert Levine draws a distinction between research and
ordinary medical practice based on the purpose of each activity18. Clinical practice, he
argues, involves a health professional acting solely for the purpose of ameliorating the
health of her patient. Research, on the other hand, is “…a systematic investigation,
including research development, testing and evaluation, designed to develop or contribute
to generalizable knowledge”8. Research may include interventions that offer benefit to
research subjects, but these are not an essential component of an activity whose primary
purpose is to benefit society in the form of expanded knowledge.
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The insight that the intent of research is different from the intent of clinical practice
leads to an important distinction between the physician-patient relationship and the
investigator-subject relationship. Elucidating the difference in these two relationships helps
us to identify the distinctive feature of research subjects.
In clinical practice, the health professional and patient are in a fiduciary relationship.
A fiduciary relationship is characterized by structural vulnerability, in which the
beneficiary (in this case, the patient) entrusts the fiduciary (in this case, the health
professional) with discretionary powers to act in the beneficiary’s interests19. Health
professionals are empowered and obligated to act in patients’ health interests, and are also
obligated to protect their privacy interests. Levine points out that in ordinary clinical
practice, patients can be confident that their health professionals will act with patients’
interests in mind, as the sole purpose of clinical practice is to ameliorate the health of the
patient18.
The relationship between researchers and subjects is somewhat different. Levine18
and Rothman20 note that clinician-investigators face a conflict of interests. On the one
hand, they have an obligation to act in the best interests of their patient-subjects. On the
other hand, clinician-researchers also have obligations to the study, such as ensuring
compliance with experimental treatment protocols, that may conflict with their obligations
to a patient’s welfare. As Rothman writes, “The bedrock principle of medical ethics—that
the physician acted only to promote the well-being of the patient—did not hold in the
laboratory…The doctor-patient relationship could no longer serve as the model for the
investigator-subject relationship.” 20 Research regulations evolved specifically to safeguard
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the interests of research subjects, as investigators’ conflict of interest prevents them from
effectively acting in subjects’ interests20.
Research subjects are vulnerable because a clinician-investigator’s obligation to
protect subjects conflicts with his or her scientific obligations. As Levine puts it, the role of
a research subject approximates that of a means to an end18. Both the Common Rule and
Australian National Statement criteria specify ways in which a subject’s interests could be
compromised for scientific purposes. When an investigator intervenes on a subject, either
with an experimental intervention or in order to collect data, the subject’s welfare may be
at risk. The same is true if an investigator interacts with a subject. By collecting personal
information, the investigator may violate the subject’s privacy.
3.

A principled definition of “research subject”.
As noted above, the Common Rule classifies research subjects as individuals whose

interests may be compromised for scientific purposes. We therefore propose using this
criterion as the basis for a novel definition of “research subject”:
A research subject is an individual whose interests may be compromised as a
result of interventions in a research study.
In this definition, “interests” refer generally to goods that an individual would
ordinarily seek to protect. Research ethics regulations are primarily intended to protect
subjects’ health, welfare and privacy interests. Interests, as far as this definition is
concerned, may also include such things as economic interests.
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We find historical support for this definition of a research subject in the 1974 US
Department of Health, Education and Welfare (DHEW) regulations for human subjects
research21. These regulations are the immediate predecessor of the Common Rule. Rather
than define “research subject”, the DHEW regulations refer to “subjects at risk”. A
“subject at risk” is defined as:
“any individual who may be exposed to the possibility of injury, including
physical, psychological, or social injury as a consequence of participation as a subject
in any research, development, or related activity which departs from the application
of those established and accepted methods necessary to meet his needs, or which
increases the ordinary risks of daily life, including the recognized risks inherent in a
chosen occupation or field of service.21”
4.

Evaluating Current Regulations with a Principled Definition of “Research Subject”
The principled definition of “research subject” that we have developed may be used

to critically evaluate criteria in current regulations that identify research subjects. We can
do this for the Common Rule, the Australian National Statement, as well as other research
regulations. Most regulations for clinical trials refer to subjects as individuals who receive
experimental or control interventions in a clinical trial. This definition therefore identifies
subjects as those who are intervened upon. These regulations are likely adequate for
individually randomized clinical trials, but are not sufficiently exhaustive to be applied
more broadly as they omit other ways in which individuals’ interests could be
compromised9,10,12.
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As previously noted, the Australian National Statement offers a six-item list of ways
in which an individual could become a research subject. Four of these criteria (1, 2, 3 and
5) identify ways in which researchers may intervene upon or interact with subjects. We can
conclude, based on our principled definition of “research subject”, that these items are
appropriate for inclusion on a list of criteria that identify a research subject. The fourth
criterion includes “researchers having access to personal documents or materials” may
compromise subjects’ privacy interests and merits inclusion11. The sixth criterion defines
any individual about whom a researcher obtains “information (in individually identifiable,
re-identifiable or non-identifiable form) as part of an existing published or unpublished
database or source”11 as a research subject. Yet, the use of non-identifiable information
presents no risk to an individual’s privacy (or other) interests. Similarly the use of
identifiable, publicly available information such as biographical materials or items of
public record, presents no risk to an individual’s privacy (or other) interests. Our definition
of research subject would thus lead us to conclude that this sixth item in the Australian
National Statement is too broad for inclusion in a list of ways in which an individual could
become a research subject.
We can use our principled definition of research subject reflexively to examine
whether all of the components of the Common Rule are germane to a definition of research
subject. The Common Rule criteria include interventions on subjects or interactions with
subjects, and the use of identifiable private information. These categories broadly describe
means by which a research subjects’ interests could be compromised, and so merit
inclusion in a definition of research subject. The Common Rule definition further defines
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interventions as “physical procedures…and manipulations of the subject or the subject's
environment”8. Physical procedures or manipulations of the subject necessarily involve
some degree of risk, and therefore may compromise the subjects’ welfare interests.
However, the reference to environmental manipulation is insufficiently explicit and
requires further elucidation.

The Importance of Environmental Manipulation
According to the Common Rule, one way an investigator may intervene on research
subjects is by manipulating their environment. With respect to healthcare CRTs, Mann and
Reyes5 have interpreted this to mean that an intervention designed to alter a healthcare
professional’s practice pattern represents a manipulation of the environment of all patients
whose care may be influenced by a professional’s participation in a CRT. Thus, according
to Mann and Reyes, every patient of a professional whose care may be influenced by a
CRT intervention meets the regulatory definition of a research subject. This claim is
understandable, given that much of the literature on the ethics of CRTs assumes that cluster
members (in this case, patients) will necessarily be subjects16,22-25. If correct, their view has
considerable implications for the conduct of CRTs. If, in CRTs targeted at health
professionals or health systems, all patients are considered research subjects, the
administrative burdens associated with protecting patients as research subjects would
threaten the feasibility of many trials. We explore below whether the indirect effects of a
research intervention at the group level (such as an educational intervention administered to
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health professionals) implies that all individuals within the group (such as the patients of
professionals participating in a CRT) must be considered research subjects.
1.

Can environmental manipulation make an individual a research subject?
The CIOMS International Ethical Guidelines for Biomedical Research Involving

Human Subjects14 includes in its definition of research any study that manipulates an
individual’s social or physical environment, including field studies of pathogenic
organisms or toxic chemicals. These guidelines, along with the CIOMS International
Ethical Guidelines for Epidemiological Studies 17, address issues of informed consent in
epidemiologic research and the analysis of harms and benefits for such research. Therefore,
without actually defining “research subject” the CIOMS guidelines appear to acknowledge
that individuals who may be affected by public health interventions that manipulate the
environment such as water fluoridation or pesticide use are, in fact, research subjects 14,17.
A broad interpretation of “environmental manipulation” is untenable, however,
because it leads to absurd conclusions. It seems impossible that everyone whose
environment is manipulated in the context of a research project must be considered a
research subject. The term “environment” refers to “the surroundings or conditions in
which a person, animal, or plant lives or operates” 26. Using this definition, “manipulations
of the…subject’s environment” would imply that every person on Earth is a research
subject in every research study. For example, studies in particle physics at the Large
Hadron Collider (LHC) meet the Common Rule definition of research, in that they are
systematic investigations designed to develop generalizable knowledge8. One concern
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regarding the LHC project was that some experiments could create microscopic black holes
that might be hazardous to the planet and all of its inhabitants27. If we were to employ a
broad interpretation of “manipulations of the…subject's environment”, the Common Rule
would require that particle acceleration experiments at the LHC be considered a
manipulation of the environment for all human beings, meaning that everyone on Earth
must be considered research subjects. This notion seems patently absurd. We therefore
require a better understanding of what environmental manipulations are sufficient to make
an individual a research subject.
It is helpful to consider what the US National Commission for the Protection of
Human Subjects of Biomedical and Behavioral Research may have meant when they
included “environmental manipulation” in their definition of a research subject. In a paper
prepared for the National Commission in 1975 (included in the 1979 Appendix to the
Belmont Report), Robert Levine defined research as “…manipulation, observation, or other
study of a human being--or of anything related to that human being that might subsequently
result in manipulation of that human being--done with the intent of developing new
knowledge and which differs in any way from customary medical (or other professional)
practice.”18 Specific reference to manipulation of an individual’s environment did not
appear until the National Commission defined a research subject in their 1978 Report and
Recommendations on Institutional Review Boards, and this language was incorporated into
the Common Rule28. The Common Rule’s reference to manipulation of an individual’s
environment took the place of Levine’s “anything related to that human being that might
subsequently result in manipulation of that human being.” Exploring the reasons for this
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change in regulatory language helps to clarify what kinds of environmental manipulation
are sufficiently meaningful to consider an individual a research subject.
Given the sorts of issues being discussed in the research ethics literature at the time, it
seems likely that the National Commission was seeking to protect individuals who
participated in studies evaluating the psychological effects of various environmental
stimuli. Inclusion of environmental manipulation in the definition of research subject seems
intended to capture research that deliberately manipulated subjects and placed their welfare
at risk without direct intervention or physical contact from investigators.
Examples of this type of research include studies examining the psychological and
behavioural effects of habitation in simulated fallout shelters sponsored by the US Office
of Civil and Defense Mobilization29, and studies evaluating the psychological effects of
other environmental manipulations such as sensory deprivation30,31. Environmental
manipulations in the Civil Defense studies includes such things as living in a confined
space for prolonged periods, crowding, variable air quality, variable availability of potable
water and exposure to variations in temperature. The individuals participating in these
studies were subjected to physical or psychological discomfort resulting from the
manipulation of their environment in the context of a research study. What these studies
have in common, then, is that the study interventions placed the welfare of the subjects in
jeopardy by manipulation of their environment rather than via direct intervention or
physical touching by the investigators.
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These practices support a narrower reading of the environmental manipulation clause.
We suggest that environmental manipulation must have a direct impact on an individual in
order to make him or her a research subject. In other words, the environmental
manipulation must be designed to produce a direct effect on the individuals whose
environment is being manipulated. We believe that this interpretation is consistent with the
intent of the National Commission. We will therefore expand our definition of “research
subject” to include any individual who is deliberately affected via manipulation of his/her
environment by an investigator (Box 1).
This conclusion is consistent with the language enshrined in the Final Report of the
National Bioethics Advisory Commission. In their 2001 Report and Recommendations:
Ethical and Policy Issues in Research Involving Human Participants, the Commission
agrees that the term “subject” “…connotes the fact that the individual is ‘subjected’ to an
action by the investigator.”32 The Commission specifically recommends that “…Research
be considered to involve human participants when individuals 1) are exposed to
manipulations, interventions, observations or other interactions with investigators or 2) are
identifiable through research using biological materials, medical and or other records, or
databases.”32
2.

Do indirect effects of CRT interventions on health professionals or health systems

make patients research subjects?
Mann and Reyes have construed a change in physicians’ practice patterns that result
from educational or quality improvement interventions in a CRT to be a manipulation of
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their patients’ environment, therefore requiring those patients to be considered research
subjects5. We respectfully disagree.
First, in order to turn an individual into a research subject, the environmental
manipulation must be designed to produce a direct effect on that individual. This is not the
case in CRTs that intervene on health professionals. The CRT design is chosen because the
interventions under study are cluster-level interventions. The interventions being evaluated
in these studies are intended to change health professionals’ behaviour by increasing
professionals’ use of evidence-based strategies to improve care. Patients are not being
directly manipulated by interventions administered to their health professionals.
Second, even if a change in a professional’s practice pattern did constitute a
deliberate manipulation of patients via a manipulation of their environment (a claim that
we do not grant), that manipulation does not jeopardize patients’ interests and is therefore
not sufficient to warrant considering patients as research subjects. Examining the
distinction between clinical research and clinical practice is again helpful with respect to
this issue. Levine writes,
“If a physician proceeds in his interaction with a patient to bring what he
considers to be the best available technique and technology to bear on the
problems of that patient with the intent of doing the most possible good for that
patient, this may be considered the pure practice of medicine. By contrast, if a
physician interacts with an individual with the intent of developing new
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knowledge (not primarily for the benefit of that individual), this activity may be
classified as research.”18
When a health professional participates in a CRT, her patients may still fully entrust
their welfare to her because she has no conflicting obligations to the trial itself. Physicians
in this situation are subjects themselves, not investigators. Although the professional may
have received an intervention aimed at improving practice, the professional is still expected
to act in the best interests of her patients and in accordance with professional practice
standards. As Henderson puts it, “In the studies in which an administrative intervention
does not directly interpose between the physician and the patient, the patient’s treatment
remains under the direction of the physician and is not removed by the process of
randomization33.” Therefore, effects on practice patterns do not jeopardize the welfare
interests of the patients of a health care provider participating in a CRT. Simply being a
patient of a professional participating in a CRT of an educational, knowledge translation, or
quality improvement intervention does not make one a research subject.
Some studies evaluate patient-level effects as an outcome measure. The fact that a
patient-level effect may be measurable is relevant to patients only insofar as their private
health information may be used, or they may be asked to submit to surveys or additional
examinations to evaluate the outcome of the CRT. Patients of professionals participating in
a CRT of an educational or quality improvement intervention need be considered subjects
only if they are directly intervened upon by or interact with investigators, or if their
identifiable private information is used.

131

This conclusion does not necessarily hold for patients in CRTs evaluating alternative
modes of health service delivery. These CRTs aim to evaluate the effect of different
methods of providing care. This is different from CRTs of interventions directed at
providers that aim to increase the use of evidence-based care while maintaining the
fiduciary relationships that providers have to patients. Examples include CRTs evaluating
the effect of employing specialist nurses in asthma management34 or the use of case
managers for the reduction of inpatient length of stay on medical wards35. These CRTs are
being conducted because the efficacy of the mode of delivery is uncertain. Randomization
in clusters is undertaken for logistical reasons and to avoid experimental contamination. A
trial evaluating the effect of an experimental mode of delivery is thus akin to a trial that
evaluates an experimental treatment. Novel modes of healthcare delivery are therefore best
thought of as direct patient-level interventions rather than environmental manipulations. In
such studies, the patients would be research subjects because they are directly intervened
upon.
3.

Implications for CRTs in fields other than healthcare
In some CRTs, particularly in public health, the purpose of the experimental

interventions is to deliberately manipulate individuals via their environment. For example,
in the COMMIT study, billboards, and mass media ads (environmental manipulations)
were intended to produce behavioural change in smokers living in intervention
communities36. Another CRT evaluating interventions aimed at individuals via
environmental manipulation is a CRT comparing rates of diarrheal illness in communities
randomly assigned to water treatment with flocculant disinfectant or a control37. In these
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studies, the purpose of the environmental manipulation is to intervene on individual
residents. The residents of communities in such studies are therefore research subjects and
entitled to regulatory protections. This does not necessarily mean that informed consent is
required from all residents. Rather, many of these studies of environmental manipulations
would meet regulatory criteria for a waiver of informed consent8,15,17.
CRTs in education are roughly analogous to CRTs in healthcare: the teacher-student
relationship has many of the characteristics of a fiduciary relationship19. If a CRT is used to
evaluate the effect of a continuing education intervention for teachers, the indirect effect of
the change in teachers’ performance on students will not require that students be
considered research subjects. However, CRTs of experimental curricular programs may be
more similar to CRTs evaluating novel methods of health service delivery, and may require
treating students as research subjects.

What is the importance of random intervention assignment?
The importance of random intervention assignment has caused some concern in the
literature on the ethics of CRTs. In CRTs, random group assignment is often performed
before subjects are enrolled38. Indeed, in CRTs of large cluster-level public health
interventions clusters may be randomly assigned to interventions that some cluster
members may never receive, leading to the concern that the act of random assignment may
make these individuals who are not affected by the intervention research subjects25. Some
of the concern over randomization in CRT stems from how subjects are assigned in
individually-randomized trials. In any randomized controlled trial, assignment to the
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intervention or control arm (whether individually or in clusters), is determined by a
mechanism that is beyond the control of the individual or group being randomized. For
example, in healthcare clinical trials, treatment assignment is specified by the study
protocol. Treatment is not determined by the clinician-patient dyad. Random assignment
has been viewed by some as a research intervention39, which leads to the conclusion that
randomization in and of itself makes an individual a research subject.
We argue that random trial arm assignment is, in and of itself, not sufficient to make
an individual a research subject. In any comparative study, regardless of the method of
intervention assignment (random or non-random), assignment is out of the control of the
individual or group being assigned. For this reason, the use of random intervention
assignment is immaterial to the determination that an individual in a trial is a research
subject. If some non-random method of intervention assignment were used in place of
random assignment, the threats to subjects’ liberty and welfare interests would be
unchanged. A research subject is an individual whose interests are threatened in the context
of a research study. Whether intervention assignment is random or non-random is a moot
point.
Random assignment of clusters is, by itself, insufficient to make cluster members
research subjects. The fact that, in many CRTs, group assignment is determined before
subject enrolment should be acknowledged in consent discussions with individuals who are
identified as research subjects according to a principled definition.
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Implications for Cluster-Randomized Trials
To summarize our conclusions, we suggest that the following four criteria may be
used to define research subjects:
1.

An individual who is directly intervened upon by an investigator for

research purposes;
2.

An individual who is deliberately intervened upon via manipulation

of his/her environment by an investigator for research purposes;
3.

An individual with whom an investigator interacts for the purpose of

collecting data;
4.

An individual about whom an investigator obtains identifiable

private information for the purpose of collecting data.
A detailed discussion of these criteria and their implications for CRTs follows.
A research subject is an individual whose interests may be compromised as a result of
interventions in a research study including:

1.

An individual who is directly intervened upon by an investigator for research

purposes
Individuals are research subjects if, in the context of a research study, they are the
recipients of an experimental intervention (active or control) or if they undergo an
intervention to collect data, such as an additional examination.
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If an intervention is targeted at individual cluster members but random assignment is
done at the cluster level (typically to avoid treatment contamination or for logistical
reasons) then the individuals receiving the intervention should be considered research
subjects. In healthcare, this would include CRTs evaluating therapeutic or health promotion
modalities aimed at individual patients, as well as CRTs evaluating new modes of health
service delivery. An example of the former includes a CRT evaluating the effect of
individualized exercise prescriptions for patients, randomized by physician practice40. An
example of the latter includes a CRT evaluating the effectiveness of asthma management
using specialist nurses34. In these studies, the individuals themselves are being
manipulated, and should therefore be considered research subjects.
In healthcare CRTs, the intervention under study is often not administered to patients,
but rather to healthcare professionals, and the outcomes are evaluated using patient data. It
may be reasonably asked whether the health professionals who receive an educational
intervention in a CRT are research subjects or collaborators. Collaborators are individuals
who contribute to the design of, or participate in the conduct of, a research study.
Collaborators are not recipients of experimental interventions. In healthcare CRTs, the
health professionals are receiving an experimental educational or quality improvement
intervention. When they are directly intervened upon in this way, health professionals
participating in a CRT meet the definition of a research subject5,6,41.
Some healthcare CRTs evaluate complex interventions that may include
combinations of health professional education, novel modes of health service delivery and
patient-level interventions. An example is a CRT evaluating a primary care program aimed
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at reducing obesity42. In this trial, primary care providers in the intervention arm received
an educational intervention on motivational techniques and physical activity for obese
patients. Patients in the intervention arm were screened for obesity, and obese patients were
counseled by the physician and referred to local sports foundations to receive
individualized exercise counseling. In determining whether or not patients need be
considered research subjects for these CRTs, an ethics committee needs to examine each
intervention in such a CRT to determine whether a particular intervention is directed at
patients, or whether data collection includes interaction between researchers and patients or
the use of identifiable private information. Interventions on health professionals mean that
the health professionals will be research subjects. Patients will not necessarily be research
subjects because of interventions on health professionals. But, patients will be research
subjects if there are patient-level interventions (either therapeutic interventions or direct
interventions to collect data) or novel modes of health service delivery are used, if
researchers interact with patients, or if the study uses patients’ identifiable private
information to evaluate outcomes.

2.

An individual who is deliberately intervened upon via manipulation of his/her

environment by an investigator for research purposes
Individuals who are intervened upon via manipulation of their environment are
research subjects. This includes individuals who will be affected by CRTs of public health
interventions, whether the unit of randomization is a municipality, a neighborhood, a
family, or some other group whose environment may be manipulated. Because these
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individuals are research subjects, they are entitled to regulatory protections, including the
determination by a research ethics committee that the risks to their interests do not
outweigh the potential benefits offered by the CRT. Many of these studies would meet
regulatory criteria for a waiver of informed consent because the interventions in these
studies pose only minimal risk and would likely be unfeasible without a waiver of consent.
We concluded above that the indirect effects that a CRT may have on an individual
are not sufficient to warrant considering that individual to be a research subject. In
healthcare CRTs, patients may be indirectly affected by educational or quality
improvement interventions that are directed at healthcare professionals or institutions. The
physicians under study continue to have an obligation to act in patients’ best interests, and
have no competing obligations to the study itself. The physician-patient relationship is
preserved. If there are no patient-level interventions, if the researcher has no interaction
with individual patients, and there is no use of identifiable private information for research
purposes, patients are not research subjects.

3.

An individual with whom an investigator interacts for the purpose of collecting data
Any individual from whom an investigator, in the context of a research study, obtains

data through any kind of interaction should be considered a research subject. Interaction
includes any kind of communication or interpersonal contact between investigator and
subject, for example interviews, focus groups, or questionnaires. Such modes of interaction
may be employed in CRTs when collecting data reported by individual cluster members.
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Any data collection through interaction means that the respondents are entitled to
protections as research subjects8,11.

4.

An individual from whom an investigator obtains identifiable private information

for the purpose of collecting data.
Obtaining identifiable private information about individuals within a cluster will
make these individuals research subjects, and therefore make them entitled to protections.
Conversely, there is no risk to an individual’s privacy if the researchers are only collecting
anonymized or aggregate group-level information43. Individuals whose data have been
anonymized before transfer to the investigators, or whose administrative or health-related
information is used to generate aggregate measures for a cluster are not research subjects
unless they are manipulated in some other way.

Practical Applications for Ethics Review of CRTs
We will now apply our new definition to the issues raised earlier in ‘Examples:
Challenges in identifying the research subject in CRTs”:
Example 1: The COMMIT Trial
The COMMIT trial1,2 evaluated a multimodal community-level intervention,
including a media and billboard campaign and targeted messaging toward smokers, aimed
at reducing cigarette consumption. These interventions did not directly manipulate
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individuals, but did intervene on individuals via environmental manipulation. Therefore,
individuals in the participating communities are research subjects.

Example 2: A CRT of bed net distribution to reduce malaria prevalence
The distribution of bed nets constitutes a direct intervention on individuals.
Therefore, all residents of the intervention communities who received a bed net are
research subjects. Individuals contributing blood samples, whether from intervention or
control communities, were also directly intervened upon and are research subjects. In this
study, no private identifiable information was collected. Therefore, citizens of control
communities who did not contribute blood samples, were not recipients of an intervention,
were not intervened upon via manipulation of their environment, did not interact with
researchers, did not contribute identifiable personal information, and were not research
subjects.
Example 3: A CRT comparing interventions to improve primary care prescribing
The physicians in this study were recipients of an experimental intervention, and are
research subjects. The patients received no intervention from study personnel, had no
interaction with the study personnel, and contributed no identifiable private information.
Therefore, the patients of physicians participating in this particular study are not research
subjects.
Example 4: A CRT comparing modes of educating patients prior to breast cancer surgery
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In this study, the patients were recipients of an experimental intervention in that they
received one of two candidate modes of education about their surgical options. They
responded to questionnaires to generate outcome data, and contributed identifiable medical
information. For all of these reasons, they are research subjects. The surgeons delivering
the experimental decision tool underwent training, while those in the control group had
their practices modified by using additional printed information. These educational
interventions and changes in practice are research interventions, meaning that the surgeons
participating in both arms of the study are also research subjects.

Conclusions and Future Work
We have defined a research subject as an individual whose interests may be
compromised as a result of interventions in a research study, and have specified four ways
in which research subjects’ interests may be compromised (Box 1). Research subjects are
those individuals who are intervened upon by researchers, either by direct interventions or
by deliberate manipulations of their environment, those who interact with researchers to
provide data, or those whose identifiable private information is used to generate data.
In articulating a principled definition of a research subject, with specifications that
help to identify research subjects, this paper represents an essential first step in addressing
additional questions on how to protect research subjects in CRTs. The specifications that
help define the research subject may be used by investigators and research ethics
committees to help ensure that research subjects in CRTs receive necessary protections and
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that important research is not hindered by incorrect application of research ethics
guidelines and regulations.
Subsequent papers will rely on this novel definition of research subject and analyze
the implications of this innovation on such issues as: informed consent; harm-benefit
analysis; subject selection and protection of vulnerable subjects; and the role and authority
of cluster gatekeepers in CRTs.
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Box 1. Definition of a Research Subject

A research subject is an individual whose interests may be
compromised as a result of interventions in a research study
including:
1. An individual who is directly intervened upon by an
investigator
2. An individual who is deliberately intervened upon via
manipulation of his/her environment by an investigator
3. An individual with whom an investigator interacts for the
purpose of collecting data
4. An individual about whom an investigator obtains
identifiable private information for the purpose of collecting
data.
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When is Informed Consent Required in Cluster Randomized Trials?
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Introduction
The question of when it is necessary to seek informed consent from subjects in
cluster randomized trials (CRTs) has stirred substantial discussion in the CRT literature.
In an article published in the British Medical Journal entitled “Ethical Issues in the
Design and Conduct of Cluster Randomized Controlled Trials”, Edwards et al. describe
the difficulties associated with obtaining informed consent in CRTs1. The authors suggest
that the requirement to seek informed consent is inextricably linked to the type of
interventions being evaluated. Their analysis relies on a distinction between two types of
CRTs: individual-cluster trials and cluster-cluster trials.
In individual-cluster trials, experimental interventions are directed at individual
cluster members but subjects are randomized in clusters in order to avoid experimental
contamination1. In these studies, it is generally possible to seek subjects’ informed
consent, just as in an individually-randomized trial.
Cluster-cluster studies, on the other hand, evaluate experimental interventions that
target entire clusters1. In these studies it may not be possible for cluster members to avoid
the experimental interventions, thus making individual refusal of the study interventions
meaningless.1,2 In addition, when dealing with large clusters, it may be logistically
impossible to seek consent from all cluster members1,3.
The relationship between trial type (individual-cluster or cluster-cluster) and the
feasibility of obtaining informed consent lies at the heart of the United Kingdom Medical
Research Council (MRC) document Cluster Randomized Trials: Methodological and
Ethical Considerations4. The authors of this document conclude that , if seeking consent
from individual subjects is feasible, then investigators are obligated to do so. If, on the
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other hand, seeking consent from individual subjects is not feasible, authorization to
enroll a cluster in the study must be sought from a cluster representation mechanism—an
entity or an individual charged with making decisions in the interest of the entire cluster.
Thus, according to both Edwards et al., and the authors of the MRC guidelines, whether
or not consent is required from individual subjects in CRTs depends on the feasibility of
doing so.
The association Edwards and colleagues identify between the type of interventions
being evaluated and the feasibility of seeking informed consent from individual cluster
members seems intuitively correct. Moreover, their conclusions are reflected in actual
practice, in that investigators routinely seek consent in CRTs evaluating individual-level
interventions, but not in CRTs evaluating cluster-level interventions5-7. Unfortunately, the
conclusion that the need to seek consent depends solely on the feasibility of doing so fails
to follow the general principles guiding human subjects research. If consent cannot be
obtained, then other conditions must be satisfied in order to safeguard subjects’ interests.
When must investigators obtain informed consent from human subjects in CRTs?
This paper seeks to answer this question by examining the challenges related to obtaining
informed consent in CRTs through the lens of research ethics. We first examine the
ethical principles and moral theories that underpin consent requirements in order to
develop a conceptual framework that lays out the fundamental purpose of informed
consent requirements. Using this framework, we address the key questions related to
informed consent in CRTs, namely: 1) How may CRTs proceed if seeking informed
consent is not feasible? 2) Is it permissible to seek informed consent after randomization
of clusters? 3) What information must be disclosed to potential subjects? 4) May opt-out,
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or passive consent strategies be used instead of seeking informed consent? 5) Do
professionals have an obligation to participate in CRTs?

Prior work: Who is a research subject?
Clearly identifying who is a research subject in a CRT—and who is not—helps to
address some of the concerns outlined in the CRT literature regarding the feasibility of
seeking consent in cluster-cluster trials1-3,7-9. In the preceding article in this series, entitled
“Who is the Research Subject in Healthcare Cluster Randomized Trials?” we developed a
principled definition of “research subject”10. We argued that a research subject is an
individual whose interests may be compromised in the context of a research study. This
includes any individual: 1) who is directly intervened upon by an investigator; 2) who is
deliberately intervened upon via manipulation of his/her environment by an investigator;
3) with whom an investigator interacts for the purpose of collecting data; 4) about whom
an investigator obtains identifiable private information for the purpose of collecting
data10. As a general rule, informed consent for CRT participation must be sought from
research subjects. Conversely, seeking consent from cluster members who are not
research subjects is not required.
The implication of using a principled definition of “research subject” are illustrated
using the example of patients managed by primary care physicians in the NEXUS trial 11.
In this CRT, 247 primary care practices were randomly assigned to receive interventions
designed to increase general practitioners’ compliance with radiography guidelines for
patients with nontraumatic back and knee pain. The comparative efficacy of the
interventions was evaluated by examining the change in number of lumbar spine and knee
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radiographs ordered per thousand patients per year for two years. These data were
obtained by abstracting data from patient records from a random sample of primary care
practices in each trial arm11.
The primary care physicians who received the experimental interventions were
research subjects, according to the definition of “research subject” outlined above.
Consent issues for professionals who are intervened upon in CRTs are discussed further
below.
The patients of physicians participating in the NEXUS study were not intervened
upon, either directly or via manipulation of their environment, nor did investigators
interact with them10,12. Investigators obtained identifiable private information from the
medical records of a sample of patients. Patients whose private information was used
were research subjects. Whether or not consent was necessary for this sample of patients
is discussed below. Patients whose medical records were not used were not research
subjects. Their consent was not required10,12.
The remainder of this paper will address consent requirements for research subjects
in CRTs. As a general rule, research subjects in a CRT must provide informed consent for
trial participation. As will be discussed below, exceptions to informed consent
requirements may apply to CRTs in clearly defined circumstances.
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Moral Foundations of the Requirement for Informed Consent
for Research Participation
Informed consent for research participation is a central ethical safeguard for
research subjects13-15. This section outlines the moral foundations of informed consent
requirements and examines how they apply to CRTs.
In the Belmont Report the National Commission for the Protection of Human
Subjects in Biomedical and Behavioral Research identified three basic ethical principles
for research involving human subjects: respect for persons, beneficence, and justice.
Consent requirements for research participation stem from the principle of respect for
persons14, which requires: 1) that the wishes of autonomous individuals be respected, and
2) that individuals with diminished autonomy be protected14.
Autonomous individuals may be understood as those who are capable of selfgovernment and are able to make responsible choices for themselves. Autonomous
choices are those that are intentional, substantially informed, and substantially free of
coercing influences16,17.
The principle of respect for persons may be viewed as deriving from deontological
moral theory, which defines right action as the satisfaction of moral duties16-19. Kantian
deontological theory posits that autonomous individuals have intrinsic moral worth in
virtue of their capacity for rational decision-making about their ends. Respect for the
intrinsic moral worth of others entails respect for their autonomous choices. The famous
Kantian dictum exhorts us to always treat others as ends in themselves rather than merely
as the means to an end17,18,20,21.
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The requirement to obtain informed consent for research participation is consistent
with the kinds of duties owed by investigators to autonomous individuals. According to
Freedman, consent requirements arise,
“…from the right which each of us possesses to be treated as a person, and in the
duty which all of us have, to have respect for persons, to treat a person as such, and
not as an object. For this entails that our capacities for personhood ought to be
recognized by all─these capacities including the capacity for rational decision and
for action consequent upon rational decision. 19”
Research necessarily involves “using” subjects as a means of acquiring scientific
knowledge. Why would an individual choose to become a research subject, thereby
jeopardizing her privacy or welfare for the sake of science? We suggest that the rational
research subject would only agree to such constraints if she agreed with the goals of the
study. In consenting to study participation, the research subject adopts the scientific ends
of the study as his or her own. Granting one’s consent to participate would, therefore,
signal that the research participant is treated as an end in and of herself and not merely a
means of and was fulfilling the researchers’ objectives.
Another way of getting at the essence of informed consent may be by contrasting
two operational definitions thereof, namely, autonomous authorization and effective
consent. Autonomous authorization is a moral concept according to which a person
chooses to adopt the goals of research as his or her own and thereby consents to study
participation17. The individual must be informed, competent and free from coercion.
Effective consent, by contrast, is a legal concept, relating to a legally or
institutionally circumscribed definition of the conditions for valid decision-making17.
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Autonomous authorization and effective consent are often functionally synonymous.
However, this is not always the case. For example, a teenager may have the rational
capacity to make an autonomous authorization but not to provide effective consent if
proscribed from doing so on account of his or her age17.
We can therefore understand autonomous authorization to research participation
practically as the subject’s agreement to the interventions that are part of the research
protocol, and conceptually as the subject’s embracing of the goals of the research study19.
Ideally, legal or policy criteria for effective consent should be derived from the necessary
conditions for autonomous authorization. If the purpose of informed consent regulations
is to enable autonomous decision-making i.e., to allow subjects to choose whether or not
to adopt the ends of the study as their own, then research ethics regulations and guidelines
must be evaluated on the extent to which they accomplish this purpose 17.
Research ethics guidelines lay out the criteria for effective consent for research
participation, and thus fulfil the end of enabling autonomous authorization. Informed
consent guidelines require that potential subjects have the capacity to decide whether or
not to participate in the research study at hand; that their decision be free of coercion; that
they be adequately informed of the details of the study’s purpose and interventions; and
that they understand the information given to them15,22-24.
Disclosure requirements almost universally include the following: an explanation of
the purpose of the study; a description of the study interventions; a description of the risks
and potential benefits to subjects from research participation; a description of alternatives
available to potential subjects should they choose not to participate; a description of
confidentiality protections; a statement assuring potential subjects that participation is
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voluntary, that they may withdraw at any time, and that their quality of care will not be
affected should they choose not to participate or to withdraw; and information on whom
they may contact with questions15,22-24. If these disclosure requirements are met, then
potential subjects will be able to decide whether or not to embrace the study’s ends as
their own.
In the remainder of this article, we address the ethical challenges associated with
obtaining informed consent in CRTs will be addressed using the following ethical
framework:
1)

Consent requirements stem from the basic ethical principle of respect for
persons, which requires that the choices of autonomous individuals be
respected.

2)

The principle of respect for persons may be rooted in deontological moral
theory, which posits that autonomous individuals have an intrinsic worth
and are entitled to respect.

3)

Autonomous individuals shall not be used solely as means to an end. They
must also be treated as ends in themselves.

4)

The purpose of seeking informed consent is to enable potential subjects to
embrace the ends of the research study as their own.

Addressing consent challenges in CRTs
Prior to considering specific issues related to seeking consent in CRTs, it is
important to be clear about what consent is for. In individually randomized clinical trials,
consent is obtained prior to randomization and includes consent for random assignment,
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for the experimental interventions in either study arm, and for the interventions used to
collect data. In CRTs, all of these may be disaggregated: consent for random assignment,
experimental interventions, and for the interventions used to collect data may be sought
separately. This disaggregation may be necessary because of the intrinsic features of the
CRT design. It may not be possible to seek consent for random assignment if individual
cluster members are not identifiable at the time of cluster randomization. In individualcluster trials, seeking consent for the experimental interventions may be feasible,
independent of whether or not it is possible to seek consent for random assignment. In
cluster-cluster trials, it may or may not be feasible to seek consent for the experimental
interventions. Furthermore, if the interventions are unavoidable, refusal would be
meaningless. Even if it is not possible to seek consent for randomization or for
experimental interventions, it may be possible—and necessary—to seek consent for data
collection procedures such as physical examinations, interviews and the use of
identifiable private information.
Specific questions relating to seeking consent in CRTs are addressed in detail
below.
1)

How may CRTs proceed if seeking consent is not feasible?
Edwards et al.1, Hutton2, and Donner and Klar3 have noted that, in certain

circumstances, seeking informed consent from cluster members in a CRT may not be
feasible. There are two reasons for this. Firstly, that clusters may be large enough that the
logistical difficulties associated with seeking consent from all cluster members would
make the study infeasible3. Secondly, some cluster-level interventions may be
unavoidable, effectively rendering individual refusal meaningless1,2.
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A CRT conducted in India randomly assigned nine geographical sectors in Punjab
either to an insecticide spraying program to reduce malaria transmission, or to no
intervention25. The effect of the spraying program on malaria incidence was evaluated by
collecting blood samples from residents reporting a fever and also through cross-sectional
surveys in which blood samples were collected from schoolchildren in participating
communities. The spraying program intervened on residents via environmental
manipulation; therefore all residents of sectors in the intervention arm were research
subjects10,22.
In this case, it would have been exceedingly difficult to seek informed consent from
all individuals in intervention sectors. Moreover, even if it were possible to obtain
consent, the environmental intervention was unavoidable. What would have been the
point of obtaining informed consent? This begs the question: how may such a CRT be
performed if seeking subject consent for the experimental intervention is impossible?
Such a trial may qualify for a waiver of informed consent as provided for in many
national and international research ethics guidelines15,22,26. The moral justification for a
waiver of informed consent lies in the relationship between the basic principles of respect
for persons and beneficence14,16,17. When a conflict between basic principles occurs, we
must weigh the relative importance of the competing moral demands of each
principle27,28. The principle of respect for persons entails the moral requirement to seek
informed consent from potential subjects. Beneficence requires that investigators
minimize harms while maximizing benefits, and that risks to subjects must be offset by
either benefit to the subjects themselves, or to society14. We may argue that beneficence
entails a requirement to pursue valid research for the betterment of society. Because
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neither principle supersedes the other, a moral justification for a waiver of informed
consent lies in prioritizing the competing demands of each.
Seeking informed consent from subjects allows them to exercise their autonomy in
adopting the ends of the study as their own, and allows them to safeguard their own
interests. If subjects’ interests can be safeguarded in another way, then there may be cases
in which the demands of beneficence—producing valid research to benefit society—may
reasonably outweigh the demands of respect for persons—to seek informed consent from
subjects. A waiver of consent is only permissible if the risks to subjects’ interests, and the
consequences of setting aside their autonomy rights, are minor, and if the social benefits
that may accrue from the research cannot be otherwise obtained.
This is not a utilitarian argument. A utilitarian might conclude that societal benefit
necessitates overriding the autonomous wishes of a small number of research subjects
even when consent could be obtained, and where subjects’ interests at stake are
significant. Rather, this is a principled moral foundation for guidelines permitting a
waiver of consent in narrowly-specified circumstances.
Numerous examples exist22-24,29,30, but the oldest regulation outlining the
requirements for an alteration or waiver of informed consent is found in the US Common
Rule (45 CFR 46.116d), first published in 198122. The Common Rule requires that
following conditions all be met in order for an alteration or waiver of consent
requirements to be approved by an ethics committee:
(i) The research involves no more than minimal risk to the subjects;
(ii) The waiver or alteration will not adversely affect the rights and welfare of the
subjects;
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(iii) The research could not practicably be carried out without the waiver or
alteration; and
(iv) Whenever appropriate, the subjects will be provided with additional pertinent
information after participation31.
The majority of national and international guidelines for waivers of consent are based on
the protections outlined above, and are substantively similar in both language and
application22-24,29,30. A detailed discussion of each of these requirements follows.

1.1) The research involves no more than minimal risk to the subjects
According to the rules and regulations governing human subjects research drafted
by the US Department of Health and Human Services, minimal risk means that “the
probability and magnitude of harm or discomfort anticipated in the research are not
greater in and of themselves than those ordinarily encountered in daily life or during the
performance of routine physical or psychological examinations or tests.32” In other words,
the risks to subjects from interventions in a CRT must be similar to the risks posed by
interventions in routine healthcare, public health or educational practice. Minimal risk
interventions for data collection include, but are not limited to, interviews, surveys,
physical examinations, and collection of data from patients’ medical records32.
Many CRTs would meet this minimal risk criterion. In healthcare CRT, for
example, the interventions being evaluated are generally variations on routine care and do
not pose any additional risk. Data collection is often accomplished using subjects’
medical records, or by using physical examinations or interviews. Thus, the datacollection interventions in healthcare CRTs often pose only minimal risk.
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In the malaria prevention CRT described above25, geographical districts were
randomly assigned either to a pesticide spraying program or to a control. The
implementation of a pesticide spraying program is consistent with the kinds of measures
that a public health department would ordinarily undertake, so the pesticide spraying is
consistent with the risks of daily life for residents of intervention communities. Therefore,
the experimental intervention poses only minimal risk to subjects. If it can be successfully
argued that seeking consent from individual residents for spraying is not feasible, a
waiver of consent for the pesticide spraying intervention is reasonable.

1.2) The waiver or alteration will not adversely affect the rights and welfare of the
subjects
The meaning of the second requirement, that the waiver or alteration must not
adversely affect the rights and welfare of subjects, is not elaborated on in the text of the
Common Rule. So what, exactly, does it mean? The National Bioethics Advisory
Commission has suggested that safeguarding subjects’ rights means ensuring that
investigators and ethics committees adhere to other federal or state statutes that might
offer more stringent privacy protections than the Common Rule33. This interpretation
seems redundant, in that any other regulations with more stringent privacy protections
will override the Common Rule.
It seems counterintuitive that a requirement to preserve the rights and welfare of
subjects is included in regulations permitting a waiver of consent, which outline precisely
when the autonomy rights of research subjects may be set aside. It is, perhaps, more
helpful to consider this second requirement as a complement to the first requirement that
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risks be minimal. Both of these requirements are aimed at ensuring that subjects’ interests
(be they welfare interests, financial interests, economic interests or other) are not
unreasonably jeopardized in the context of a research study that uses a waiver of consent.

1.3) The research could not practicably be carried out without the waiver or alteration
CRT investigators have suggested that some studies may not be feasible without a
waiver of consent for a variety of reasons. These generally relate either to the feasibility
of obtaining consent from individual subjects1,2,8, or to the potential for biased responses
because of information disclosed during the consent process1,2,5,9. Each of these reasons
for seeking a waiver of informed consent will be examined separately.

1.3.1) Seeking consent may not be feasible
In CRTs of cluster-level interventions, it may be impossible for cluster members to
avoid the intervention1,2. Informed refusal is effectively meaningless if the intervention is
unavoidable. Some CRTs may randomize clusters that are so large as to make obtaining
consent from all subjects logistically impossible1,2,8.
The preamble to the Common Rule explicitly states that large scale public health
studies in which it is impossible to obtain consent from all individuals who may be
affected by the study intervention may be eligible for a waiver31. It is reasonable to extend
this conclusion to CRTs in other fields of inquiry.
A waiver of consent may be used in studies that do not involve an interaction with
or intervention on subjects, but that do use identifiable private information to collect
outcome data 33. This practice has been justified because the logistical effort required to

162

obtain consent from subjects for the use of their private information is prohibitively
difficult21. This applies particularly to healthcare CRTs that intervene on health
professionals and only use patient information to generate effect measures for the
interventions under study. In such studies, it would not be necessary to seek the consent
of the patients whose private information is used to generate data. In the NEXUS study
cited above, for example, consent was not sought for abstracting identifiable private
information from the medical records of patients to evaluate the effect of experimental
interventions administered to those patients’ primary care physicians11.
No sharp demarcation exists to determine when seeking consent is practicable or
impracticable. This determination, rather, is within the discretionary authority of a
research ethics committee. An ethics committee may consider a number of factors in
making this determination, including the size of the population, as well as the cost and
logistical feasibility of seeking consent from all subjects34. If a waiver is desired, CRT
investigators must convince the research ethics committee that seeking consent from
subjects is not feasible. The ethics committee, in turn, is charged with making the
qualitative determination as to whether the risks to subjects are minimal and the societal
benefit that may be gained by performing the research without obtaining informed
consent outweighs the autonomy interests of individual subjects.
The malaria-prevention pesticide study cited above25 would likely satisfy the
criterion that the study could not practicably be carried out without the waiver. The
spraying intervention could not be avoided by residents of intervention clusters. The
clusters are also sufficiently large that seeking informed consent from individual residents
for the spraying intervention would be so logistically difficult as to make seeking
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informed consent infeasible. Therefore, because seeking consent is infeasible and because
the spraying intervention poses only minimal risk, the pesticide spraying study would
likely be eligible for a waiver of informed consent for the spraying intervention under
current research ethics guidelines15,22,26.

1.3.2) Potential for bias because of information provided to subjects during consent
negotiations
It has been suggested that the potential for bias in CRTs as a result of information
disclosed in the consent process may be sufficient to justify a waiver of consent1,9,35,36.
CRTs often evaluate interventions aimed at modifying the behaviors of cluster members.
Knowledge of the purpose and nature of interventions offered to the other arms of a trial
may bias the outcome of the study. For example, a CRT may evaluate an intervention to
improve physician uptake of clinical practice guidelines. If members of the control group
know the details and purpose of the intervention, they may choose to familiarize
themselves with the guidelines, thus biasing the estimate of the intervention’s effect35.
Some commentators have suggested that the potential biasing effect of the consent
process for such trials may justify modifying or waiving consent requirements, because
undertaking an experiment that is scientifically invalid is unethical1,9,35,36.
There is no specific regulatory guidance that provides criteria for determining when
concerns for study validity might outweigh obligations to seek subjects’ informed
consent34. Concern for bias is one justification for the use of a waiver4,34. Investigators
concerned that information disclosed during the consent process might bias study findings
may apply for a waiver of consent. An application to the research ethics committee for a
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waiver must demonstrate that the CRT meets regulatory criteria for a waiver. Specifically,
investigators should provide convincing evidence that disclosure would so bias the study
findings as to make the study impracticable. Investigators must also demonstrate that the
interventions under study pose only minimal risks to subjects. This approach fits with the
moral justification for a waiver of consent: that the societal benefit of research knowledge
may not be obtained otherwise and the risks to subjects’ interests, and that the
consequences of setting aside their autonomy rights, must be minor.

1.4) Whenever appropriate, the subjects will be provided with additional pertinent
information
Respecting the research subject as a person, not simply as a means to an end,
requires that the nature and purpose of the research be disclosed. Providing subjects with
information about the study when a waiver of consent is used is therefore important in
ensuring that subjects are respected as persons19. Yet, how does this requirement apply to
CRTs that use a waiver of consent? If obtaining consent from subjects in large CRTs is
logistically impossible, it is likely that providing subjects with additional information is
equally impossible. Providing additional information to subjects through the media or
signs in healthcare institutions that a study is being conducted, and that they are entitled
to seek more information from study investigators may be one way of satisfying this
requirement.
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Waivers of consent in CRTs with cluster-level and individual-level interventions
It is important to note that a waiver of consent may apply to some, but not all,
interventions in a CRT. Some studies evaluating cluster-level interventions evaluate
outcomes by collecting data from a smaller sample of each cluster. For example, in the
pesticide-spraying example CRT cited above, malaria incidence was ascertained by
screening residents and obtaining blood samples of individuals with fevers and from a
cross-section of school children25.
Because each individual who undergoes additional examinations, interviews, or
tests to generate data is identifiable and accessible, it is feasible to seek consent for datacollection interventions. In this case, a waiver of consent would only apply to the
pesticide-spraying intervention.
Informed consent for data-collection procedures should be sought when doing so is
feasible, even if these interventions pose only minimal risk. One example of a datacollection intervention that may be eligible for a waiver is the review of a large number of
medical records, as was done for research subjects in the NEXUS study cited above11.

2)

May informed consent be sought after randomization of clusters?
As random assignment of clusters is often done before the intervention is

administered, it may be impossible to obtain consent until after randomization has been
completed35. Hutton notes, “Scientific and logistical constraints associated with [CRTs]
imply that consent cannot necessarily be requested before an intervention is assigned to a
person…In some cases it is logically impossible to obtain consent for the intervention
prior to randomization of clusters. 2”
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An example of such a study is a CRT conducted in Nepal that evaluated the
comparative efficacy of three different strategies for umbilical stump cleansing on
neonatal mortality and incidence of omphalitis (infection of the umbilical stump)37. The
units of randomization were geographical sectors of rural Nepal. Mothers were randomly
assigned in geographical clusters to use either dry cord care (the standard technique, used
in the control arm), to washing the stump with soap and water, or to use a disinfectant
solution for stump cleansing. The stump care techniques were performed on the infants by
health workers who visited new mothers on a predetermined schedule. Neonatal mortality
and incident cases of omphalitis were recorded by the visiting health workers. Each
mother gave informed consent for study participation during a prenatal health visit37.
Enrolling subjects prior to randomization of clusters was not possible because mothers
had not yet become pregnant at the time of cluster randomization.
Some commentators have expressed concern that seeking subjects’ consent for CRT
participation after cluster randomization may not respect subjects’ autonomy rights2,8.
Based on our understanding of the purpose of seeking informed consent, this concern
appears unjustified.
The purpose of seeking informed consent is to enable subjects to autonomously
embrace the ends of the study as their own. This purpose is still achieved if consent for
CRT participation may only be sought after random assignment of clusters, and if
subjects are approached for consent at the earliest possible opportunity. If potential
subjects are informed that group assignment has already been determined, then they may
freely choose whether or not to participate in the CRT. The fact that group assignment has
already been determined does not limit potential subjects’ autonomy or their ability to
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embrace the study’s objectives as their own. Potential subjects may freely choose whether
or not to participate in the CRT. Thus, it is permissible to seek informed consent for CRT
participation after randomization has been done.
In the Nepalese CRT cited above, it was impossible to seek informed consent prior
to randomization of clusters. However, mothers were free to decide whether or not to
participate in the study. The purpose of seeking informed consent─enabling potential
subjects to make autonomous choices to adopt the scientific purpose of the study as an
end of their own─was still achieved in this trial, even though consent was sought after
random assignment of clusters.

3)

What information must be disclosed to subjects?
Potential research subjects must be given sufficient information to allow them to

decide whether or not to participate in a study19. As outlined above, guidelines for
disclosure during consent processes generally include a statement of the study’s purpose,
a description of the nature, risks and potential benefits of the interventions involved, and
the potential subjects’ options should they choose not to participate 15,22-24.
If subjects are enrolled after randomization of clusters has taken place because
seeking consent prior to randomization is impossible, they must still be informed of: the
purpose of the study, detailed information about the trial arm to which they have been
assigned, and information about their options should they choose not to participate in the
trial.
Information about the purpose of the study is essential to a potential subjects’
decision as to whether or not they can embrace the study’s scientific ends as their
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own17,18,20,21. Therefore, the purpose of the study must be described in sufficient detail so
as to allow potential subjects to decide whether or not the study’s ends are consistent with
their values.
Potential subjects must be provided with a detailed description of the interventions
administered in the trial arm to which their cluster has been randomly assigned.
However, detailed information about other arms in a CRT is not necessary. The choice
facing the potential subject is whether to participate in the CRT, in the arm to which their
cluster has been assigned, or not to participate in the CRT. Detailed information about the
interventions offered in other arms of the trial (i.e. interventions that the subject would
not receive) is immaterial to the potential subject’s decision whether or not to participate.
In the Nepalese umbilical stump care study cited above37, a consent form provided
to mothers whose clusters were assigned to the chlorhexidine arm, for example, would
include the following details:
“The purpose of this study is to determine whether any of three different
techniques for cleaning your infant’s umbilical stump is more effective in
preventing stump infection or death. Health workers in participating communities
were randomly assigned to use one of three different stump cleaning techniques.
The health workers from your community who visit you after the birth of your
baby will be using a mild disinfectant solution to cleanse your baby’s umbilical
stump. Specifically, on the 1st, 2nd, 3rd, 4th, 6th, 8th, 10th, 12th, 14th, 21st and 28th day
after your baby’s birth, you will be visited by a health worker who will cleanse
your baby’s umbilical stump using the mild disinfectant solution. They will also
examine the umbilical stump for infection and examine your baby for signs of
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more serious infection. On day 1 and 14, they will also ask you questions about
factors that may affect your baby’s risk of infection”
One fortuitous effect of the use of tailored disclosure between different arms of a
CRT is that the potential for bias may be mitigated. Commentators have expressed
concern that, if subjects assigned to the control arm were informed about the content of a
behavioural intervention in the experimental arm during the consent process, they may
modify their behaviour in such a way that their response to the control interventions may
spuriously approximate the response of individuals in the intervention arm1,9,35,36.
For example, in the umbilical stump care study37, if mothers assigned to the dry
stump care arm surreptitiously used soap and water because they were informed of this
technique during the consent process, the study’s findings may be biased toward a null
effect of the intervention. But, if consent is sought after randomization of clusters, it is not
necessary to provide subjects in one arm of a CRT with information about the
interventions in other arms. Thus, the potential for bias is minimized.

4)

May passive consent be used in CRTs?
In some large CRTs of cluster-level interventions36,38-40, investigators have used a

“passive consent” approach to subject recruitment. In the passive consent approach,
investigators take steps to inform potential subjects that a research study is being
conducted, and may even provide information about the study itself. If investigators
receive no indication from a potential subject that he/she objects to being enrolled in the
study, then that subject is presumed to have agreed to participate. This technique is
commonly used in CRTs in education. Information about the purpose and interventions in
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a study are sent home with students. If the students do not return a document, signed by
their parent or guardian, that they decline participation, then they are presumed to agree to
study enrolment38.
In health services research, passive consent is used somewhat differently. In many
studies conducted in healthcare settings, notices are posted in patient areas that research is
being conducted, although detailed information about the study is not provided. The
notices indicate that, if the patients do not wish to participate in the research study, then
they may contact the investigators in order to opt out36,39,40. It may be impossible for
subjects to opt out of some cluster-level interventions, although it may be feasible for
subjects to opt out of data collection1,7.
A passive consent model is best thought of as an alteration of consent processes that
are permitted under various waiver of consent guidelines22,23,26. When used as described
above in healthcare CRTs, an opt-out model satisfies none of the elements of informed
consent. Subjects cannot be assumed to have embraced the study’s scientific ends as their
own. There is no assessment of subjects’ decision-making capacity. There is no assurance
that potential subjects are making decisions freely. The notices posted typically do not
offer sufficient information for potential subjects to make a responsible choice whether or
not to participate. There is no assurance that potential subjects understand the information
provided in the notice. Indeed, there is no assurance that all potential subjects have even
seen the notice.
When passive consent is used in school-based studies, the information sent home
with students often contains sufficient information to enable a capable parent or guardian
to decide whether or not to allow their child to participate in the CRT38. However, there is

171

no assurance that each child will give the information to their parent. There is no
assurance that the parent or guardian understands the information. Nor is there any
assurance that the parent or guardian is capable of deciding whether or not to permit their
child to participate in the CRT38.
The use of a passive consent model is subject to the same regulatory demands as the
use of a waiver of consent. An investigator must convincingly argue that the research is
not feasible without the alteration of typical consent practices. The interventions in a
study using a passive consent model must pose only minimal risk. Because passive
consent models are subject to the same regulatory requirements as a waiver of consent,
passive consent approaches are not any more protective of subjects’ autonomy and
welfare interests than a waiver.
Although passive consent models do not offer any additional protection beyond that
offered under waiver of consent guidelines, the use of passive consent may be justified on
pragmatic grounds. For example, in school-based CRTs, passive consent may be required
by school administrators or parent groups38. A hospital-based CRT evaluating a quality
improvement intervention for diabetes care used a passive consent model because
“clinicians and the laboratories owned by community hospitals were worried about public
concern as patients discovered they were enrolled without consent into a research
project.39” CRT investigators may choose to use a passive consent strategy for similar
pragmatic reasons.
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5)

Are professionals obligated to participate in CRTs of interventions designed to

improve their practice?

In CRTs evaluating an educational intervention on professionals, such as teachers or
health care workers, the professionals are the recipients of an experimental
intervention2,10,41,42 and are, therefore, research subjects10,41,42. In order to reasonably bear
the burdens of research participation, they must be able to embrace the study’s ends as
their own. Therefore, informed consent must generally be obtained10,41,42. However, there
may be circumstances in which seeking consent from professionals is logistically
difficult. In such cases, CRTs may meet regulatory criteria for a waiver of consent.
The NEXUS study cited above evaluated the comparative efficacy of educational
reminder messages or audit and feedback on adherence to clinical practice guidelines for
lumbar spine and knee radiography11. Two-hundred-and-forty-seven clusters of primary
care practices were randomly assigned to receive either reminder messages, audit and
feedback, both interventions, or simply a mailed copy of the practice guidelines. The
study investigators argued that seeking consent from all physicians in each of those 247
primary care practices was so impracticable as to make the study unfeasible, and that the
interventions were sufficiently similar to routine activities that they posed only minimal
risk35. Similar large-scale studies of interventions designed to improve professional
practice may meet regulatory criteria for a waiver of consent for health
professionals15,22,23,26
Some investigators have argued that professionals may have obligations to
participate in CRTs that would override their right to autonomously choose whether or
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not to participate2,5,35. This suggestion is based on two claims. First, that professional
obligations to engage in continuing professional development entail an obligation to
participate in CRTs5,35. As Hutton claims: “In some cases, the experimental units, that is,
professionals, might have a duty to enrol as part of their continuing professional
development.2” Second CRTs may offer direct or indirect benefits to patients, thereby
obligating health professionals to participate5,35. According to Hutton and colleagues,
“…If a health care professional chooses not to participate in a study, they are in effect
denying their patients the potential benefits of participation.35” Both of these claims may
be refuted.
Health professionals are required to engage in continuing professional development
as a matter of professional obligation and as a condition of licensure in many
jurisdictions43. Physicians, in particular, have a great deal of latitude in determining the
means by which the continuing education is completed. Acceptable options may include
self study, conference attendance, preparation for teaching, and formal educational
programs leading to a degree or diploma44. This wide discretion in choosing professional
development activities undermines any claim that health professionals have an obligation
to participate in CRTs. Participation in a CRT of an educational intervention may be one
among many acceptable options for engaging in continuing education. Given the
numerous ways in which a health professional may meet their continuing professional
development obligations, there is no basis on which an obligation to participate in CRTs
of educational interventions can be derived from continuing professional development
obligations.

174

The fact that an educational or quality improvement intervention is being evaluated
in a CRT means that its efficacy is unproven45,46. If there were certainty as to the efficacy
of an educational or quality improvement intervention, a CRT would be unethical45, and
professionals would be able to access that effective intervention through ordinary means.
The uncertainty about the efficacy of an educational or quality improvement intervention
undercuts any argument that professionals ought to participate in CRTs for the good of
those that they serve.
In addition, control groups in CRTs may receive either no intervention or some
other intervention that approximates routine practice. This further undermines arguments
that professionals ought to enroll in CRTs because of their obligation to act in the interest
of those whom they serve.
It is therefore possible to make three conclusions about professionals who are
research subjects in CRTs: 1) neither fiduciary obligations nor professional obligations to
engage in continuing education require health professionals to participate in CRTs; 2)
when it is possible to seek consent from professionals for participation in a CRT, their
consent should be sought; 3) some CRTs, in which it is not feasible to seek consent from
all professional subjects, and in which the interventions under study pose only minimal
risk, may be eligible for a waiver of consent.

Summary
Numerous commentators1-3,7,9,35 have identified the difficulties associated with
obtaining informed consent for participation in CRTs. This paper has addressed these
challenges by appealing to basic ethical principles, and to the moral theories that underpin
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these principles. Consent requirements stem from the principle of respect for persons,
which requires that the choices of autonomous individuals be respected. Seeking
informed consent empowers research subjects to choose to adopt the study ends as their
own, authorizing interventions that serve a scientific purpose. This conceptual framework
leads to specific conclusions about key ethical issues that arise because of the unique
methodological features of CRTs. These may be formulated as a set of guidelines for
investigators and research ethics committees to identify when consent must be obtained
from participants in CRTs:

1.

As a general rule, consent must be obtained from all subjects in CRTs.

This includes cluster members, as well as individuals who may be the recipients of
interventions designed to produce a cluster-level effect such as health professionals or
teachers. However, many CRTs may meet the regulatory criteria for a waiver of informed
consent.
2.

If random cluster assignment occurs prior to subject enrolment, subjects

must be informed of the purpose of the study, the nature of the interventions to which
they will be exposed in the arm of the study to which they have been assigned, and their
options should they choose not to participate.
3.

There is no obligation to inform potential subjects of interventions that are

exclusive to other study arms and inaccessible by other means. Potential subjects must be
informed of the details of the trial arm to which their cluster has been randomized, and of
other options should they choose not to participate.
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4.

Passive consent strategies are not a sufficient substitute for obtaining

informed consent, nor do they offer any advantage to subjects beyond the additional
protections that are required for a waiver of consent. However, a passive consent strategy
may be chosen for pragmatic reasons, provided that regulatory criteria for a waiver of
consent are met.
5.

Large CRTs that intervene on professionals may be eligible for a waiver of

consent from those professionals, provided that seeking consent from all of the
professionals is impracticable and that the interventions pose only minimal risk. However,
CRT participation cannot be construed as a professional obligation. If seeking consent
from professionals who are research subjects is feasible, then such consent must be
obtained.
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Chapter 7

Summary and Discussion
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Summary of Findings
This dissertation has two principal objectives. The first objective is to empirically
describe current practices in addressing ethical challenges in healthcare CRTs, with an
emphasis on informed consent. The second objective is to answer two normative questions:
1) Who is the research subject in CRTs? and 2) When is informed consent required from
subjects in a CRT?
Empirical Work:
Chapter Three
The empirical evaluation of current research ethics practices began by identifying
features of CRTs that are associated with the reporting of obtaining informed consent from
patients in a large sample of published CRTs. A sample of 161 CRTs performed in
healthcare settings were identified from a random sample of CRTs published between
2000-2008. Both bivariable and multivariable regression analyses were used to examine the
relationship between reporting of patient consent and such features as: the date of
publication; country of study conduct; journal impact factor; average cluster size; use of
patient-level experimental interventions and patient-level data collection interventions; and
reporting of the study as quality improvement research.
In our sample of healthcare CRTs, reporting of informed consent from patients was
independently associated with the use of experimental interventions directed at patients,
with the use of patient-level data collection interventions, with smaller cluster sizes, and
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with publication in recent years. Lack of reporting of informed consent from patients was
independently associated with publication in lower impact journals, and with study conduct
in developing countries.
It is not unreasonable to infer that reporting of patient consent reflects actual
consent practices. Therefore, investigators are more likely to seek patient consent in CRTs
that use patient-level interventions and in studies with small cluster sizes. These findings
are in keeping with published commentaries on the ethics of CRTs which speculate that it
may not be possible to seek informed consent in studies evaluating cluster-level
interventions1-5 or in studies with large cluster sizes1,5.
Consent practices were only described in 60% of CRT reports: consent was
obtained in 53%, while consent requirements were waived in another 7% of studies. 40%
of study reports do not mention consent practices, in spite of the requirement to document
in study reporting guidelines6. It may be that a waiver of consent was used in a large
proportion of studies that did not report their consent practices. However, this should have
been documented. The fact that consent procedures were not described is a significant
failure of these reports and the journals that published them.
Chapter Four
A purposive sample of twenty experienced CRT investigators was interviewed with
the goal of describing how experienced researchers have addressed ethical challenges in
practice. Informants participated in a semi-structured interview, which included questions
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on ethical challenges encountered in practice, experiences with the ethics review process,
and the need for comprehensive international ethics guidelines for CRTs.
The scope of ethical concerns identified by informants paralleled the scope of
ethical concerns identified in the CRT literature. Informants’ responses focused largely on
consent issues and the role of cluster decision-makers. The analysis of the interviews
suggested that, as in the CRT literature, important ethical challenges such as the analysis of
harms and benefits of CRTs and justice issues are less important to, or unappreciated by,
experienced CRT investigators.
With respect to informed consent practices, the findings of this study were similar
to those of the quantitative analysis in the previous chapter. Informants confirmed that
whether consent was sought from individual cluster members in practice depended on the
kinds of intervention under study. Informed consent is sought more often in CRTs of
individual-level experimental interventions than in CRTs of cluster-level interventions.
Informants also offered testimony that ethics review procedures and consent
requirements have become more stringent in recent years. This qualitative finding agrees
with the quantitative finding that investigators reported seeking patient consent more
frequently in studies published 2005-2008 compared to studies published 2000-2004.
Informants had differing views of the impact that the ethics review process has had
on their work. Some informants felt that the questions asked by research ethics committees
had a positive effect on CRT protocols. Others felt that requirements imposed by research
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ethics committees, such as the need to seek subjects’ consent, had a negative impact on
study validity.
Informants cited variability in research ethics review as an important impediment to
the conduct of multicentre CRTs. They also felt that comprehensive international ethics
guidelines would be useful in educating research ethics committees about the unique
methodological features of CRTs and the ethical issues stemming therefrom. One important
purpose for international ethics guidelines for CRTs would be to encourage uniformity in
research ethics review.
Normative Work:
Chapter Five
Prior to being able to address issues relating to consent, the analysis of risks and
potential benefits, and equitable subject selection, it is essential to be clear about who is the
research subject in a CRT. Research subjects in CRTs must be correctly identified to
ensure that subjects are adequately protected and that research is not hampered by the
inappropriate application of research ethics regulations in situations in which cluster
members are not research subjects.
The question of who is a research subject was answered by identifying the features
common to different regulatory definitions of “research subject”, and evaluating these
features in the light of conceptual work describing the distinction between a patient and a
research subject in a clinical trial. We define a “research subject” as an individual whose
interests are put at risk in the context of a research study. This may occur if the individual
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is directly intervened upon, is intervened upon via manipulation of his/her environment,
interacts with the research team, or contributes identifiable private information.
This definition of “research subject” has important implications for the ethics of
CRTs. First, individuals who receive interventions intended to produce a cluster-level
effect are research subjects. This includes health professionals and teachers who receive
educational or quality improvement interventions that are being evaluated in the CRT. It is
important to recognize that these individuals have interests that may be compromised in the
context of a CRT, and that they merit protection as research subjects. This is a separable
issue from whether or not consent is required from these subjects—a question considered
in chapter six.
Second, some cluster members may not fulfil the definition of “research subject”.
Cluster members who are not intervened upon, either directly or via manipulation of their
environment, who do not interact with investigators, and who do not contribute identifiable
private information are not research subjects. This includes patients whose health
professionals are intervened upon in a CRT of an educational or quality improvement
intervention. They are not intervened upon directly, nor does any indirect effect of the CRT
intervention on their care constitute an environmental manipulation. If they do not interact
with researchers or contribute identifiable private information, then they are not research
subjects. It follows that, if they are not research subjects, their consent for research is not
required.
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Chapter Six
Working with this definition of “research subject”, we then addressed the question
of when consent is required in CRTs. We did so by relying on a conceptual framework
grounded in the basic ethical principles and a moral theory that supports these principles.
This framework outlines the purpose of seeking informed consent and may be summarized
as follows: consent requirements stem from the basic ethical principle of respect for
persons, which requires that the choices of autonomous individuals be respected. The
principle of respect for persons may be viewed as being rooted in deontological moral
theory, which posits that autonomous individuals have an intrinsic worth and are entitled to
respect. Autonomous individuals must not be used solely as means to an end; they must be
treated as ends in themselves. The purpose of seeking informed consent is to enable
potential subjects to embrace the ends of the research study as their own.
As a general rule, informed consent must be obtained from all research subjects in a
CRT. If it is not possible to obtain informed consent from subjects prior to randomization
of clusters, then seeking informed consent after randomization is permissible. Potential
subjects may choose to participate in the CRT—or not—knowing the trial arm to which
their cluster has been assigned. That cluster randomization has taken place before cluster
enrolment does not diminish a potential subject’s ability to freely choose whether or not to
embrace the study’s ends as their own. Nor does it treat a subject solely as means to an end,
provided that informed consent is sought at the earliest opportunity—and before any
research interventions are performed on that subject.
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If subjects are enrolled after clusters have been assigned to different trial arms, then
they need only be provided with information material to their choice whether or not to
participate in the CRT, namely the purpose of the study; the nature, risks and potential
benefits of interventions that they would undergo in the arm to which their cluster has been
assigned; and their options should they choose not to participate.
In studies of cluster-level interventions that are impossible to avoid, the use of a
waiver of consent for the study interventions may be permissible, although consent for
some data collection procedures may still be required. A waiver of consent may be used for
CRTs of minimally risky interventions if seeking informed consent from all subjects would
make the study unfeasible. This may be the case in very large clusters, or if the only
individual-level intervention is the use of identifiable private information that is collected
from administrative sources such as medical records. If data collection interventions such
as physical examinations, interviews or specimen collections are performed on cluster
members, then informed consent should be sought for these interventions.
Professionals cannot be required to participate in a CRT as a consequence of
professional obligations. However, circumstances may exist in which a CRT that examines
interventions on professionals may meet regulatory criteria for a waiver of informed
consent: specifically, if seeking consent is not feasible; if the interventions pose only
minimal risk; if rights and welfare are not adversely affected; and (if appropriate) subjects
are debriefed after the study is completed.
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Discussion
Reflections on the relationship between empirical and normative work
In recent years, there has been a growing academic movement which suggests that
answering some research questions requires a methodology that combines both empirical
work and ethical analysis7. McMillan and Hope offer a cyclical model for the interaction
between empirical and normative work. It is not simply that empirical work generates
questions for ethical reflection, or that an ethical analysis led to an empirical question.
Rather, some problems require both empirical and normative work. The findings of
empirical work may stimulate ethical reflection, which may, in turn, drive policy change,
the effects of which can be evaluated empirically7.
Tan and Hope provide an example of how this model is applied to questions around
informed decision-making in patients with anorexia nervosa8. Tan and Hope sought to
determine whether traditional conceptions of decision-making capacity were adequate to
guide decisions about when it is appropriate to impose treatment against the wishes of
anorexic patients. They began with a qualitative interview study to gain a detailed
appreciation of the rationale for choices that anorexic patients make about whether or not to
comply with treatment. The data indicated that patients refuse treatment based on values
that are related to the disorder itself, such as the sense of control that anorexic behaviour
gives to patients. These data conflicted with the traditional conception of lack of decisionmaking capacity, which assumes that incapable patients make decisions based on false
beliefs or faulty reasoning. Therefore, the data prompted further conceptual work that
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sought to determine whether or not values closely related to a mental disorder may justify
refusal of treatment in the way that other kinds of values justify an informed refusal. Tan
and Hope offer that the conclusions of this conceptual work would drive the
implementation of policy with regard to the imposition of treatment for anorexic patients8.
This dissertation fits this cyclical model as proposed by McMillan and Hope7: both
empirical analysis and normative work is essential in order to comprehensively address
important ethical problems in CRTs. The empirical work identified the ethical problems
posing the most important challenges to CRT investigators, and described how ethical
problems in CRTs are addressed in practice. These findings stimulated reflection on
specific ethical questions, namely “Who is the research subject in CRTs?” and “When is
consent required in CRTs?” The conclusions of the normative work enabled critical
reflection on the empirical data. This included identification and discussion of deficiencies
in ethics practices, and the use of a conceptual framework for the ethics of human subjects
research to identify important ethical issues that were not reported by CRT investigators.
The conclusions of the normative work, and critical reflection on current practice, will
guide the development of comprehensive guidelines for the ethical conduct of CRTs
Empirical work identifying normative questions
The interviews done in chapter four documented CRT researchers’ views on the
ethical problems in CRTs, and asked detailed questions about how these issues were
addressed in practice. The principal ethical challenges noted by study informants were
related to seeking informed consent from cluster members in CRTs. Namely, they
identified issues of feasibility of seeking consent, potential for bias as a result of disclosure
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of study details to subjects, and whether or not consent was required from professionals
who were intervened upon. Prior to being able to address investigators’ concerns over
consent issues, normative work was required to clearly identify who is the research subject
in a CRT. Therefore, the key question of who is a research subject in a CRT was examined
in chapter five.
The question of who is a research subject was addressed by appealing to scholarly
work that supports this conceptual framework for research ethics. This scholarly work
distinguished clinical research from medical practice, and subjects from patients. These
distinctions illuminated our analysis of current regulatory definitions of “research subject”,
enabling the development of a definition of research subject that is applicable to the entire
range of human subjects research. This work has important implications for CRTs. First, in
CRTs in which individual cluster members are not intervened upon, do not interact with
investigators and do not contribute identifiable private information, these individual cluster
members are not research subjects, and therefore, their consent is not required. Second,
individuals, such as professionals, who receive an experimental intervention intended to
produce a cluster-level effect, are research subjects and, as a result, their consent may be
required.
The normative work in chapter six was directly stimulated by the findings of the
empirical work in chapters three and four. In addressing the question “When is informed
consent required in CRTs?” the relationship between the types of interventions under study
and the need to seek informed consent was examined, as well as issues of post-
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randomization consent, potential from bias resulting from disclosure of study interventions,
and the need for consent from professionals who are intervened upon in a CRT.
We drew on the principle of respect for persons, and on a moral theory on which
this principle is based, to address challenges related to seeking informed consent from
subjects in CRTs. Consent requirements stem from the principle of respect for persons.
This principle, which may be viewed as being rooted in deontological theory, is based on
the unconditional worth of autonomous individuals, and demands that the wishes of
autonomous individuals be respected. By adequately informing subjects during the consent
process, and by allowing subjects to make free choices, subjects are able to freely adopt the
scientific ends of the CRT as their own, effectively authorizing interventions that may put
their welfare at risk. When it is not possible to seek subject consent prior to random cluster
assignment, seeking consent at the earliest opportunity post-randomization is sufficiently
respectful of subjects’ autonomy, provided that they are informed of the study’s purpose
and the interventions that they would be subjected to should they choose to participate. If
obtaining consent is not feasible, or if the study intervention cannot be avoided, then
waiving consent is permitted, provided that risks to subjects are minimal.
Reflecting on empirical work based on findings of normative work
The conclusions of the normative work in this dissertation make it possible to
critically reflect on the empirical findings.
Studies with small cluster sizes and that used patient-level interventions were more
likely to report seeking patient consent. This fits with the opinions of informants in chapter
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three, who related that they only sought consent when feasible to do so. The normative
work in this dissertation leads us to conclude that whether consent may be waived for study
interventions is related to more than just the feasibility of seeking consent. Waiving
consent requirements is only permissible when seeking consent is not feasible and when
threats to subjects’ welfare interests are minor, i.e. when interventions for which the waiver
of consent is sought pose only minimal risk. Thus, we can conclude that researchers and
investigators require clear guidelines outlining the necessary conditions for use of a waiver
of consent.
Consent issues in CRTs represent a paradigmatic example of how both empirical
work and normative work can be used in concert to address key challenges in the ethics of
human subjects research. Empirical work identified concern among researchers about
consent requirements and a practice of waiving consent that may or may not be sufficiently
respectful of subjects’ interests. Normative work laid out a moral justification for a waiver
of consent, and criteria establishing when a waiver of consent is permissible. These
conclusions enabled reflection on current practice, and identified how current practice must
be improved. The conclusions of the normative work can also guide the development of
policy to ensure that subjects’ interests are adequately protected while ensuring that
methodologically valid CRTs may be carried out.
This dissertation applied both empirical findings and normative work in reaching
other conclusions about how ethical issues in CRTs ought to be addressed. In Chapter four,
experienced CRT researchers rarely mentioned issues relating to the analysis of risks and
potential benefits, fair subject selection, and the use of vulnerable populations. However,
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these issues are critically important in the conceptual framework based on the Belmont
Report principles. Thus, the use of a conceptual framework is important in identifying
areas that require further education for investigators and research ethics committees, and
clear guidelines addressing these issues, to ensure optimal protection of subjects in CRTs.

Implications for Current Practice
The findings of the empirical work and the conclusions of the normative work in
this dissertation lead to conclusions about how current practice in CRTs should change.
1.

Investigators and ethics committees must recognize that individuals who
are intervened upon in order to produce a cluster-level effect (such as
professionals) are research subjects. Their consent is required (unless
criteria for a waiver are met), the risks and potential benefits to these
individuals must be considered, and rules for fair subject selection should
apply to these individuals.

2.

Investigators and ethics committees should use a principled definition of
“research subject” determine whether or not individual cluster members
are research subjects. Cluster members who are not research subject need
not be approached for consent. Cluster members who are research
subjects should be approached for consent unless criteria for a waiver are
met.
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3.

With respect to seeking consent, investigators and ethics committees
should consider randomization, experimental interventions and
interventions used to collect data separately. Consent for random cluster
assignment may be waived if subjects are not identifiable prior to cluster
randomization or if clusters are sufficiently large so as to make seeking
consent for cluster randomization infeasible. A waiver of consent may be
sought for experimental interventions if seeking consent is not feasible
and if the interventions pose only minimal risk. If seeking consent is
feasible or if interventions pose more than minimal risk, then consent for
experimental interventions should be sought prior to randomization of
clusters (when feasible) or at the earliest possible opportunity after
randomization of clusters. The same requirements apply to data collection
interventions: consent may be waived if the seeking consent is infeasible
and the interventions pose only minimal risk. Otherwise consent for data
collection interventions must be sought from each subject.

Implications for Ethics Guidelines for CRTs
The empirical and normative work in this dissertation is intended to inform the
development of international consensus guidelines for the ethical conduct of CRTs9. Ethics
guidelines for CRTs should be comprehensive, addressing all of the ethical challenges
posed by the CRT design.

196

Guidelines should address the concerns of CRT investigators and ethics
committees, and protect the rights and welfare of research subjects. In order to optimally
protect research subjects, guidelines should be comprehensive in scope. The use of a
conceptual framework, based on the Belmont Principles, facilitates the identification of
ethical challenges that have not been identified by CRT investigators or addressed in
literature. In particular, challenges related to the analysis of harms and benefits, and the just
selection of research subjects have not been addressed, and require further work in order to
inform the development of ethics guidelines for CRTs.
Given the findings in this dissertation, international ethics guidelines for CRTs
should include the following:
1. A statement of basic ethical principles: respect for persons, beneficence and
justice. These will be derived from the principles articulated in the Belmont
Report.
2. A definition of “research subject”. A research subject is an individual whose
interests may be compromised as a result of interventions in a research study
including:
a. An individual who is directly intervened upon by an investigator
b. An individual who is deliberately intervened upon via manipulation of
his/her environment by an investigator
c. An individual with whom an investigator interacts for the purpose of
collecting data
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d. An individual about whom an investigator obtains identifiable private
information for the purpose of collecting data.
3. A detailed statement of consent requirements. Generally, consent for CRT
participation must be obtained from all individuals meeting the definition of
“research subject” in a CRT.
a. If subject enrolment is done prior to randomization of clusters,
information to be disclosed to potential subjects must include the
purpose of the study; detailed information about the nature, risks, and
potential benefits of the experimental interventions in each study arm;
detailed information about the nature and risks of any interventions done
solely to collect data; and information about the potential subjects’
options should they choose not to participate.
b. If it is not feasible to seek consent for participation prior to
randomization of clusters, seeking a potential subjects’ consent for CRT
participation in the arm to which their cluster has been assigned is
permissible. This consent refers to the experimental interventions in the
arm to which the potential subjects’ cluster has been assigned, as well as
any interventions used to collect data.
c. If subject enrolment is done after randomization of clusters, information
to be disclosed to potential subjects must include the purpose of the
study; detailed information about the nature, risks, and potential benefits

198

of the experimental interventions in the study arm to which that potential
subject’s cluster has been assigned; detailed information about the
nature and risks of any interventions done solely to collect data; and
information about the potential subjects’ options should they choose not
to participate.
d. A waiver of consent for experimental interventions is permissible if:
i. The interventions pose only minimal risk;
ii. The study could not reasonably be conducted without the use of
a waiver of consent for the experimental interventions.
e. A waiver of consent for data collection is permissible if:
i. The interventions pose only minimal risk;
ii. The study could not reasonably be conducted without the use of
a waiver of consent for the experimental interventions.
f. Passive consent strategies are subject to the same restrictions as the use
of a waiver of consent.
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Implications for other fields of inquiry
The findings in this dissertation have implications for CRTs in fields other than
healthcare, as well as for nonrandomized studies that examine interventions that are
administered in clusters.
In chapter five, a principled definition of “research subject” was developed.
Although this definition was developed by appealing to examples in healthcare research, it
is intended to be applicable to all fields of human subjects research, including CRTs in
other fields. A research subject is an individual whose interests may be compromised in the
context of a research study, either by being intervened upon (either directly or by
environmental manipulation), by interacting with investigators, or if their identifiable
private information is used.
CRTs are widely used in public health, education and a variety of other domains of
research. In public health research, research subjects include includes individuals residing
or visiting communities participating in a CRT of a public health intervention that cannot
be avoided, such as a CRT evaluating water decontamination strategies. In education
research, students of a school or school district participating in a CRT of a novel curricular
innovation would be considered subjects. These research subjects merit regulatory
protections in order to safeguard their interests, including being asked to provide informed
consent to study participation (unless criteria for a waiver of consent are met), and the
careful review of risks and potential benefits by a research ethics committee.
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Our conclusions may also be extended to nonrandomized trials. Consider, for
example, a nonrandomized study in which intensive care units in Michigan were assigned
to employ either educational and safety interventions intended to reduce catheter-associated
bloodstream infections, or to no intervention10. The healthcare providers were intervened
upon by investigators and are therefore research subjects. The patients were not intervened
on, interacted with, nor were they deliberately manipulated via environmental
manipulation. No identifiable private information was used to ascertain the relative
effectiveness of the educational and safety interventions: only administrative data on
infection rates was used. Therefore, the patients in this study are not research subjects, and
consent was not required.
Our work on the issue of informed consent in CRTs is also applicable to other fields
of inquiry. Our conclusions regarding the timing of consent, disclosure requirements and
the use of a waiver of consent is applicable to nonrandomized studies in other fields that
employ CRTs, such as public health and education. If group assignment is determined
before subject enrolment, and consent could not have been obtained at that time, then
seeking consent after group assignment is permissible. Potential subjects must be informed
of the study’s purpose, the nature, risks and potential benefits of the interventions that they
will undergo and their alternatives should they choose not to participate.
The application of waivers of informed consent is the same for nonrandomized
studies as for CRTs. Investigators must argue that he research is not feasible without the
waiver, and the study must meet the other regulatory criteria for a waiver 11. Similarly, optout consent practices offer no protection to subjects beyond those outlined in waiver of

201

consent regulations. Investigators may choose to employ an opt-out strategy for pragmatic
reasons, but requirements for a waiver of consent must be met before such a strategy is
used.

Future Work
Future work will examine how risks and potential benefits to subject CRTs ought to
be evaluated by research ethics committees12. The definition of “research subject”
developed in this dissertation leads to the conclusion that CRTs often include different
types of subjects. Subjects may include individual cluster members (who are either
intervened upon or contribute identifiable private information), as well as subjects who are
intervened upon in order to produce a cluster-level effect, such as teachers or health
professionals. The analysis of risks and potential benefits in a single CRT will likely be
different for each different type of subject. Furthermore interventions directed at one type
of subject may have consequences for another. For instance, interventions directed at health
professionals may present both risks and potential benefits for their patients. Conversely,
interventions directed at patients may have consequences for their treating professionals, in
that they may either contribute to or alleviate professional workload burdens. How ought
these indirect risks and potential benefits be considered by a research ethics committees?
Questions associated with the evaluation of risks and potential benefits in CRTs will
be the focus of additional papers from the CIHR-funded working group referenced in
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chapters one and two9,12. The conclusions of this work will inform the development of
comprehensive international guidelines for the ethical conduct of CRTs.
The work done in this dissertation will also serve as the basis for my own future
work. In particular, the conclusions of this work will be applied to work on the ethics of
knowledge translation and quality improvement research, and the methodology involving
the joint application of empirical and conceptual work will be used in addressing epistemic
questions in clinical trials.
The CRT design is often used in large knowledge translation (KT) or quality
improvement (QI) studies. KT is an activity aimed at increasing the uptake of high quality
scientific evidence in medical practice and healthcare policy13. QI is an activity intended to
improve outcomes or the efficiency of processes in health care systems14. KT and QI
interventions are administered to health care systems or health care professionals. If
successful, they lead to improvements in patient outcomes. KT and QI research evaluates
the efficacy of these interventions. Research in these fields poses many of the same ethical
questions as do CRTs: Who is the research subject? When is consent required? How ought
a research ethics committee evaluate the risks and benefits of the interventions being
studies? What does it mean to be fair in the selection of research subjects and research
populations in KT and QI research? The conclusions of the work in this dissertation are
likely to be very relevant to KT and QI research. Both empirical work, in order to evaluate
current ethics practices in KT and QI research, and normative work will be required to
comprehensively address the range of ethical questions posed by research in these fields.
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Thus, future work will involve the application of both the methodology of this dissertation,
and its conclusions, to ethical questions raised by KT and QI research.
Epistemic questions raised by clinical trials in medicine can also be addressed by an
approach combining both empirical and normative work. One particular challenge
amenable to this approach is the question, “When should a clinical trial be stopped in the
face of mounting evidence of the superior efficacy of one experimental treatment?”15
Answering this question is important, in order to ensure that research subjects are not
assigned to a treatment that is known to be inferior. In addressing this question, the work of
Benjamin Freedman is useful starting point. Freedman writes that a clinical trial should be
designed such that, at its completion, its findings will resolve a state of disagreement in the
clinical community as to the preferred treatment16. In other words, the findings of a clinical
trial should be sufficiently convincing as to broadly influence clinical practice. In reality,
the results of a single trial rarely change practice13 (hence the need for knowledge
translation interventions), it is an empirical question as to how much evidence is sufficient
to be convincing to expert clinicians to stimulate a change in practice. This empirical
information may help to set an evidentiary standard that researchers should hope to meet
with the design of a clinical trial. The question of when to stop a trial early will then be
reduced to “when will accumulating clinical trial data be sufficient to meet this standard?”
Answering this question involves both empirical work on the effect of stopping early on the
accuracy and precision of estimates of effect15, and normative work that addresses the
ethical implications of enrolling subjects in clinical trials in the face of mounting evidence
of the superiority of one trial arm. By combining the findings of both normative and

204

empirical work on this issue, robust guidelines for early stopping of clinical trials may be
formulated. I propose to address this challenge in future work.
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Appendix A. Data abstraction form for published CRTs used in chapter two.
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1.
2.
3.
4.

Study ID (this is the Medline UID number – also the pdf file name)
Reviewer name
Publication year
Journal name
General Study Characteristics

5. Country of study recruitment (for identification of developing nations, use World Economic outlook
database April 2008 edition at http://www.imf.org/external/pubs/ft/weo/2008/01/weodata/groups.htm#oem):
1
2
3
4
5
6

Canada
USA
UK or Ireland
Australia
Other developed country /countries (specify) (e.g., Canada and USA)
Other developing country/countries (specify)

6. Country of first author (attempt to identify online if not reported):
1
Same as country of study recruitment (or one country of study recruitment)
2
Other (specify)
7. Study funding source reported?
1
Yes
2
No
8. If Q7=Yes, specify funding source: (If unclear, confirm online or with author; NA if Q7=No)
a) Industry
b) Government agency, international development agency, university
c) Foundation, special interest group (e.g., Bill and Melinda Gates Foundation,

Yes

No

NA

1

2

3

1

2

3

1

2

3

Alzheimer’s society, charitable/non-profit organization)

9. Type of clusters (units of randomization):
1
Primary care practices (intact practices – includes multiple health professionals in at least some practices)
2
Individual primary care physicians (individual GPs)
3
Other individual health professionals (specify)
(e.g., dentists, surgeons, nurses, midwives)
4
5
6
7
8
9

Hospitals
Nursing Homes
Primary care clinics
Units of time (specify setting) (e.g., primary care clinics, nursing homes)
Households/ families
Residential areas (specify) (e.g., villages,
neighbourhoods, parishes, hamlets, balozi, household clusters)

10
11
12

Public health clinics
Schools
Classrooms
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13
14
15

Worksites
Churches
Other (specify) (e.g., teams of health professionals)
Study Design

Note: In order to complete data abstraction, a single primary outcome must be
identified for each trial. Use the following hierarchy: First primary outcome stated by
authors; if no primary outcomes specified, use outcome in sample size calculation; if
sample size calculation not reported or reported for a sub-study only, use first outcome
listed under ‘Objectives’; if still unclear, refer trial to arbitration before proceeding.).
Note: Data abstraction pertains to main study component (the patient population on
which the primary outcome evaluation is carried out), i.e., disregard sub-studies within
the main trial, e.g., if a smaller group of patients are enrolled for more intensive followup.
10. Were primary outcome measure(s) identified by authors? (Authors clearly distinguished
between main (or primary) and secondary outcomes measures?) (Note: Not acceptable if authors merely stated
primary objectives without operationalizing in terms of specific variables.)
1
2

Yes (specify number)
No

11. For quality control purposes, state the single primary outcome data abstraction will
be based on:

12. Trial design at cluster-level:
1
Parallel trial (clusters independently randomized to different treatments with or without pre-test)
2
Factorial trial (specify factors and levels) (e.g., 2x2)
3
Cross-over trial
4
Other (specify) (e.g., latin squares, split-plot, stepped wedge)
13. Method of random allocation:
1
Completely randomized design (unrestricted randomization)
2
Stratified design
3
Pair-matched design
4
Other (specify) (e.g., minimization algorithm)
14. a) Data collection schedule for primary outcome:
1
Posttest only design (primary outcome measure observed post-intervention only)
2
Pretest-posttest design (primary outcome measure observed both pre- and post-intervention)
b) Specify number of discrete observation time points or indicate 99=“continuous
surveillance” (Note: Post-test only design with continuous surveillance would typically correspond with a
cohort design in Q15 (and patient attrition is possible in Q28), whereas post-test only design with one discrete
observation time point only would correspond with a cross-sectional design (and no patient attrition possible in
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Q28). (E.g., patients enrolled at baseline and followed for 30 days to observe hospitalization = continuous
surveillance.)

15. Trial design at patient-level (primary outcome):
1
Nested cross-sectional design (each patient measured only once or different patients measured each time point)
2
Nested cohort design (same patients measured at different time points or in continuous
surveillance) (NOTE: Patient-level attrition is possible in a cohort design but NOT in a cross-sectional design)
3
Primary outcome evaluated on both cross-sectional and cohort components
Characteristics of Outcomes and Interventions
16. Type(s) of experimental interventions (all components of intervention):
Yes

a) Educational/ quality improvement interventions targeted at health professionals

No

1

2

1

2

1

2

1

2

(e.g., distribution of educational materials, outreach visits, audit and feedback)

b) Quality improvement interventions targeted at organization of health care or
health services delivery (e.g., financial, shifting of professional roles, multi-disciplinary teams,
integration of services, changes in setting or equipment, home visits by nurses)
c) Patient health promotion or educational intervention (e.g., promotion of breastfeeding,
smoking cessation intervention, decision aid, disease screening promotion)
d) Direct patient therapeutic intervention (e.g., experimental intervention includes specific drug to
be prescribed to all patients, vaccines/vitamin supplements, insecticide spraying, surgery, testing of new clinical
pathway – distinguish from indirect changes to patient therapies as a result of guideline adherence)

e) Other (specify)
17. Type of intervention administered in control arm (Note: disregard activities administered in all
clusters prior to randomization e.g., to ensure similar levels of knowledge before starting the intervention):
1
2
3

4
5
6

Not reported
No active intervention (i.e., usual care)
Scaled down version of active intervention (includes some basic elements of
active intervention) (e.g., one educational visit, printed guidelines only)
Placebo or sham intervention (e.g., vitamin placebos, education on unrelated medical conditions)
Other active intervention (head to head comparison)
Other (specify)

18. Typology of trial interventions (options are hierarchical and based on ability to opt
out): (For more detailed explanation and notes, see notes document or Eldridge ea, 2005, Clinical Trials v2)
1
Cluster-cluster (Targeted at cluster organization, health professional, or cluster population individuals cannot opt out of the intervention) (e.g., information on patient population fed back to health
professional, change in organization; changes to electronic medical records/ software system; mass media campaign, water
fluoridation, insecticide spraying, posters, changes to physical environment) (Primary reason for clustered design is
intervention cannot be carried out any other way)
2

Professional-cluster (Targeted primarily at health professional – individuals can decline to
have their data used, but intervention is still likely to have an effect on them) (e.g., physician
education intervention to improve detection of dementia) (Primary reason for clustered design is to avoid contamination)

3

External-cluster (Additional staff) (Targeted at cluster organization - individuals can opt
out by declining to see the additional staff) (e.g., specialist nurses) (Primary reason for clustered design is
logistical and/or financial)
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4

Individual-cluster (Targeted primarily at individuals but may be delivered by health
professional – individuals can opt out in the same way as they would in an individually
randomized trial) (e.g., vaccines, vitamin supplements, patient decision aid administered by physician, intervention to
promote breastfeeding delivered by midwives, clinical pathway to treat pneumonia in nursing home residents) (Primary
reason for clustered design is to avoid contamination and increase individual compliance)

19. Type(s) of data collection interventions for primary and secondary outcomes:
Yes

a) Medical record review or use of routinely collected data
b) Patient specimen collection or physical examination not required for normal
patient care
c) Interviewer-administered patient questionnaires (telephone/face-to-face) (Disregard if

No

1

2

1

2

1

2

1

2

1

2

Yes

No

applied to follow-up non-respondents to the initial postal survey only)

d) Self-administered patient questionnaires (postal, e-mail, internet)
e) Health professional survey questionnaires or interviews
f) Other (specify if none of the above)
g) Specify which one of a) to f) above applies to the primary outcome
20. Primary and secondary outcomes observed:
a) Patient outcomes (clinical or non-clinical outcomes e.g., morbidity, mortality, depression/anxiety scores,
patient satisfaction, quality of life. Note: Length of hospital stay could be either a patient outcome (as an indicator
of degree of illness) or a process measure (as an indicator of physician adherence to guidelines).
b) Process measures (“process measures” refers to actual medical care such as diagnoses, treatment,
referral and prescribing, e.g., hospitalization, number of guideline-adherent prescriptions, number of healthcare
visits, % visits where guidelines were followed)
c) Other health professional outcomes (e.g., satisfaction, quality of care, behavioural intentions)

d) Economic outcomes (even if reported in separate publication)
e) Other (specify)
f) Specify which one of a) to e) above applies to the primary outcome
Cluster and Patient Flow
21. Were patients recruited to the study (including recruitment for data collection
purposes only)? (Refers to main study component- disregard substudy involving smaller group of patients)
1
Yes
2
No
22. Number of study arms (we need to know if there were multiple intervention or control arms so that patient
numbers can be divided up appropriately when assessing imbalances):

a) Intervention arms
b) Control arms
NOTE: In Q23 to 28, combine across arms if multiple intervention or control arms; If
head-to-head comparison, choose the reference intervention as control arm. If reference
intervention not clear, refer trial to arbitration.
If not reported or unclear, indicate as missing = -1.

1

2

1

2

1

2

1

2
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23. Number of clusters randomized:
a) Total
b) Intervention arm
c) Control arm
24. Number of randomized clusters included in baseline data collection (assess postrandomization withdrawals) (Note: randomized clusters not identifying any eligible patients at baseline
are considered as withdrawals):

a) Total
b) Intervention arm
c) Control arm
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25. Number of clusters (from those in Q24) that were lost to follow-up (Note: clusters not
identifying any eligible patients at follow-up are considered lost to follow-up ):

a) Total
b) Intervention arm
c) Control arm
26. Number of patients providing data at baseline: (As reported in flow diagram or in table
describing baseline characteristics of clusters and patients. Will be used to assess average cluster size.)

a) Total
b) Intervention arm
c) Control arm
27. Number of eligible patients invited but excluded from baseline data collection (e.g.,
refusal/ non-response): (Note: If there was no patient recruitment (Q21=2), report as 0; if patients recruited
prior to randomization (Q32=2), record b) and c) as NA=-9; if not reported, record as missing = -1.) (Will be used
to assess risk of selection bias).

a) Total
b) Intervention arm
c) Control arm
28. Number of patients (from those in Q26) that were lost to follow-up at final
observation time (or time that was used to assess primary outcome): (Note: Report as 0 if
cross-sectional design (Q15=1); disregard in-migration / patients added to clusters after baseline data collection):

a) Total
b) Intervention arm
c) Control arm
Methodological Quality Indicators
29. Sample size / power calculations presented?
1
Not presented or presented for substudy or outcome regarded as secondary only
2
Patient-level accounting for ICC (“Sample size was based on a significant effect size of 0.5, incorporated an

3

4
5

6

ICC of 0.05 and was based on enrollment of 4 patients per physician”; “Based on a mean (SD) number of admission days
per resident enrolled, within cluster variance of 2 days and between-cluster variance of 3 days and 10 residents per nursing
home”. Usually will involve stating at least the average cluster size and the ICC/ design effect/ overdispersion
factor/within-and between-cluster variance or stated that accounting for clustering without reporting value of ICC.)
Cluster-level (Should be clear that cluster-level summary data are used for calculation e.g., “sample size was based
on the hospital as the unit of analysis…assuming a rate of episiotomy of 42% at baseline, with a standard deviation of
15%, we need 18 hospitals to identify a decrease in episiotomy rate.” Use of standard deviation in the case of proportions
indicates that binary data was summarized at cluster-level and treated as continuous data for the purpose of sample size
calculation.)
Patient-level without accounting for ICC (usually difficult to tell whether at patient- or cluster-level unless
specifically stated)
Unclear whether at patient- or cluster-level or whether accounted for clustering (e.g., “sample
size was calculated to give a power of 80% of detecting a difference of 1 SD at 5% significance in mean diagnosis
concordance score”; “sample size of 500 participants would result in 80% power to detect a difference of 10 points
between groups”)

Other (specify) (e.g., based on intermediate level of clustering)
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30. If there was no patient recruitment (Q21=No), assess risk of patient selection
(“identification”) bias: (Optional: use explain field to clarify your choice): (We want to
avoid option 6 as far as possible)
1
2
3

NA (Q21=Yes)
Not possible (patient identification was completed prior to randomization)
Unlikely (patient identification post-randomization but: done by person blinded to group allocation, computerized
process without regard to group allocation, or researcher/independent person without knowledge of clinical characteristics
of patients; OR eligibility criteria such that unlikely to be subverted by knowledge of random assignment (e.g., all women
delivering in hospitals within specified time period were included))

4
5
6

Possible (e.g., unblinded individuals with knowledge of clinical characteristics of patients identified participants
prospectively after randomization)
NA (patient identification is aim of intervention, e.g., intervention to improve detection of dementia in primary care)

Unclear (explain) (e.g., not clear who identified patients)

31. If patients were recruited to the study (Q21=Yes), who approached patients?
1
NA (Q21=No)
2
Health professional usually involved in patient’s care or regular program staff
3
Member of research team or someone not usually involved in patient care or service delivery
4
Mail questionnaire (specify sent by …) (e.g., researcher, GP)
5
Not reported or unclear
6
Other (specify)
32. If there was patient recruitment (Q21=Yes), assess risk of patient selection
(“recruitment”) bias: (Optional: use explain field to clarify your choice): (We want to
avoid option 5 as far as possible)
1
2
3
4
5

NA (Q21=No)
Not possible (patients were identified and recruited prior to randomization and same patients followed over time)
Unlikely (identification and recruitment post-randomization but: done by person blinded to group allocation, or invitation
by mail questionnaire most likely with identical information to patients in different arms)
Possible (e.g., identification or recruitment by unblinded individuals with knowledge of clinical characteristics of patients,
or possibly different information to patients in different arms)

Unclear (explain) (e.g., not clear who recruited patients)

33. Concealment of allocation (secure allocation) (Note: EPOC distinguishes between sequence
generation and allocation concealment – however, our eligibility criteria likely will exclude trials subject to bias as
a result of sequence generation):
1
Done (Unit of allocation was institution or professional and randomization was performed on all units at the start of the
study –this will be the case for most cluster trials; or unit of allocation was by household, patient or episode of care and there
was some form of centralized randomization scheme, on on-site computer system or sealed opaque envelopes.)
2
3

Not done (open list of random numbers/ coin flip was used or security could have been compromised, or allocation was
altered by investigators, professionals or patients)
Not clear (unit of allocation was by household, patient or episode of care and method of concealment not described)

34. ITEM DELETED
35. Protection against contamination: (EPOC)
1
Done (e.g., allocation by community, institution or practice and unlikely that control arm received the intervention)
2
Not done (likely that control arm received intervention, e.g., cross-over trials or patients within the same cluster allocated
to control and intervention arm)
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3

Unclear (e.g., professionals allocated within an institution and communication among professionals may have occurred)
36. Analysis for primary outcome:
1
At patient-level accounting for ICC (e.g., using mixed-effects logistic regression, GEE taking account of
2

clustering by physician, Chi-square statistic adjusted for clustering, random effect for physician, hierarchical modeling, multilevel modeling, alternating logistic regression)
At cluster-level (clearly stated that analysis at cluster-level, e.g., “analyses performed using patient-level variables
aggregated at the provider-level”, analysis was based on hospital rates, t-test weighted by inverse variance etc.)

3

At patient-level not accounting for ICC (more difficult to distinguish, e.g., multivariable regression analysis of
patient-level data with no mention of clustering, or standard 2-sample test on patient-level data without mention clustering or
stated that since ICCs were low, clustering was ignored in presentation of results)

4

Unclear whether at patient-level or cluster-level or whether accounted for clustering
Other (specify) (e.g., based on intermediate level of clustering, both individual-level

5

and cluster-level analyses used for primary outcome analysis)

37. Primary outcome reported as statistically significant?
1
Yes
2
No
38. Type of test for primary outcome evaluation in Q37: (purpose of item is to distinguish between
trials where a significant result is desirable versus not desirable, e.g., equivalence study, intervention is
harmful/not safe)
1
2
3
4

Effectiveness/Efficacy
Safety/Tolerability (e.g., safety of iron supplementation in malaria-prone settings)
Equivalence/Non-inferiority
Other (specify) (e.g., descriptive study only)

39. ICC or design effect estimates reported for any outcomes recorded at patient-level?
(not referring to ICC used for sample size calculation):
1
Yes
2
No
40. Blinding of health professionals: (use the following hierarchy to identify relevant HPs: a) HPs
targeted by intervention, b) individual HPs that were the units of randomization, c) if HPs were not the units of
randomization, the HPs in each cluster involved in administering interventions to patients, d) regular HPs involved
in patient care.
1

2

Yes (stated explicitly that health professionals were blinded/ not informed of their
allocation status)
No (stated explicitly that health professionals could not be blinded to allocation status, or
that they were informed of their allocation status or obvious) (e.g., the same specialist nurses/surgeons
administered both treatment and control)

3

Not reported or reported but unclear (e.g., reported as “double blind trial” without specifically identifying who
was blinded, or “participants” were blinded but unclear whether referred to patients or health professional participants)

41. If Q40=1 or 2, capture verbatim the relevant statements including what information
was given to different arms (e.g., “physicians were not informed of their study group assignment”,
“allocation was revealed to surgeons after random assignment”) or state “Obvious” and reason.
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42. Blinding of patients:
1
Yes (stated explicitly that patients were blinded/ not informed of their allocation status OR
obvious) (e.g., there was no patient recruitment and patients were clearly unaware of the trial)
2
No (stated explicitly that patients could not be blinded to allocation status or that patients
were informed of their physician’s allocation status)
3
Not reported or reported but unclear (e.g., patient decision aid and not reported whether patients knew
whether they have received the experimental or control intervention; or trial reported as “blinded” without specifically
identifying who was blinded)

43. If Q42=1 or 2, capture verbatim any relevant statements including what information
was given to different arms (e.g., “patients in intervention and control arms received identical
information about the trial”) or state “Obvious” and reason.

44. Blinding of primary outcome assessment:
1
Yes (stated explicitly that primary outcomes were assessed blindly or obvious) (e.g., based on
computer algorithm applied to electronic records without regard to random allocation or based on identical postal
questionnaires in both groups)
2

3

No (stated explicitly that outcome assessors / interviewers / data abstractors were not
blinded to allocation status or obvious) (e.g., GPs aware of allocation status assessed primary outcomes)
Not reported or reported by unclear

45. If Q44=1 or 2, capture verbatim the relevant statements or state “Obvious” and
reason:

46. Capture verbatim any other statements regarding blinding where it is unclear who the
blinding refers to (e.g., “participants were not informed of their study group assignment”, “double-blind
trial”)

47. Relevance of blinding for primary outcome measure assessment:
1
Primary outcome measure is objective (unlikely to be influenced by knowledge of allocation status; e.g.,
length of hospital stay, mortality, blood pressure) OR patient identification is aim of intervention (e.g.,
intervention to improve detection of dementia in primary care)
2

Primary outcome measure is subjective (vulnerable to bias from knowledge of allocation status, e.g., patient
self-report of health status, depression scales, quality of life measures, subjective diagnoses)

3

Not clear
Ethical Quality Indicators

48. Study reported as “Quality Improvement” / QI anywhere in text?
1
Yes
2
No
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49. Stated whether requirements of Declaration of Helsinki followed?
1
Yes
2
No
50. REB review reported?
1
Stated REB approval and identified committees (e.g., “The Ottawa Hospital REB”)
2
Stated REB approval – did not identify committees (e.g., “local research ethics committees of each
study site” and the study sites themselves are not identified)
3
4

Stated REB exempt (specify reason)
Not reported

51. Number of ethics committees involved (indicate as missing if not reported)
52. Data and Safety Monitoring Board in place?
1
Yes
2
No
3
Not reported
53. Was a gatekeeper identified (separate from the REB) that allowed access to each
cluster?
1
Yes (specify) (e.g., hospital administrators, lead physicians, nursing home
2

management, “responsible authorities”, government initiated program)
No (e.g., “practices agreeing to participate were randomized…”, or cluster is individual health professional)

54. Was gatekeeper consent reported? (should be explicitly reported as “consent”)
1
Yes (e.g., “hospital administrators provided consent to randomization”)
2
No
55. Capture verbatim any statements about any form of gatekeeper agreement to
participate, including what consent was for (e.g., participation, review of medical records)

56. Reporting of any health professional consent procedures (requires specific reference
to “consent”):
1
Reported informed consent was provided including method (e.g., “physicians provided written/ verbal
consent”)
2

Reported informed consent was provided but no details on method (e.g. “consenting GPs were
randomized”)

3

4

Reported waiver of informed consent
(specify reason) (e.g., to avoid Hawthorne type effect)
Not reported (e.g., “physicians agreeing to participate were randomized”, “participating physicians were
randomized”, nursing homes were enrolled in the trial and no report of consent from nurses administering interventions)
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57. Capture verbatim any statements about any form of health professional agreement to
participate, including what “consent” was for (e.g., participation, review of medical records) and
use of opt-in versus opt-out procedures:

58. Reporting of patient consent procedures (Note: refers to main study component):
1
Reported informed consent was provided including method (e.g., written, verbal)
2
Reported informed consent was provided but no details on method
3
Reported waiver of patient consent (specify reason)
4

(e.g., routine outcome data, no personal identifiers collected)
Not reported (e.g., “patients agreeing to participate…”, implied by return of survey questionnaire but not reported, or
there was no patient recruitment and waiver of informed consent not reported)

59. Capture verbatim any statements about patient “consent”/agreement to participate,
including what consent was for (e.g., participation, review of medical records), and use of opt-in
versus opt-out procedures:

60. Capture verbatim any statements about attempts to protect patient confidentiality or
privacy (e.g., “anonymized data were collected”, “no personal identifiers were transmitted”)

61. Incentives offered? Specify as nr = “not reported” or verbatim (e.g., CME credits, $1000 for
computers):
a) Gatekeeper
b) Health professionals
c) Patients
62. Capture verbatim any author comments on REB review process or impact of
informed consent procedures on study: (e.g., impact on study
duration/costs/feasibility/recruitment/scientific validity/ differential process and outcome among centres):

63. Capture verbatim any other statements relating to ethical issues (e.g., “patients who declined
to participate were offered the successful treatment after completion of the trial”; “individuals in control clusters
were not prevented from seeking active treatment”)
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64. Any other general reviewer comments about ethical or methodological issues? (e.g.,
trial was stopped early for harm, stopping rules were in place, adverse events reported)

65. Do authors reference a separate publication which may provide further details on
items required in this data abstraction form?
1
Yes
2
No
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Appendix B. REB approval from the University of Ottawa and UWO
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Appendix C. Interview guide used for key informant interviews in chapter four
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Key Informant Interview
1. What types of cluster randomized trials have you been involved with?
[Prompt: We are interested in the type of research that you have done, i.e., primary, secondary or
tertiary care, public health, and the types of interventions and outcomes you were looking at]

2. What was your involvement in these trials?
[Prompt: Clinical investigator, social scientist, statistician, epidemiologist…?]

3. Approximately how many cluster randomized trials have you been involved with?
ethical issues
4. Have you come across any ethical issues in the cluster randomized trials you have
been involved with? What were these issues and why did they arise?
5. How did you try to resolve these issues? Were the solutions satisfactory?

6. Tell me about your experiences with obtaining ethics approval for the cluster
randomized trials you have been involved with.
7. Has the ethics review process had any impact (positive or negative) on the quality of
your trials?
8. Can you identify a particular trial which presented the most challenging or interesting
ethical issues? Tell me more about this trial.
[Prompt: Nature of the intervention, outcomes of interest, types of clusters, ethical issues…]

9. Has this trial been published? Where?
particular trial.
10. What were the main reasons for using cluster randomization?
[Prompt: To avoid contamination, cluster-level intervention, ethics, feasibility…?]

11. Now we are interested in the clusters that were selected for recruitment to the trial.
How were they identified or selected? Who consented on behalf of each cluster and
how were the decision-makers identified?
12. Did the decision-makers receive any incentives or benefits from their participation?
13. Were there any ethical concerns with the role of the decision-maker in this trial?
14. Did you experience any difficulties in recruiting clusters to the trial?
[Prompt: What reasons given for refusing to participate?]
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15. Now we are interested in the individuals that participated in the trial. How were they
identified or selected?
[Prompt: e.g., through random sampling, had to satisfy eligibility criteria…]

16. Did the individuals consent prior to being randomized? If not, why not?
17. Did the individuals consent to receiving the intervention? If not, why was consent not
sought?
18. What information was given to individuals about the trial and the interventions
involved?
[Prompt: where individuals aware of the trial?]

19. How were the outcomes assessed?
[Prompt: telephone survey, in-person interview, secondary data sources…]

20. Did all individuals providing data for analysis consent to data collection? If not, why
was consent not obtained?
21. Did you experience any difficulties in recruiting individuals to the trial?
[Prompt: What reasons given for refusing to participate?]

22. Describe any potential risks or benefits to individuals, and clusters or communities in
this trial.
23. What opportunities existed for individuals to withdraw from the trial?
24. Did individuals have access to the intervention outside the trial?
25. Did individuals in the control group have access to the intervention during or after the
trial?

26. Do you have any other comments about ethical issues, the ethics review process, or
ethics guidelines for cluster randomized trials?
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Appendix D. Final coding template for descriptive qualitative analysis in chapter
four
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Consent from Individuals
 Active vs. passive consent
 Awareness of trial
 Completion of questionnaire as consent
 Consent from individuals with limited capacity
 Consent process as source of bias
 Consent to data collection
 Consent to receive intervention
 Implied consent for data collection within consent for care
 Incentives to individuals
 Individual consent superseding need for cluster or community consent
 Individual (informant’s) perception of need for consent
 Information provided to individuals
 Opting out of data collection
 Opting out of intervention
 Subject coercion
 Timing of individual consent re: randomization, Zelen design
 Waiver of consent from individuals/need for consent from individuals

Consent from Gatekeeper
 Alternatives to individual gatekeepers (e.g. advisory boards)
 Gatekeeper authority
 Gatekeeper consent overriding individual consent
 Identification of appropriate gatekeeper
 Incentives to gatekeepers
 Information provided to gatekeepers
 Multiple levels of gatekeepers

Consent from Cluster Participants (e.g. physicians, teachers)
 Cluster level drop-outs
 Coercion of cluster participants
 Compensation for time or activity
 Democratic consent of cluster or practice
 Influence of opinion leader
 Incentives to clusters (financial, infrastructure)
 Need for consent from cluster participants
 Professional obligation for research participation
 Reasons for refusal

Risks and Potential Benefits
 Equipoise between intervention arms
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Intervention as standard or nonstandard care
Obligations to research subjects
Overburdening of some clusters
Perception of no risk to individuals or clusters
Risks to professional reputation
Tradeoff of benefits to society vs. risks to individuals
Uncertainty about intervention safety or efficacy

Privacy
 Access to patient data
 Breaking of privacy protections during trial
 Obstacles from healthcare bureaucracy
 Privacy protections for individual data

Conflicts of Interest

Methodological Concerns
 Contamination
 Selection of clusters
 Fairness
 Selection criteria
 Practicality of consent
 Stopping rules

Ethics Board Review Process
 Access to intervention for control groups
 Access to intervention for non-study individuals
 Change in regulations or review over time
 Difference in regulation or review between jurisdictions
 Duration of ethics review process
 Importance of type of intervention for ethics review
 Need to educate ethics boards about cluster trials
 Negative impact of review process
 No impact of review process
 Positive impact of review process

Ethics Guideline Recommendations
 Conflicts of interest with professional obligations
 Distinction between health services research, KT, and QI
 Education about cluster design
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 Need for ethics approval
 Reporting standards
 Requirements for valid design and analysis
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